Predicting adverse events during therapy for HIV and hepatitis C : the role of ITPase activity and ITPA genotype by Peltenburg, N.C. (Nicole Chantal)
Predicting adverse events during therapy for HIV and hepatitis C
The role of ITPase activity and ITPA genotype
Nicole Chantal Peltenburg
Predicting adverse events during therapy for HIV and hepatitis C. The role of ITPase activ-
ity and ITPA genotype.
ISBN 978-94-6361-281-4
The studies reported in this thesis were performed at the departments of Internal Medicine, 
Medical Microbiology and Infectious Diseases and Gastro-enterology and Hepatolgy of the 
Erasmus MC University Medical Center, Rotterdam, The Netherlands, the departments of 
Internal Medicine, Clinical Genetics and Medical Microbiology of the Maastricht University 
Medical Center, Maastricht, The Netherlands and the Faculty of Science, Leiden Academic 
Centre for Drug Research, Analytical BioSciences, Leiden.
Financial support for reproduction of this thesis was provided by Virology Education B.V., 
Gilead Sciences Netherlands B.V., Erasmus Medical Center Rotterdam
Cover design: Chantal Peltenburg, Gwenny vd Oetelaar, Jolanda v Deventer and Optima 
Grafische Communicatie.
Lay-out and printing by Optima Grafische Communicatie (www.ogc.nl)
©Nicole Chantal Peltenburg, 2019, Rotterdam
All rights reserved. No part of this thesis may be reproduced, stored in a database or re-
trieval system, or published, in any form or by any means, without permission of the author.
Predicting adverse events during therapy for HIV and hepatitis C
The role of ITPase activity and ITPA genotype
Het voorspellen van bijwerkingen tijdens therapie voor HIV en hepatitis C
De rol van ITPase activiteit en ITPA genotype
Proefschrift
Ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam
op gezag van de 
rector magnificus
Prof. dr. R.C.M.E. Engels 
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 3 juli 2019 om 15:30 uur
door
Nicole Chantal Peltenburg
Geboren te ’s-Gravenhage
Promotiecommissie
Promotor:  Prof. dr. A. Verbon
Overige leden: Prof. dr. M.E. Rubio Gozalbo
 Prof. dr. E.J.G. Sijbrands
 Prof. dr. A.T. van der Ploeg
Copromotoren: Dr. J. Bierau
 Dr. J.A. Bakker
Table of contents
Chapter 1. General introduction and outline of the thesis 7
Chapter 2. Inosine triphosphate pyrophosphohydrolase activity: more accurate 
predictor for ribavirin-induced anemia in hepatitis C infected 
patients than ITPA genotype.
33
Clinical Chemistry and Laboratory Medicine
Chapter 3. Inosine triphosphate pyrophosphohydrolase expression: decreased 
in leukocytes of HIV-infected patients using combination 
antiretroviral therapy.
51
Journal of Acquired Immune Deficiency Syndromes
Chapter 4. Erythrocyte inosine triphosphatase activity: a potential biomarker 
for adverse events during combination antiretroviral therapy for 
HIV.
65
PLoS One
Chapter 5. Inosine 5’-triphosphatase activity is associated with TDF-associated 
nephrotoxicity in HIV.
83
Submitted
Chapter 6. Metabolic events in HIV-infected patients using abacavir are 
associated with erythrocyte inosine triphosphatase activity.
95
Journal of Antimicrobial Chemotherapy
Chapter 7. Persistent metabolic changes in HIV-infected patients during the 
first year of combination antiretroviral therapy.
111
Scientific Reports.
Chapter 8. Summarizing discussion and future perspectives 147
Chapter 9. Nederlandse samenvatting 167
Chapter 10. List of publications 177
PhD portfolio 181
Curriculum vitae 183
Dankwoord 185

 Chapter 1.
General introduction and outline 
of the thesis

9General introduction and outline of the thesis
HumaN ImmuNOdefICIeNCy VIrus
In 1983 the Human immunodeficiency virus (HIV) was discovered after the clinical ob-
servation in 1981 of a cluster of patients who were suffering from Pneumocystis jirovecii 
(previously carinii) pneumonia.1 This rare opportunistic infection was only reported in 
patients with a severely impaired immune system, but this cluster of patients did not have a 
medical history of immune deficiency. In 2017, there were an estimated 36.9 million (31.1-
43.9 million) people living with HIV worldwide and in July 2018 21.7 million (19.1-22.6 
million) of those people had access to antiretroviral therapy.2 
The HIV is a single-stranded ribonucleic acid (RNA) virus, that specifically infects CD4+ 
T-helper lymphocytes, macrophages and dendritic cells by binding of glycoprotein 120, a 
protein on its trimeric envelope complex, to the CD4-receptor and one of the co-receptors 
CCR5 or CXCR4 on the target cell.3-5 After a series of steps, HIV glycoprotein 41 is inserted 
into the host cellular membrane and then undergoes a significant conformational change, 
forming a hairpin and bringing the membranes of the HIV and the host cell together, thereby 
allowing them to fuse.6 After the fusion process, the HIV capsid enters the cytoplasm of 
the target cell, where it releases its content: the enzymes reverse transcriptase, integrase 
and protease, some minor proteins, the major core protein and two single-stranded RNA 
strands.7 Inside the cytoplasm, HIV uses its enzyme reverse transcriptase and the nucleotides 
of the host to transform its single-stranded RNA into a double-stranded deoxyribonucleic 
acid (DNA) molecule.8 This DNA is transported to the nucleus of the host cell and via the 
enzyme integrase incorporated into the DNA of the host.9 The nucleotide metabolism of the 
host further transcribes this incorporated DNA into new RNA strands, that, after transla-
tion of new essential HIV proteins, are assembled together with these proteins into a new 
HIV virion that buds from the host membrane and is released from the host cell.7 Finally, 
the HIV enzyme protease completes the last step of the HIV cycle, maturing the virus to a 
new infectious particle. The HIV-cycle is displayed in Figure 1.
If left untreated, HIV infection eventually leads to a depletion of CD4+ T-lymphocytes. The 
mechanism behind the slow decrease of CD4+ T-lymphocytes is not completely understood, 
but probably consists of a combination of factors. HIV is causing a direct cytotoxicity, lead-
ing to massive CD4+ T-cell destruction, occurring in the early course of the infection. It 
is thought that this massive destruction is followed by a regenerative response of CD4+ 
memory T-cells, preserving CD4+ T-cell numbers and immune function. However, this ho-
meostatic balance eventually fails, due to factors such as infection and death of progenitor 
cells,10 destruction of the secondary lymphoid tissues that support the homeostasis11 and 
chronic inflammation. The chronic inflammation is also sustained by a combination of fac-
tors, like gastrointestinal mucosa loss (leading to microbial translocation),12 pyroptosis (a 
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highly inflammatory form of programmed cell death like apoptosis, leading to the release of 
the dying cells contents among which inflammatory cytokines)13 and polyclonal activation 
of B-cells14 and pro-inflammatory cytokines.15 Failing of the homeostasic balance between 
CD4+ T-cell destruction and regeneration, leads to a critical effector T-cell population 
loss,16 resulting in the Acquired Immune Deficiency Syndrome (AIDS). AIDS is the last 
stage of HIV-infection, defined by a CD4+ T-cell count below 200 cells/mm3 or the presence 
of an AIDS-defining illness, which are opportunistic infections or certain types of cancer, 
and ultimately death. However, this lethal chain of events can be reversed by combination 
antiretroviral therapy; cART. Antiretroviral therapy has become increasingly effective over 
the last decades in inhibiting the replication of HIV and enabling the restoration of the im-
mune system. The drugs used in antiretroviral therapy for HIV can be categorized as CCR5 
antagonists, fusion and entry inhibitors, non-nucleoside reverse transcriptase inhibitors 
(NNRTI), reverse transcriptase inhibitors that are nucleoside/nucleotide analogues (NRTI), 
integrase inhibitors (INSTI) and protease inhibitors (PI), based on their target in the HIV 
replication cycle (Figure 1). A cART regimen consists of a combination of drugs from dif-
ferent classes. According to all commonly used guidelines17-21 the preferred initial treatment 
for all cART naïve patients consists of two NRTIs combined with either an NNRTI, a PI with 
a pharmacoenhancer (also called a booster) or an integrase inhibitor. Very recent studies, 
however, have shown equal effectiveness with combinations of 2 drugs instead of 3, and thus 
the guidelines might be adapted on short notice.22-24
After the introduction of cART, the life-expectancy of people living with HIV is now ap-
proaching the life-expectancy of the non-HIV infected general population in the Western 
world.25 Additionally, cART significantly reduces new HIV transmissions to HIV-negative 
sexual partners either by treatment of the HIV-positive partner (Treatment as prevention; 
TASP)26,27 or by treating the HIV-negative partner prior to sexual intercourse (Pre-exposure 
prophylaxis; PREP).28 Although these therapeutic strategies are highly effective, cART is not 
curative and cessation leads to a rebound of HIV viremia. Treatment of HIV requires a life-
long commitment to medication with the risk of adverse effects, sometimes severe, which 
have been reported for all drugs used in cART regimens. Besides HLA-B*57:01, a marker to 
predict hypersensitivity for abacavir, no other biomarkers or genetic susceptibility traits are 
known to predict the occurrence of adverse events during cART use.
Thus HIV treatment needs to be further ameliorated, in order to diminish adverse reactions 
during cART use, and new biomarkers to predict adverse reactions would be very helpful 
tools. Both the replication of HIV and the mechanism of action of the NRTIs, the backbone 
of the cART regimens currently recommended in the HIV treatment guidelines, depend for 
an important part on the human nucleotide metabolism. Further, also in other viral infec-
tions, like hepatitis C (HCV), hepatitis B (HBV) and herpesviridae, nucleotide analogues 
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are used in the treatment. Knowledge regarding the nucleotide metabolism is therefore 
important to improve inhibition of HIV replication and decrease adverse events during 
therapy with nucleotide analogue drugs in HIV and various other infectious diseases.
HumaN NuCleOTIde meTabOlIsm
Canonical nucleotides
Nucleotides are the building blocks of DNA and RNA, and the basis for the function of all 
cells in all living species (including humans). In humans, DNA is located in the nucleus 
(chromosomal DNA) and in the mitochondrion (circular mtDNA). Nucleotides contain a 
nucleobase, a deoxyribose (together a nucleoside) and a phosphate group (Figure 2a). In 
RNA the nucleoside contains a ribose instead of a deoxyribose.
DNA is composed of 2 strings of nucleotides, bound together via the nucleobases by hy-
drogen bonds and forming the genetic code (Figure 2b). The nucleobases incorporated in 
nucleic acids are adenine, guanine, cytosine and thymine, and are considered the canonical 
nucleobases. These nucleobases can be divided in 2 groups according to their chemical 
structure. Cytosine and thymidine (and uracil in RNA) are pyrimidines and have a core in 
figure 1. HIV replication cycle and drug targets for combination antiretroviral therapy. Adapted from: Deeks, 
S.G.; Overbaugh, J.; Phillips, A.; Buchbinder, S.; HIV Infection. Nature Reviews Disease Primers, October 2015; Vol 
1; p1-22. Licensed by Springer Nature RightsLink.
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the shape of a pyrimidine ring (C4H4N2). Adenine and guanine are purines and have a core 
consisting of a heterocyclic aromatic ring (with the same structure as the pyrimidine ring) 
fused to a imidazole ring (C3H4N2) (Figure 3).
figure 2a. Chemical structure of nucleoside and nucleotide 5’-mono-, di- and triphosphate. Adapted from: 
Yikrazuul, own work, general overview of nucleotides and nucleosides, may 26th 2010, URL https://commons.
wikimedia.org/wiki/File:Nucleotide_nucleoside_general.svg, accessed June 28th 2018.
figure 2b. Schematic DNA structure (left ) and nucleobase bonds (right). Adapted from: Pearson Education, 
Inc., publishing as Pearson Benjamin Cummings, URL http://logyofb io.blogspot.com/2016/02/structure-of-dna-
and-nucleotides.html, accessed June 28th 2018.
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role of canonical nucleotides in human metabolism
Besides being building blocks for DNA, the nucleotides have additional important functions 
in the human cell metabolism. The nucleotide-5’-triphosphates function as energy carriers 
because energy is released when the phosphate groups are hydrolysed from the nucleoside 
base by kinases. From the nucleotide-5’-triphosphates, adenosine 5’-triphosphate (ATP) is 
the most preferred nucleotide for most cellular processes. The preference for ATP has been 
observed in a large study investigating over 200 kinases and found that most had affinity for 
ATP and only a small number of the kinases exhibited affinity for guanosine 5’-triphosphate 
(GTP).29 Further, cyclic nucleotides act as secondary messengers, transducing signals from 
outside the cells to intracellular. For example: the primary messenger epinephrine stimulates 
the liver cell via triggering the secondary messenger cyclic adenosine 3’5’-monophosphate 
(cAMP) to convert glycogen to glucose (glycogenolysis).30 cAMP is generated from ATP 
by adenylyl cyclase and has three major targets in most cells: protein kinase A (PKA), 
exchange proteins activated by cAMP (Epacs) and cyclic-nucleotide-gated ion channels.31 
PKA phosphorylates numerous metabolic enzymes, among which enzymes regulating 
glycogen, sugar and lipid metabolism, depending on the cell type. The Epac proteins are 
involved in multiple cellular functions such as (among others) cell adhesion, cell differentia-
tion, apoptosis and secretion.32-34 Cyclic guanine 3’5’-monophosphate (cGMP), produced 
from GTP by two families of guanylyl cyclases: transmembrane particulate guanylyl cyclase 
(pGC) and soluble guanylyl cylclase (sGC), activate protein kinase G (PKG). PKG phos-
phorylates several enzymes responsible for multiple cellular processes, like vascular tone 
and remodeling, neuronal adaptation, intestinal water secretion and bone growth.35 cGMP 
modulates cAMP concentration36 and, like cAMP, also regulates cyclic nucleotide-gated 
ion channels.37 Nucleotides are also important constituents of the coenzymes nicotinamide 
adenine dinucleotide (NAD+), nicotinamide adenine dinucleotide phosphate (NADP+) and 
Flavin adenine dinucleotide (FAD), which play a role in oxidation-reduction reactions. 
And finally, nucleosides are involved in the synthesis of polysaccharides, for instance UDP-
glucose which is an intermediate in the glycogen synthesis in mammals.38
figure 3. Chemical structure of the canonical pyrimidines and purines.
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Purine nucleotide synthesis
In the human metabolism two pathways of purine nucleotide synthesis exist: the ‘de novo’ 
synthesis pathway, in which the purine base is synthesized step by step on the ribose-5’-
phosphate, and the salvage pathway, in which a ribose-5’-phophate is added to the preformed 
purine base or phosphates are added to a preformed, or rather recycled, purine nucleobase. 
In the de novo purine synthesis pathway (Figure 4), inosine 5’-monophosphate (IMP) is 
formed from the active form of ribose: 5-phosphoribosyl-1-pyrophosphate (PRPP) through 
10 enzymatic steps. IMP is further converted into either adenosine 5’-monophosphate 
(AMP) or guanosine 5’-monophosphate (GMP) in two final steps (Figure 5). To form AMP, 
first the carbonyl oxygen atom at C6 is substituted for an amino group on which aspartate 
is added by the enzyme adenylosuccinate synthetase. Finally, fumarate is released from 
the amino group by adenylosuccinase. GMP is formed by oxidation of IMP at C2 by IMP 
dehydrogenase using NAD+ and H2O, followed by transfer of the amido-N of glutamine to 
the C2 position by GMP synthetase. Note that for the synthesis of AMP, GTP is used and for 
the synthesis of GMP, ATP is used.
figure 4. Purine nucleotide de novo pathway. Inosine 5’-monophosphate (IMP) is formed from 5-phospho-
ribosyl-1-pyrophosphate (PRPP) in 10 enzymatic steps: (1) glutamine phosphoribosylpyrophosphate amido-
transferase (GPAT activity - PPAT gene); (2) glycinamide ribonucleotide synthetase (GARS activity - GART 
gene); (3) glycinamide ribonucleotide formyltransferase (GART activity - GART gene); (4) phosphoribosyl-
formylglycinamide synthase (PFAS activity - PFAS gene); (5) aminoimidazole ribonucleotide synthetase (AIRS 
activity - GART gene); (6) aminoimidazole ribotide carboxylase (AIRC activity - PAICS gene); (7) succinyl-
aminoimidazolecarboxamide ribonucleotide synthetase (SAICAR activity - PAICS gene); (8) adenylosuccinate 
lyase (ADSL activity - ADSL gene); (9) 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase 
(AICARFT activity - ATIC gene); (10) IMP cyclohydrolase (IMPCH activity - ATIC gene). From: Lane A.N. and 
Fan T.W.-M. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Research, 2015, 
Vol 43(4): p.2466-2485.
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In erythrocytes the ‘de novo’ pathway is absent, so the erythrocyte relies completely on 
the salvage pathway (Figure 6) for the requirement of the purine nucleotides. The salvage 
pathway provides a way to utilize purine bases derived from diet (exogenous) or from the 
normal turnover of nucleic acids (endogenous) and reconverts these purine bases to their 
corresponding nucleotides by phosphoribosylation. As in the de novo synthesis pathway, 
PRPP serves as the activated ribose-5-phosphate. The enzymes involved in the process of 
resynthesis of nucleotides from bases are adenine phosphoribosyltransferase (APRT) for 
adenine and hypoxanthine-guanine phophoribosyltransferase (HGPRT) for hypoxanthine 
and guanine. Thereafter, the purine nucleosides are degraded in several steps to the ultimate 
end product uric acid, which is excreted in the urine.
NrTIs in HIV
The mechanism of action of the NRTIs, used as backbone of the cART regimens currently 
recommended in HIV treatment guidelines, is based on the human nucleotide metabolism. 
Abacavir, tenofovir disoproxil fumarate (from now on referred to as tenofovir) and didano-
sine (which is currently no longer widely used) are NRTIs resembling the natural purine 
nucleosides (Figure 7); abacavir and didanosine being guanosine nucleoside analogues and 
tenofovir being an adenine nucleotide analogue.
These drugs are first metabolized inside the cells and converted to their active 5’-triphos-
phate forms. For instance, carbovir is the active ’triphosphate’ form of abacavir. The ac-
tive 5’-triphosphate forms compete with the natural purine nucleotide triphosphates for 
incorporation in the growing viral DNA, but due to the lack of a 3’-hydroxyl group, the next 
nucleotide cannot be added to the DNA strand and further DNA synthesis is terminated.
figure 5. Interconversion of purines; synthesis of AMP and GMP from IMP. Adapted from: Berg J.M., Tymoczko 
J.L. and Stryer L. Biochemistry. 5th edition 2002. New York: W.H. Freeman.
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figure 6. Purine salvage pathway. PNP, Purine nucleotide phosphorylase; APRT, Adenine phosphoribosyl-
transferase; HGPRT, Hypoxanthine-guanine phosphoribosyltransferase; AMP, Adenosine 5’-monophosphate; 
IMP, Inosine 5’-monophosphate; XMP, Xanthosine 5’-monophosphate; GMP, Guanosine 5’-monophosphate; 
NMPK, Nucleoside monophosphate kinase; ADP, Adenosine 5’-diphosphate; IDP, Inosine 5’-diphosphate; 
XDP, Xanthosine 5’-diphosphate; GDP, Guanosine 5’-diphosphate; NDPK, Nucleoside diphosphate kinase; 
ATP, Adenosine 5’-triphosphate; ITP, Inosine 5’-triphosphate; XTP, Xanthosine 5’-triphosphate; GTP, Guano-
sine 5’-triphosposphate.
figure 7. Chemical structures of the purine analogues non-reverse transcriptase inhibitors, abacavir, didano-
sine and tenofovir and their resemblance with the natural purine nucleosides guanosine and adenosine.
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Non-canonical nucleotides
Besides the canonical purine nucleobases (adenine and guanine), other non-canonical 
nucleobases exist that are not building blocks of the genetic code. For instance, xanthine 
and hypoxanthine are important non-coding intermediates in purine metabolism. Their 
respective ribonucleosides are xanthosine and inosine (see Figures 6 and 8). There are also 
extraordinary metabolites like 8-oxo-deoxyguanosine that are damaged, potentially harm-
ful, non-canonical purines.
The non-canonical nucleotides are formed when canonical nucleotides are damaged by 
oxidative stress and deamination.39-41 While the role of the canonical adenine and guanine 
based nucleotides is extensively studied, the potential role of the non-canonical purine 
based nucleotides xanthosine and inosine in the human metabolism has not yet been fully 
clarified and may be both beneficial and harmful. Inosine, inosine 5’-triphosphate (ITP) 
and to a lesser extend also inosine 5’-diphosphate (IDP) and IMP were found to have anti-
inflammatory effects.42-44 Cyclic ITP (cITP) may function as a second messenger.45 On the 
other hand, incorporation of deaminated nucleotides like deoxy-Inosine 5`-triphospate 
(dITP) and deoxy-Xanthosine 5`-triphosphate (dXTP) into DNA and RNA is thought to 
have mutagenic consequences.46,47 Multiple enzymes have been described that clear the 
cellular nucleotide pool from these potential harmful non-canonical nucleotides.48 One of 
those enzymes is Inosine 5’-triphosphate pyrophosphohydrolase (Inosine triphosphatase 
or ITPase), which dephosphorylates ITP to IMP and xanthosine 5`-triphosphate (XTP) to 
xanthosine 5`-monophosphate (XMP). IMP and XMP are further processed to the canoni-
cal nucleotides AMP and GMP as described above (Figures 5 and 6).
figure 8. Chemical structures of the non-canonical purine nucleobases Xanthine and Hypoxanthine and the 
nucleotide Inosine 5’-triphosphate.
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INOsINe TrIPHOsPHaTe PyrOPHOsPHOHydrOlase (ITPase)
substrates, expression and function
In 1964 Liakopoulou and Alivisatos were the first to describe this enzyme in human eryth-
rocytes, found it to be very specific for ITP49 and called it ITP phosphohydrolase (ITPase). 
Their initial conclusion that ITPase hydrolysed ITP to IDP and further to IMP was refuted 
by Vanderheiden, who showed in his experiments that IDP was not involved in the reaction 
and that ITPase pyrophosphohydrolysed ITP to IMP.50 The natural substrates for ITPase are 
ITP, dITP and XTP.51 Potentially the enzyme is somewhat promiscuous, for (d)GTP, (d)ATP, 
(d)CTP, TTP and UTP were found in some assays to be pyrophosphohydrolysed by ITPase, 
although 10-100 fold less efficient.51 It was shown that (d)IMP and (d)IDP are no substrates 
at all, and that IDP is in fact an inhibitor of ITPase.52 The specificity of ITPase for (d)ITP 
and XTP is unusually high compared to other enzymes of the nucleotide metabolism53 and 
this is probably due to the structure of the enzyme (Figure 9).54 ITPase consists of two 
monomers of 21.5 kDa, composed of 194 amino acids, forming a dimer. Each monomer 
consists of a long central β-sheet forming the floor of the active site, with an upper and a 
lower lobe, between which the substrate binds. The substrate specificity for ITP and XTP 
is explained by the hydrogen bonds they can form with the active site, while ATP and GTP 
have amino-groups in those binding locations, which do not allow hydrogen bonding.55 Be-
cause neither of the ribose hydroxyl groups make strong contacts with the protein, ITPase 
can utilize both ITP as well as dITP.55
ITPase is not only expressed in erythrocytes but in a wide range of human tissues (from 
leukocytes, bone marrow and lymph nodes to solid organs, skeletal muscle, spinal cord and 
reproductive organs).51,52 Both the specificity of the enzyme for (d)ITP and XTP and the 
fact that ITPase is more or less ubiquitously expressed in human tissues are consistent with 
the hypothesis that ITPase cleans the nucleotide pool from potential harmful nucleotides. 
Indeed, in embryos of mice with no ITPase activity, eight times higher levels of deoxy Ino-
sine were found in the nuclear DNA compared to control mice embryos. Furthermore, the 
embryonic fibroblasts of these ITPase devoid mice embryos showed increased chromosome 
aberrations and accumulation of single-strand breaks in the nuclear DNA.46
Genetic basis of ITPase deficiency
In 1969 Vanderheiden measured elevated levels of ITP in the erythrocytes of different fami-
lies. He suggested that these high levels of ITP were due to ITPase deficiency and that this 
deficiency was an inheritable trait.56 In 1980, analysis of a de novo translocation between 
chromosomes X and 20 of a 13-year-old female showed that the gene ITPA encoding for 
ITPase was appointed to the short arm of chromosome 20.57 However, it was not until 2001 
that the ITPA gene was cloned and characterized.51 One year later five single nucleotide 
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polymorphisms (SNPs) in this gene were identified. Three silent SNPs (138G>A, 561G>A 
and 708G>A) and two SNPs that lead to decreased ITPase activity: 94C>A (p.Pro32Thr, 
rs1127354) and 124+21A>C (or IVS2+21A>C, rs7270101). The 94C>A missense mutation 
leads to a substitution of proline to threonine amino acid at codon 32. This substitution dis-
rupts the protein structure (Figure 9) and also leads to missplicing of exons 2 and 3.58,59 Only 
homozygotes for the 94C>A SNP have nearly complete ITPase deficiency in erythrocytes, 
in the 94C>A heterozygotes 23% of the ITPase activity remains.58 The 124+21A>C SNP 
leads to a less severe state of ITPase deficiency, by miss-splicing exon 3 only,59 resulting in 
60% of mean ITPase activity in heterozygotes and 30% in homozygotes.58,60 The distribution 
of the ITPA SNPs varies within the different world populations. The 94C>A mutation is 
highest in Asian populations (14-19%) compared to Caucasian/African populations (6-7%) 
and Central/South American (1-2%).61 The 124+21A>C SNP is extremely rare in Asian 
populations,62,63 but more frequent in Caucasian populations (11-13%).58,64,65 Since then, 
more SNPs have been identified, with varying degrees in residual ITPase activity.60,62,66 
figure 9. Structure of the Inosine triphosphate pyrophosphohydrolase enzyme. In blue: the unbound (apo) 
structure, in pink: the ITP-bound structure. The site of the SNP 94C>A (p.Pro32Thr, rs1127354) which leads to 
a decreased activity of the enzyme is indicated by an arrow for both monomers. Adapted from: Stenmark, P. et al. 
Crystal structure of human inosine triphophatase. Substrate binding and implication of the inosine triphosphatase 
deficiency mutation P32T. The Journal of Biological Chemistry 2006, 282(5): 3182-3187.
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Phenotypic correlation of ITPase deficiency with human diseases 
Over the years, multiple studies have been done to find phenotypic abnormalities in indi-
viduals with SNPs in the ITPA genotype or a decreased ITPase activity. The first to report an 
increased incidence (16%) of ‘High ITP’ in a mentally retarded population versus a popula-
tion with normal intelligence (3%), was Fraser67 in 1975. Additionally, in chronic paranoid 
schizophrenic patients a significant decrease in ITPase activity was found compared to a 
non-psychiatric control population.68 In 2015 the association between Early Infantile En-
cephalopathy was found in 7 patients with several pathogenic mutations in ITPA that led to 
a severe degree of ITPase deficiency not restricted to erythrocytes.66 And recently, in 2018, 
two families with a very distinctive clinical presentation of lethal infantile-onset dilated 
cardiomyopathy and the rare Martsolf syndrome, which is characterized by congenital 
cataracts, postnatal microcephaly, developmental delay, hypotonia and short stature, were 
found to have mutations in the ITPA gene leading to undetectable ITPase protein.69
A connection between ITPA mutations and malignancy has been hypothesized, although 
studies investigating this subject are still sparse. In one study an increase in mitochondrial 
DNA mutations was found in adult hematology patients (consisting of myelodysplastic 
syndrome, acute myeloid leukemia and chronic lymphocytic leukemia patients), carrying 
the 94C>A SNP, compared to patients carrying wild-type ITPA.70 In another study ITPA is 
mentioned as one of the genes mutated in adenocarcinoma of the pancreas.71
One study reported on an unusually high prevalence of decreased ITPase activity and ITPA 
genotypes with SNPs in patients with pulmonary Langerhans’ cell histiocytosis compared to 
a reference population (50% versus 11% respectively).72 
THe rOle Of ITPA sNPs IN druG meTabOlIsm
ITPA SNPs have been found to influence drug metabolism of azathioprine and its active 
metabolite mercaptopurine, methotrexate and ribavirin. Azathioprine is used as an im-
munosuppressive drug prescribed after organ transplantation, and for multiple autoim-
mune diseases, like inflammatory bowel disease, rheumatoid arthritis and systemic lupus 
erythematosus. Azathioprine is metabolized to mercaptopurine (6-MP) which is then 
further metabolized by multiple enzymatic steps of the purine salvage and interconver-
sion pathways, including ITPase. In 2004, an association between adverse drug reactions of 
azathioprine such as influenza-like symptoms, rash and pancreatitis was described for the 
ITPA SNP 94C>A in a cohort of patients treated for inflammatory bowel disease.73 However, 
these findings could not be confirmed in another study.74 Since then, some studies reported 
an association between the 94C>A SNP and bone marrow depression such as decreased 
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leukocytes75-77 or agranulocytosis,78 flu-like symptoms79 or arthralgia,80 but in other studies 
no association could be demonstrated81-84 in patients with inflammatory bowel disease. Also 
the outcome of azathioprine therapy was not clearly associated with ITPA SNPs.80,85 SNP 
124+21A>C was in all the studies but one86 not associated with adverse events.75,77,80,81,83,84 
In patients with systemic lupus erythematosus (SLE) 94C>A was associated with a better 
response to low-dose azathioprine therapy,87,88 but in patients with renal or liver transplants 
studies were inconclusive.89-91 Taken together, in adult patients treated with azathioprine, 
the SNP 94C>A is associated with adverse events, although not undisputed.
In children treated with mercaptopurine (6-MP) for acute lymphoblastic leukemia the SNP 
94C>A in the ITPA gene was associated with hepatic toxicity,92-94 decreased leukocytes94-96 
and decreased event-free survival,97 although again, these findings were not undisputed, 
as another study found the opposite effect on event-free survival in a comparable group of 
patients.98 In patients treated with methotrexate for rheumatoid arthritis the SNP 94C>A a 
possible association with a worse clinical response was found.99,100 
ITPA, ITPase aNd INfeCTIOus dIseases
Hepatitis C
In patients treated with PEG-Interferon gamma and ribavirin for a hepatitis C virus (HCV) 
infection, the effect of SNPs in the ITPA gene on the occurrence of anemia and hemoglobin 
(Hb) decline is extensively studied.101-107 In a meta-analysis by Pineda-Tenor in 2015,108 the 
SNPs 94C>A, 124+21A>C and rs6051702 were all associated with protection against Hb 
decline. Furthermore, 94C>A was also significantly associated with protection against the 
occurrence of severe anemia and the necessity for ribavirin dose reduction during therapy. 
None of these studies investigated the association between ITPase activity and the occur-
rence of anemia and the degree of Hb decline.
HIV
In spite of a genotype distribution comparable to a non-HIV infected population, ITPase 
activity was found to be significantly decreased in erythrocytes of HIV-infected patients 
compared to a non-HIV infected control population.64 However, no further studies were 
done to investigate whether this affected the occurrence of adverse events during the 
use of cART. For replication, HIV depends on the nucleotide metabolism of the infected 
host. For instance, HIV uses reverse transcriptase to convert its single-stranded RNA into 
double-stranded DNA, using the nucleotides available in the human cell, and further tran-
scribes new RNA from this DNA after incorporation into the human genome, using the 
human nucleotide mechanism. The NRTIs are analogues of the natural ribonucleotides and 
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compete with these natural ribonucleotides for incorporation in the growing RNA chain. 
When incorporated, further RNA synthesis is stopped (chain termination) because of the 
NRTIs miss a 3’-hydroxyl group on the deoxyribose. To further improve HIV therapy by 
decreasing adverse events, more insight into the association between ITPA genotypes and 
ITPase activity on the one hand and adverse events during use of cART on the other hand 
could be important. Anti-retroviral drugs mimicking all nucleobases exist, but since ITPase 
is an enzyme in the human purine metabolism, we concentrated on the drugs abacavir (a 
guanosine analogue) and didanosine and tenofovir (adenosine analogues).
OuTlINe Of THe THesIs
The general aim of this thesis is to investigate the influence of the ITPA genetic SNPs 94C>A 
and 124+21A>C and the activity of the enzyme ITPase on the occurrence of adverse events 
during treatment for the infectious diseases HCV and HIV. While ITPA SNPs were previ-
ously found to be protective against hemolytic anemia during therapy with ribavirin for 
HCV, it is not clear to what extent other SNPs contribute to ITPase activity. Therefore, in 
Chapter 2, ITPase activity is compared with ITPA genotype for prediction of anemia during 
ribavirin use for HCV.
In HIV-infected patients the ITPase activity in erythrocytes was found to be decreased 
compared to a population not infected with HIV. As leukocytes are the main target cells 
for HIV-infection, in Chapter 3 the expression of the ITPase protein in leukocytes and 
leukocyte subpopulations is explored in association with ITPA genotype. The results in 
HIV-infected patients are compared to a non-HIV infected population.
As the current therapy for HIV is highly effective, the main obstacle for treatment nowadays 
is adverse events during cART. In Chapter 4, we investigate the association of ITPase activ-
ity and ITPA genotype with the occurrence of adverse events during combination antiret-
roviral therapy for HIV. One of the most important adverse drug events during tenofovir 
use is nephrotoxicity. In order to test if ITPase activity and ITPA genotype could be used 
as a biomarker to predict nephrotoxicity during tenofovir use for HIV,these parameters are 
determined and compared in HIV-infected patients with and without nephrotoxicity, in 
Chapter 5.
Other important aspects brought on by the current effective HIV therapy, are long term 
consequences of cART and increasing diseases of older age, one of them being cardiovas-
cular diseases. The association of ITPase activity and ITPA genotype with the occurrence 
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of cardiovascular diseases and metabolic events during cART for HIV-infection is further 
explored in Chapter 6.
To further unravel effects caused by HIV-infection itself and effects caused by cART, in 
Chapter 7, basic cell metabolomics of untreated HIV-infected patients are compared to 
a control population (the effect of HIV-infection). In addition metabolomics data prior 
to start of cART were compared to 12 months of therapy successfully suppressing HIV 
replication (the effect of cART).
In Chapter 8 the results of these studies are discussed with respect to future perspectives.
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absTraCT
background
ITPA polymorphisms have been associated with protection against ribavirin-induced ane-
mia in chronic hepatitis C (HCV) patients. Here we determined the association of inosine 
5’-triphosphate pyrophosphohydrolase (inosine triphosphatase or ITPase) enzyme activity 
with ITPA genotype in predicting ribavirin-induced anemia.
methods
In a cohort of 106 HCV patients, hemoglobin (Hb) values were evaluated after 4 weeks 
(T4) and at the time of lowest Hb value (Tnadir). ITPase activity was measured and ITPA 
genotype determined. Single-nucleotide polymorphisms (SNPs) tested were c.124+21A > C 
and c.94C> A. ITPase activity  ≥ 1.11 mU/mol Hb was considered as normal.
results
After 4 weeks of treatment, 78% of the patients with normal ITPase activity were anemic 
and 21% of the patients with low ITPase activity (p< 0.001). Stratified by genotype, the 
percentages of anemic patients were: wt/wt 76%, wt/c.124+21A > C 46% (p = 0.068), and 
wt/c.94C> A 29% (p =0.021). At Tnadir virtually all patients with normal ITPase activity were 
anemic, compared to only 64% of the patients with low activity (p= 0.02). Thirteen patients 
had wt/c.124+21A> C genotype. Within this group all five patients with normal ITPase 
activity and only four of eight with decreased activity developed anemia. Presence of HCV 
RNA did not influence ITPase activity.
Conclusions
This study is the first to report that ITPase activity predicts the development of anemia 
during ribavirin treatment. ITPase activity and ITPA genotype have high positive predic-
tive values for development of ribavirin-induced anemia at any time during treatment, but 
ITPase activity predicts ribavirin-induced anemia more accurately.
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INTrOduCTION
The prevalence of hepatitis C (HCV) infection is estimated at approximately 2.2%–3% of 
the world population (130– 170 million people).1 The life expectancy of infected patients is 
reduced significantly because of high risks for liver cirrhosis and hepatocellular carcinoma.2 
HCV therefore is one of the main reasons for liver transplantation in Europe and the US.3,4 
In order to prevent these complications, patients with HCV infection have been treated with 
the combination of pegylated-interferon-α plus ribavirin,5-7 in later years combined with 
protease inhibitors, such as telaprevir8 or boceprevir9 and since recently simeprevir10 or the 
nucleoside polymerase inhibitor sofosbuvir.11 Response to anti-HCV therapy is influenced 
by both viral and host factors as well as drug toxicity.12 Viral genotype has been a strong pre-
dictor for treatment response. While viral remission is around 70%–80% in patients infected 
with HCV genotypes 2 and 3, only 50%–60% of the patients with HCV genotypes 1 and 4 
acquire a sustained virological response (SVR).13 Host factors contributing to therapeutic 
outcome have been identified as single-nucleotide polymorphisms (SNPs) in the IL28B and 
LDLR genes.14-18 An important and common adverse drug reaction limiting optimal HCV 
therapy is ribavirin-induced anemia. It has been demonstrated that two functional ITPA 
SNPs, rs1127354 (c.94C > A) and rs7270101 (c.124+21A > C), are associated with protection 
from ribavirin-induced anemia.19-25 
In recent years, the biological and pharmacogenetic significance of ITPA and its corre-
sponding enzyme inosine 5’-triphosphate pyrophosphohydrolase (inosine triphosphatase 
or ITPase) have become a focal point of research, bringing many interesting and surprising 
data. Complete ITPase deficiency is strictly confined to erythrocytes and is considered to 
be a benign condition. No primary, causal, clinical symptoms are known under normal 
circumstances. However, ITPase activity lowering SNPs in ITPA are associated with adverse 
drug reactions to the thiopurines azathioprine and 6-mercaptopurine. This association is 
still subject of a lively discussion.26-30 The pharmacogenetic significance of ITPA appeared 
not to be limited to the thiopurines, but may also be of significance for the purine analog 
ribavirin. In our present study we demonstrate that ITPase activity seems a more accurate 
predictor for ribavirin-induced anemia than ITPA genotype.
maTerIals aNd meTHOds
Patients
Consecutive HCV infected patients attending the outpatient clinic of the Erasmus Medical 
Center in Rotterdam, The Netherlands were included during 6 months with the aim of 
inclusion of 100 patients. The following data were collected: gender, age, hemoglobin (Hb), 
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white blood cell count (WBC), HCV genotype and HCV RNA in serum, type of medication, 
start and end of treatment, and treatment outcome. Treatment was given according to the 
Dutch national guidelines at that time31 with peginterferon-α-2a or peginterferon-α-2b (in 
a dosage of 180 μg or 1.5 μg/kg once a week), in combination with ribavirin 800–1200 mg a 
day depending on patient weight. One patient also received boceprevir and one patient also 
received miravirsen in addition to the ribavirin and peginterferon-α.
Plasma HCV-RNA levels were measured with the use of the COBAS AmpliPrep/COBAS 
TaqMan HCV assay, version 1.0 (Roche molecular systems) from October 2008 until March 
2012, version 2.0 (Roche molecular systems) was used from March 2012 until June 2012. 
Anemia was defined as Hb reduction of  ≥ 1.9 mmol/L compared to pre-treatment values 
and/or Hb concentrations < 7.5 mmol/L for females and  <8.0 mmol/L for males.22,32
The study was performed according to the Helsinki Declaration and approved by the Medi-
cal Ethical Committees of the Erasmus Medical Center, Rotterdam, The Netherlands. The 
participants provided their written informed consent to participate in this study.
ITPase activity
ITPase activity was determined as described previously with some minor modifications33 
and measured by formation of inosine 5’-monophosphate (IMP) from ITP. Briefly, 3 μL 
whole blood was incubated with 2.00 mM ITP, 50 mM MgCl2 , 0.5 mM Dithothreitol (DTT) 
and 0.2 mM α-,β-methyleneadenosine 5’-diphosphate (AMP- CP) in 75 mM Tris in a final 
volume of 200 μL. All chemicals were of the highest grade and purchased from Sigma-
Aldrich (Zwijndrecht, The Netherlands).
Samples were prepared and analyzed in duplicate. In addition, blanks (negative controls) 
and pool samples (positive controls) were also analyzed for ITPase activity to confirm cor-
rect sample preparation, analysis and quality control. High performance liquid chromatog-
raphy (HPLC) separations were performed on a Supelcosil LC-18 S column (Sigma-Aldrich, 
Zwijndrecht), using an Alliance separation system (Waters, Etten-Leur, The Netherlands) 
coupled to a Jasco multi-wavelength detector (Jasco Benelux, IJsselstein, The Netherlands). 
Data were analyzed with TotalChrom data acquisition and handling software (Perkin-Elmer, 
Groningen, The Netherlands). ITPase activity was expressed as milliUnits of IMP formed 
from ITP per mol hemoglobin (mU/mol Hb). The intra-assay variation coefficient was  < 5%, 
and the inter-assay variation coefficient was  < 10%. The cut-off value discriminating between 
normal or decreased ITPase activity was set at 1.11 mU/mol Hb (= 4 mmol IMP/mmol 
Hb/h), which is the lowest value within the 95% CI for ITPA wild type (wt/wt) carriers.34,35
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ITPA genotype analysis
Genomic DNA was isolated from whole blood using the Wizard Genomic DNA purifi-
cation kit (Promega, Madison, WI, USA) and genotyped for two ITPA polymorphisms; 
wt/c.94C > A (p.Pro32Thr, rs1127354) and wt/c.124+21A> C (rs7270101). When no poly-
morphisms were detected at both positions and the ITPase activity was within the wt/wt 
reference intervals, the genotype was considered to be wt/wt. M13-tagged primers forward 
5’-TGTAAAACGACGGCCAGTCTTAGGAGATGGGCAGCAG and 5’-CAGGAAA-
CAGCTATGACCCACAGAAAGTCAGGTCACAGG reverse were used in a PCR reaction, 
which consisted of 1 x Amplitaq Gold Mastermix (Applied Biosystems, Nieuwerkerk a/d 
IJssel, The Netherlands), 8% glycerol, and 200 nM of each primer. PCR conditions were 
40 cycles with an annealing temperature of 60°C. The resulting 241 bp PCR product was 
purified and directly sequenced in both directions using the Big Dye Terminator kit and was 
subsequently analyzed on an ABI 3720 Genetic Analyzer (Applied Biosystems, Carlsbad, 
CA, USA). The resulting sequence was aligned with ITPA reference sequence NM_033453.2. 
All sequences were evaluated by two independent laboratory experts.
statistical analysis
Results were analyzed using GraphPad Prism 5.01 (Graphpad Software for Windows, San 
Diego, CA, USA), Microsoft Excel (Microsoft, Redmond, WA, USA) software and IBM SPSS 
Statistics 20 (IBM Corporation, New York, NY, USA) software. Pearson’s χ2-tests, Fisher’s exact 
tests (in the case of small sample sizes) or T-tests for independent samples were used to de-
termine significant differences. p-Values < 0.05 were considered to be statistically significant.
resulTs
Patient characteristics
A total of 106 HCV infected patients in various stages of infection were included (Table 1). 
In our cohort there was a male predominance and HCV genotype 1 was most prominent. 
In total 69 patients were treated for chronic HCV infection and SVR was reached in 30 
(43.5%) of the patients. The most prominent ITPA genotype was wt/wt (68.9%). The occur-
rence of wt/c.124+21A >C and wt/c.94C > A ITPA genotype variants were 19.8% and 9.4%, 
respectively. One patient was homozygous for c.124+21A > C and one was compound het-
erozygous, i.e. c.124+21A > C/c.94C> A. Our cohort showed expected allele frequencies for 
both loci and did not differ from the reference population.35,36 The population was in Hardy-
Weinberg equilibrium. Age, pre-treatment Hb levels and white blood cell counts were not 
significantly different between patients with different ITPA genotypes. As expected, mean 
ITPase activity correlated with ITPA genotype (Table 1).
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Table 1. Characteristics of the study population
Characteristic Total Population (n=106) Treated Population (n=69)
age, median years (min-max)
Total 51 (20-88) 52 (20-79)
Wt/wt 51 (20-88) 52 (20-79)
Wt/c.124+21A>C 51 (33-76) 52 (39-76)
Wt/c.94C>A 55 (41-65) 54 (41-59)
Gender, n (%)
Male 68 (64.2) 51 (73.9)
Female 38 (35.8) 18 (26.1)
HCV genotype, n (%)
Genotype 1 63 (59.4) 44 (63.8)
Genotype 2/3 28 (26.4) 20 (28.9)
Genotype 4 8 (7.5) 5 (7.2)
Unknown 7 (6.6) -
ITPA genotype, n (%)
Wt/wt 73 (68.9) 49 (71.0)
Wt/c.124+21A>C 21 (19.8) 13 (18.8)
Wt/c.94C>A 10 (9.4) 7 (10.1)
Other 2 (1.8) -
HCV genotype 1, n (%)
Total 63 (59.4) 44 (63.8)
Wt/wt 45 (71.4) 33 (75.0)
Wt/c.124+21A>C 11 (17.5) 7 (15.9)
Wt/c.94C>A 7 (11.1) 4 (9.1)
ITPase mean activitya ± SD
Wt/wt 1.64 ± 0.47 1.67 ± 0.50
Wt/c.124+21A>C 1.01 ± 0.29 1.03 ± 0.37
Wt/c.94C>A 0.46 ± 0.16 0.50 ± 0.17
Other 0.33 ± 0.19 -
absolute ITPase activity (%)
Wt/wt 100%
Wt/c.124+21A>C 62%
Wt/c.94C>A 28%
Other 20%
ITPase mean activitya ± SD
HCV RNA <5 copies/ml 1.44 ± 0.69
HCV RNA ≥ 5 copies/ml 1.34 ± 0.53
ITPase activitya, n (%)
< 1.11 29 (27.4) 16 (23.2)
≥ 1.11 77 (72.6) 53 (76.8)
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Table 1. Characteristics of the study population (continued)
Characteristic Total Population (n=106) Treated Population (n=69)
mean white blood cell countb ± SD 5.9 ± 2.4 5.5 ± 2.4
mean Hb pre-treatmentc ± SD 9.0 ± 1.0
Treatment outcome, n (%)
SVRd 30 (43.5)
Relapse 22 (31.9)
Non-response / termination 17 (24.6)
Spontaneous clearance 7 (6.6)
a mU/mol Hb; b x109/L; c mmol/L; d SVR, Sustained virological response
A
B
figure 1: (A) ITPase activity and HCV viral load. Plasma HCV viral load (copies/ml) is plotted against ITPase 
activity (milliUnits IMP/mol Hb). Neither the presence nor the level of plasma HCV viral load is correlated 
to ITPase activity. HCV, hepatitis C virus; ITPase, inosine triphosphate pyrophosphohydrolase. (B) Associa-
tion of ITPase activity and Hb decrease. ITPase activity (milliUnits IMP/mol Hb) is plotted against maximum 
Hb decrease during therapy. ITPA genotypes are displayed in different shapes (circles: wt/wt, squares: wt/
c.124+21A>C, triangles: wt/c.94C>A). Higher ITPase activity is associated with increased Hb decline. ITPase, 
inosine triphosphate pyrophosphohydrolase; Hb, Hemoglobin.
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Hepatitis C and ITPase activity
ITPase activity was not statistically significantly different in HCV-infected patients and 
non-HCV controls (data not shown).35 Presence or absence of HCV-RNA was not associ-
ated with ITPase activity (Figure 1A), regardless of genotype. In patients with a detectable 
HCV-RNA, the viral load was not associated with ITPase activity (Figure 1A).
Hemoglobin levels and ITPase activity
In total 53 of 77 patients with normal ITPase activity, and 16 of 29 patients with decreased 
ITPase activity were treated with pegylated-interferon-α plus ribavirin. ITPase activity was 
significantly associated with Hb decrease (Table 2, Figure 1B, p <0.001). Of the patients 
having normal ITPase activity, 78.0% (n = 39) were anemic after 4 weeks of therapy (T4), 
compared to 21.4% (n= 3) of the patients with reduced ITPase activity, see Table 2 (p <0.001). 
Exactly 92.2% of patients with normal ITPase activity developed anemia at any moment 
during therapy (Tnadir), compared to 64.3% of patients with low ITPase activity (p = 0.02, 
Table 2). Test characteristics are shown in Table 3. The positive predictive value (PPV) of 
normal ITPase activity was 78% for anemia at 4 weeks and 92% for the development of ane-
mia at any time during therapy. The negative predictive value (NPV) of a decreased ITPase 
activity for the development of anemia was 79% and 36%, respectively, for T4 and Tnadir.
Hemoglobin levels and ITPA genotype
Treatment with pegylated-interferon-α plus ribavirin was started in 49 of 73 patients with 
the ITPA wt/wt genotype, in 13 of 21 patients with ITPA wt/c.124+21A > C genotype and 
Table 2. Comparison of ITPase activity and ITPA genotype in development of anemia, and percentage of suc-
cessful treatment outcome (SVR) in the treated population (n=69).
ITPase activity (mu/mol Hb) ITPA genotype
≥ 1.11
(n=53)
< 1.11
(n=16)
p-value Wt/wt
(n=49)
Wt/c.124+21a>C
(n=13)
p-value Wt/c.94C>a
(n=7)
p-value
Pre-treatment
Hba 9.0 ± 1.0b 8.9 ± 1.0 0.84 9.0 ± 1.0b 8.9 ± 0.7 0.84 9.3 ± 1.3 0.45
T4
Hba 7.3 ± 1.0c 8.7 ± 1.0b <0.001 7.3 ± 1.0c 7.9 ± 1.2b 0.06 8.8 ± 1.4 0.001
Anemia; n (%) 39 (78.0)c 3 (21.4)b <0.001 35 (76.1)c 5 (45.5)b 0.07 2 (28.6) 0.02
Reductiona 1.7 ± 1.1c 0.4 ± 0.4b <0.001 1.7 ± 1.1c 1.1 ± 1.3b 0.17 0.5 ± 0.4 0.006
Tnadir
Hba 5.9 ±1.1b 7.5 ±1.2b <0.001 6.0 ± 1.1b 6.9 ± 1.1b 0.02 7.5 ± 1.5 0.002
Anemia; n (%) 47 (92.2)b 9 (64.3)b 0.02 43 (91.5)b 9 (81.8)b 0.32 4 (57.1) 0.04
Reductiona 3.1 ± 1.1b 1.5 ± 0.7b <0.001 3.0 ± 1.2b 2.2 ± 1.1b 0.04 1.8 ± 0.9 0.012
sVr; n (%) 23 (43.4) 7 (43.8) 0.98 22 (44.9) 5 (38.5) 0.68 3 (42.9) 0.99
aMean ± SD (mmol/L); b Values missing from 2 patients; c Values missing from 3 patients
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in 7 of 10 patients with ITPA wt/c.94C > A genotype. At Week 4 of therapy, anemia was 
observed in 76.1% of the patients carrying ITPA wt/wt, 45.5% of the patients carrying ITPA 
wt/c.124+21A > C (p = 0.07) and 28.6% of the patients with ITPA wt/c.94C>A genotype 
(Table 2, p=0.02).
Anemia at any time during treatment (Tnadir) occurred significantly less frequently in 
patients with the wt/c.94C > A genotype (57.1%) compared to patients with the wt/wt 
genotype (91.5%) (p = 0.04, Table 2). Hb at Tnadir was significantly higher in patients with the 
wt/c.124+21A > C ITPA genotype, and Hb reduction was significantly less compared to wt/
wt ITPA genotype, but there was no difference in frequency of anemia (p =0.32).
ITPase activity vs. ITPA genotype
Of the patients with the wt/c.124+21A >C genotype, 38.5% (5 of 13) had a normal ITPase 
activity (Table 4). Of these five patients, four developed anemia at T4 (80%), whereas in the 
eight patients with the same genotype, but with decreased ITPase activity, only one patient 
became anemic. At Tnadir all wt/c.124+21A > C patients with normal ITPase activity devel-
oped anemia in contrast to only four of the eight patients with decreased ITPase activity.
In all patients carrying wt/c.94C > A ITPA genotype ITPase activity was decreased and 
anemia was present in four of seven patients. Of the wt/wt genotype carrying patients, 48 of 
49 had a normal ITPase activity and the patient with low ITPase activity developed anemia.
PPV for wt/wt genotype and ITPase activity were not different for both T4 and Tnadir (Table 3). 
NPV for the ITPase activity lowering ITPA genotypes (wt/c.124+21A > C and wt/c.94C>A 
together) was lower compared to NPV for ITPase activity  < 1.11 mU/mol Hb for both T4 
(61% vs. 79%) and Tnadir (28% vs. 36%).
Table 3. Comparison of ITPase activity and ITPA genotype in occurrence of anemia after 4 weeks of therapy 
(T4) and at any time during therapy (Tnadir) and positive (PPV) and negative (NPV) predicting test character-
istics.
T4 (n=64) Tnadir (n=65)
anemia No anemia Predictive value anemia No anemia Predictive value
ITPase activitya
≥1.11 39 11 PPV: 78% 47 4 PPV: 92%
<1.11 3 11 NPV: 79% 9 5 NPV: 36%
ITPA genotype
Wt/wt 35 11 PPV: 76% 43 4 PPV: 91%
Wt/c.124+21A>C+Wt/c.94C>A 7 11 NPV: 61% 13 5 NVP: 28%
a mU/mol Hb
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Treatment outcome
SVR was achieved in 43.5% of the patients (n=30), whereas in 56.5% (n = 39) treatment 
failed due to relapse, serological non-response, or termination of therapy because of adverse 
events. SVR was not associated with ITPase activity or ITPA genotype (Table 2), nor with 
anemia (data not shown). Table 5 shows the treatment outcome stratified by HCV genotype. 
Taking into account HCV genotype, still SVR was not associated with ITPase activity (Fig-
ure 2A) or ITPA genotype (Figure 2B). Also per-protocol analysis of the patients adherent to 
the entire treatment regimen, did not show an association between SVR and ITPase activity 
or ITPA genotype (data not shown).
Table 4. Occurrence of anemia in treated patients according to ITPA genotype and ITPase activity after 4 weeks 
of therapy (T4) and at any time during therapy (Tnadir).
ITPA genotype Total, n T4, n (%) Tnadir, n (%)
Wt/wt 49
Activitya <1.11 1
No anemia 1 (100)
Anemia 1 (100)
Activitya ≥1.11 48
No anemia 10 (21) 4 (8)
Anemia 35 (73) 42 (88)
Unknown 3 (6) 2 (4)
Wt/c.124+21a>C 13
Activitya <1.11 8
No anemia 5 (63) 2 (25)
Anemia 1 (13) 4 (50)
Unknown 2 (25) 2 (25)
Activitya ≥1.11 5
No anemia 1 (20)
Anemia 4 (80) 5 (100)
Wt/c.94C>a 7
Activitya <1.11 7
No anemia 5 (71) 3 (43)
Anemia 2 (29) 4 (57)
Activitya ≥1.11 0
No anemia
Anemia
a mU/mol Hb
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Table 5. Treatment outcome per hepatitis C genotype, ITPase activity and ITPA genotype.
HCV genotype Treatment outcome ITPase activitya ITPA genotype
≥ 1.11 
(n=53)
< 1.11 
(n=16)
Wt/wt
(n=49)
Wt/c.124+21a>C 
(n=13)
Wt/c.94C>a 
(n=7)
1
SVRb 11 3 11 2 1
Non-response 6 3 5 2 2
Relapse 16 2 14 3 1
Termination 3 0 3 0 0
2/3
SVRb 11 4 10 3 2
Non-response 1 0 1 0 0
Relapse 0 2 0 1 1
Termination 0 2 0 2 0
4
SVRb 1 - 1 - -
Non-response 2 - 2 - -
Relapse 2 - 2 - -
Termination 0 - 0 - -
a mU/mol Hb; b SVR, sustained virological response
A B
figure 2. (A) The percentages of patients reaching SVR are shown when patients are stratified by hepatitis C 
genotype. No significant differences were observed between patients with ITPase activity ≥1.11 mU/mol Hb 
and with patients with ITPase activity <1.11 mU/mol Hb. SVR, sustained virological response; ITPase, inosine 
triphosphate pyrophosphohydrolase. (B) The percentages of patients reaching SVR are shown when patients 
are stratified by hepatitis C genotype. No significant differences were observed between patients with ITPA 
genotype wt/wt and patients with ITPA genotypes wt/c.124+21A>C and wt/c.94C>A. SVR, sustained virologi-
cal response; wt, wt/wt; 124, wt/c.124+21A>C; 94,wt/c.94C>A.
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dIsCussION
This is, to our knowledge, the first study evaluating the association of ITPase enzyme activ-
ity and ribavirin-induced anemia and comparing it to ITPA genotype in patients treated for 
chronic HCV. All studies evaluating the association of ITPA polymorphisms with ribavirin-
induced anemia assumed that in HCV patients, the reported ITPase activity directly cor-
responds to a specific ITPA polymorphism.19,20,22,23,37 Here we show that an ITPA variant 
such as wt/c.124+21A> C leads to a variety of ITPase activities ranging from as low as 0.19 
to as high as 1.52 mU/mol Hb and association is less direct as has previously been assumed. 
More in depth analysis showed that negative predicting value for ribavirin-associated ane-
mia of the wt/c.124+21A >C genotype was only 18%. Within this group, all the patients with 
normal ITPase activity developed anemia throughout the treatment period, compared to 
50% of the patients with decreased ITPase activity.
Most studies20,22,25,37,38 only investigated Hb values after 4 weeks of therapy as at this time 
point many patients may start with erythropoietin treatment to stimulate red blood cell 
production. In our cohort, mean time to nadir was 4 months with 61% of patients having 
anemia at T4, and 84% having anemia at Tnadir. ITPase activity was statistically significantly 
associated with anemia at both T4 and Tnadir.
In two studies ITPA genotype polymorphisms were found to be protective for anemia dur-
ing the course of the entire treatment.39,40 The predictive value of ITPA genotype was similar 
to that reported in the literature in our hands, despite the small sample size.22,24,37 Differ-
ences in occurrence of anemia were only statistically significant for ITPA wt/wt compared 
to wt/c.94C > A.
No influence of HCV presence or titer could be detected, this is in contrast with our 
observation in human immunodeficiency virus (HIV)-infected population, in which the 
geno-phenotype correlation differs significantly from the reference population.35 Similar 
to ITPA polymorphisms in other studies, ITPase activity was not predictive for SVR in 
our cohort.19,21,37 Some studies report higher SVR rates for patients with ITPase activity 
decreasing ITPA genotypes,25,41 and a recent study reported reduced relapse risk follow-
ing treatment for HCV genotype 2/3 in these genotypes.42 However, probably due to small 
sample size, we were not able to confirm these findings in our study. Addition of the new 
protease inhibitors telaprevir or boceprevir improves response rates to 70% in patients with 
genotype 1.8,9 Although the influence of protease inhibitors and the nucleoside polymerase 
inhibitor sofosbuvir on ITPase activity needs to be established, ribavirin is still a part of 
these treatment regimens and it might be cost saving to prevent adverse events like severe 
anemia by more tailor-made treatment.
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Other purines are still widely used in the treatment of other diseases (i.e., abacavir and teno-
fovir in HIV, azathioprine and 6-mercaptopurine in inflammatory bowel disease and acute 
lymphoblastic leukemia) and may be also influenced by ITPase activity. So even though 
ribavirin is becoming less important in the treatment of HCV infection, further research to 
the impact of ITPA genotype and ITPase activity on the degradation of purine analogs will 
still be important.
Despite the fact that ITPase activity was measured in whole blood, the activities measured 
correlated with the genotype-specific reference values established in erythrocytes in our 
laboratory and by others.35,43,44 Although markedly more men were included in this study, 
this did not influence the assessment of anemia, as gender-specific Hb reference values were 
used.
It is not clear why decreased ITPase activity protects from ribavirin-induced anemia. A di-
rect association between ribavirin levels, ITPase activity and anemia has been hypothesized 
but could not be proven.37 Although it has been reported that ITPase deficiency decreased 
the need for ribavirin dose reduction,40 this could not be confirmed in HCV mono-infected 
patients19 nor in HIV/HCV co-infected patients.45 Thus, direct influence of ITPase activity 
on ribavirin levels does not seem to be a plausible explanation.
Another possible explanation for the assumed protective effect of ITPA SNPs has been sug-
gested by Hitomi et al.,46 who stated that ITPA polymorphisms resulted in decreased ITPase 
activity causing accumulation of ITP. However, ITP was found to only accumulate in the 
erythrocytes of patients homozygous for c.94C> A ITPA genotype variant.44,47 Furthermore, 
Hitomi et al.46 stated that ITP was a substitute for GTP in the generation of AMP by adenylo-
succinate synthetase (ADSS). If this were to be correct, the proposed protective effect could 
only be effective in erythrocytes of patients who are homozygous for c.94C> A. However, 
neither Hitomi and coworkers, nor any other author (including our group) has, to the best 
of our knowledge, demonstrated ADSS activity in erythrocytes. The exact mechanism is still 
not elucidated and needs a more mechanistic approach.
In conclusion, this study is the first to describe the direct correlation of ITPase activity 
and decrease in Hb values during treatment with ribavirin. In addition, we demonstrated 
that ITPase activity is a better pre-treatment parameter to predict ribavirin-induced anemia 
than ITPA genotype.
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absTraCT
Objective
In HIV-infected patients, the enzyme Inosine triphosphate pyrophosphohydrolase (ITPase), 
involved in purine nucleotide homeostasis, was found to be decreased in erythrocytes. Since 
purine analogues are pivotal in the HIV treatment, a better understanding of ITPase expres-
sion in CD4+ lymphocytes may lead to better understanding of nucleotide metabolism and 
(adverse) effects.
design
Cross-sectional, cohort, observational study.
methods
HIV-infected and control patients above 18 years were included. All DNA samples were 
genotyped for the 2 functional ITPA SNPs; c.94C>A (rs1127354) and c.124+21A>C 
(rs7270101). ITPase expression was determined by flow cytometry in all leukocyte subsets.
results
Fifty-nine HIV-infected patients and 50 controls were included. Leukocyte subtype distri-
bution showed no difference in monocytes and granulocytes, but lymphocytes were higher 
in HIV-infected patients (p<0.001). ITPase expression was highest in activated monocytes 
and lowest in lymphocytes. In HIV-infected patients, the percentage of ITPase positive 
cells was less in all leukocyte and lymphocyte subsets compared with controls (p<0.01). In 
HIV-infected patients, 97.4% of CD4+ lymphocytes were ITPase positive versus 99.9% in 
controls (p=0.002) and 85.9% versus 99.6% of CD8+ lymphocytes (p<0.0001), respectively. 
Stratification according to genotype revealed no significant differences in ITPase expression 
in leukocytes in HIV-infected and control patients.
Conclusions
HIV-infection seems to be interfering with the nucleotide metabolism in leukocytes, 
including CD4+ lymphocytes, by decreasing ITPase expression, independently of ITPA 
genotype. Given that active metabolites of purine-analogue reverse transcriptase inhibitors 
are potential substrates for ITPase, these results warrant further research towards effective-
ness and adverse events of purine analogues and ITPase activity.
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INTrOduCTION
The Human Immunodeficiency Virus (HIV) is a retrovirus that copies its single-stranded 
RNA into double-stranded DNA, which is incorporated into the DNA of the host. Con-
versely, new viral RNA is transcribed from the infected host DNA and packaged into new 
virus particles. These processes are entirely dependent on human nucleotide metabolism 
in the host lymphocytes. This makes nucleotide metabolism both a target and a vehicle for 
anti-viral therapy, reflected by the numerous anti-retroviral nucleoside analogues that have 
been created. Interestingly, there are indications that nucleotide metabolism is impaired 
in lymphocytes and erythrocytes of HIV-infected individuals. HIV-1 positive lymphocytes 
were demonstrated to be unable to expand their ribonucleotide pool (both purines and 
pyrimidines) to the same extent as HIV-1 negative lymphocytes after a strong mitogenic 
stimulation, prohibiting DNA-replication and leading to cell death.1 Furthermore, the 
activities of thymidine kinase 1 and thymidylate kinase (TMP-kinase), both enzymes in the 
pyrimidine nucleotide biosynthetic pathway, were significantly decreased in lymphocytes 
of HIV-infected patients compared with controls.2,3 Purine nucleotide homeostasis may 
be compromised, as the enzyme Inosine 5’-triphosphate pyrophosphohydrolase (Inosine 
triphosphatase; ITPase) was found to be significantly decreased in erythrocytes of HIV-
infected patients compared with a control population.4 Since antiviral purine analogues are 
pivotal in the treatment of HIV-infection, a better understanding of ITPase expression in 
lymphocytes may lead to a better understanding of nucleotide metabolism and the effects 
of HIV treatment.
ITPase, encoded by the polymorphic gene ITPA (OMIM #147520), is one of the scavenger 
enzymes eliminating the potentially cyto- or genotoxic noncanonical nucleoside triphos-
phates from the nucleotide pool.5 Multiple single nucleotide polymorphisms (SNPs) of ITPA 
have been described,6 among which 2 SNPs are proven to decrease ITPase activity: c.94C>A 
(p.Pro32Thr, NCBI rs1127354) and c.124+21A>C (NCBI rs7270101). The SNP c.94C>A 
is found in most world populations, albeit with varying frequency,7 whereas the SNP 
c.124+21A>C has not been found or was extremely rare among Asian populations.8–10 ITPA 
genotype6,11–13 and decreased ITPase activity14 have been associated with protection against 
anemia in the treatment of hepatitis C with the purine analogue ribavirin. Furthermore, 
although conflicting reports exist,15,16 SNPs in the ITPA genotype have been associated with 
adverse drug events during thiopurine therapy with azathioprine and 6-mercaptopurine.17,18 
Also, the SNP c.94C>A led to higher concentrations of methyl-mercaptopurine nucleotides 
in patients treated for acute lymphoblastic leukemia and a higher probability of severe fe-
brile neutropenia in these patients, when mercaptopurine dose had been adjusted for TPMT 
(thiopurine S-methyltransferase) genotype.19 Rare truncating mutations in the ITPA gene 
have recently been associated with a severe early-infantile encephalopathy.20 In an ITPA 
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knockout mouse model, ITPase deficient mice showed features of growth retardation and 
cardiac myofiber disarray and died soon after birth.21
In HIV-infected patients, the decreased erythrocyte ITPase activity was independent of the 
presence of SNPs in the ITPA gene, as it was seen in both wild-type and SNP carriers.4 
This finding raised the question whether in leukocytes as well, ITPase activity is decreased, 
and thus purine metabolism is altered, independent of ITPA genotype in HIV infected 
patients on cART. We therefore analyzed the presence of the ITPase protein in leukocytes 
and leukocyte subpopulations, in association with ITPA genotype in a HIV-infected and a 
control population.
meTHOds
Patients
HIV-seropositive patients, visiting the HIV outpatient clinic of the Maastricht University 
Medical Centre (MUMC+) aged 18 years and older, were eligible for inclusion in the study. 
Consecutive patients were asked for participation and included after written informed con-
sent was obtained. Data regarding age, gender at birth, country of birth, race, CD4 nadir, 
and date of start combination Antiretroviral therapy (cART), were obtained from the Dutch 
HIV monitoring foundation (Stichting HIV Monitoring; SHM). The control population 
consisted of anonymous samples from the general hospital population of the Zuyderland 
Medical Center in Heerlen. All control samples were used according to the code for proper 
use of human tissue as formulated by the Dutch Federation of Medical Scientific Societies. 
The study was approved by the Medical Ethics Committee of the MUMC+ and all patients 
signed written informed consent.
flow cytometric ITPase expression analysis
ITPase expression was determined by flow cytometry as described earlier.22 In short, EDTA 
anticoagulated peripheral blood samples were processed and analyzed within 24 hours after 
collection. One hundred microliters of whole blood was incubated with a cocktail of directly 
conjugated antibodies.22 Cell suspensions were incubated for 15 minutes in the dark at room 
temperature (RT). A Fix&Perm strategy (GAS004; Caltag, Invitrogen, Carlsbad, CA) was 
performed after washing with phosphate-buffered saline. The fixation step consisted of the ad-
dition of 100 mL fixation reagent for 15 minutes at RT and 2 wash steps (phosphate-buffered 
saline). This was followed by the addition of the permeabilization medium and anti-ITPase 
MoAb (clone 2H8, isotype IgG2a, catalog number H00003704-M01, Abnova, Taipei City, 
Taiwan). Except some isoforms of ITPase protein, no other human proteins have a similar 
sequence, thus the specificity of the antibodies used to detect the ITPase protein is considered 
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to be high and the chance we measured other protein products than the ITPase protein seems 
negligible. After incubation for 15 minutes at RT and one wash step, 5 mL PE-conjugated anti-
IgG2a (Southern Biotech, Birmingham, AL) was added. Finally, after incubation (15 minutes 
at RT) and washing, 500 mL CellWash (BD) was added. Samples were analyzed with a BD FAC-
SCanto (BD Biosciences, San Jose, CA). Cell-bound fluorescent labels were excited with a 488 
nm, air-cooled, solid-state argon ion laser, followed by a 17 mW 633 nm, Helium–Neon laser. 
The flow cytometer was set up daily using 7-color beads (BD) with automatic compensation 
settings using the FACSCanto software to achieve optimal instrument performance. Sample 
analysis was completed when 5000 lymphocytes were collected. All measured events were 
stored and analyzed. The fluorescence signal data were recorded with logarithmical amplifica-
tion. FACSDiva software (BD) was used for the analysis of acquired data. A negative control 
(Fluorescence-minus-one: no anti-ITPase but with addition of PE-conjugated anti-IgG2A) 
was used to set a threshold at a maximum of 5% positivity to exclude auto-fluorescence and 
to confirm ITPase-specific labeling. The expression of ITPase was determined by determining 
the median fluorescent intensity of a certain leukocyte population.
Gating strategy
Parental gating, based on scatter signals and immuno-fluorescence staining as described 
earlier,22 resulted in a step-wise separation of subpopulations of leukocytes with accumu-
lated complexity of phenotypical characteristics.
dNa isolation and ITPA genotyping
Total DNA was extracted from blood using the Blood L Kit (Macherey-Nagel GmbH & Co. 
KG, Düren, Germany) and the Hamilton Microlab STAR Line (Hamilton, Bonaduz, Switzer-
land). Specific intronic primers with an additional M13-tag were used to amplify exon 2 of 
the ITPA gene and flanking intronic regions (ITPA_ex2F-CTTTAGGAGATGGGCAGCAG; 
ITPA_ex2R-CACAGAAAGTCAGGTCACAGG). Amplification was performed in a 10 mL 
reaction volume using Amplitaq Gold 360 Master Mix (Applied Biosystems, Nieuwerkerk 
aan den IJssel, The Netherlands) with 5% 360 GC Enhancer, 2 pmol of each primer, and 10 
ng DNA. The cycle conditions were 96°C for 5 minutes, followed by 35 cycles of 94°C for 30 
seconds, 60°C for 45 seconds, and 72°C for 45 seconds with a final elongation step of 72°C 
for 10 minutes. The resulting 245-bp PCR product was bi-directionally sequenced using the 
ABI Big Dye Terminator Cycle Sequencing Ready Reaction kit and the ABI3730XL genetic 
analyzer (Applied Biosystems, Foster City, CA). The 2 common functional polymorphisms 
c.94C>A (p.Pro32Thr; NCBI rs1127354) and c.124+21A>C (NCBI rs7270101) were deter-
mined using Mutation Surveyor DNA variant analysis software (SoftGenetics, State College, 
PA) with genomic NCBI reference sequence NC_000020. All sequences were evaluated 
independently by 2 laboratory experts.
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statistical analysis
Results were analyzed using GraphPad Prism 5.01 (Graphpad Software for Windows, San 
Diego, CA), Microsoft Excel (Microsoft, Redmond, WA) software, and IBM SPSS Statistics 
20 (IBM Corporation, New York, NY) software. Independent samples 2-tailed T-test was 
used to determine significant differences. P-values <0.05 were considered to be statistically 
significant.
resulTs
Patient characteristics
A total of 59 HIV-infected patients and 50 controls were included (Table 1). The mean age 
did not differ significantly between the groups. There was a male predominance in the HIV-
infected patients. All but 1 patient used cART and the mean CD4 nadir of this group was 
206 CD4+ lymphocytes per liter. Although all mean values of the hematological parameters 
assessed were within the reference values, significant differences between the HIV-infected 
patients and the control patients were found (Table 1). Mean corpuscular volume and 
mean corpuscular hemoglobin levels were higher in the HIV-infected population, whereas 
hematocrit and mean corpuscular hemoglobin concentration was lower. The HIV-infected 
patients had a significantly lower white blood cell and platelet count compared with the 
control population.
leukocytes and leukocyte subsets
The leukocyte subtype distribution showed no difference in percentages of monocytes (6.7% 
versus 6.7%; p=0.9, respectively) and granulocytes (56.7% versus 61.1%; p=0.08, respec-
tively) between HIV-infected and control patients (data not shown). The HIV-infected pa-
tients had a statistically significant higher percentage of lymphocytes (29.4% versus 23.1%; 
p<0.001, respectively). No difference was found in the size of the fraction of B-lymphocytes 
between HIV-infected patients and controls (9.80% versus 10.03%; p=0.80, respectively). 
The percentage of T-lymphocytes was significantly higher in HIV-infected patients (80.0% 
versus 74.0%; p=0.001, respectively), with decreased T-helper cells (CD4+ T-cells) (37.6% 
versus 61.6%; p<0.0001) and increased cytotoxic T-cells (CD8+ T-cells) (57.9% versus 32.6%; 
p<0.0001) compared with the control population. The percentage of Natural killer cells was 
significantly lower in HIV-infected patients (10.2% versus 16.6%; p< 0.0001).
Presence of ITPase in leukocyte subsets
High percentages of ITPase positive cells could be demonstrated in the control popula-
tion; lymphocytes 99.5%, monocytes 98.8%, and granulocytes 95.3% were ITPase positive. 
Less lymphocytes (90.9%) and granulocytes (77.1%) were ITPase positive in HIV-infected 
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patients (Figure 1A) compared with the control population (p<0.0001). Furthermore, all 
lymphocyte subtypes showed statistically significant lower percentages of ITPase positive 
cells in HIV-infected patients (Figure 1B). In the controls, all lymphocyte subtypes had a 
mean percentages of ITPase positive cells of 99% or more, whereas in HIV-infected patients 
91% of T-lymphocytes, 97% of B-lymphocytes, and 87% of natural killer cells were ITPase 
positive (p<0.0001 for all). Although the CD4/CD8 ratio of T-lymphocytes is decreased 
in HIV-infected patients, both CD4 lymphocytes and CD8 lymphocytes had less ITPase 
positive cells compared with the control patients; 97.4% versus 99.9% for CD4+ lymphocytes 
(p=0.002) cells and 85.9% versus 99.6% for CD8+ lymphocytes (p<0.0001).
Table 1. Demographic, clinical and hematological characteristics of patients and controls.
Characteristic HIV-infected 
(N=59)
Controls 
(N=50)
reference values, 
range
p-value
age, Median years (range) 49.6 (28.3-68.2) 56.8 (15.9-90.2)
male gender, n (%) 45 (76.3) 50 (50.0)
ITPA genotype, n (%)
Wt/wt 40 (67.8) 26 (52.0)
Wt/c.124+21A>C 7 (11.9) 12 (24.0)
Wt/c.94C>A 7 (11.9) 9 (18.0)
c.124+21A>C/c.124+21A>C 1 (1.7) 3 (6.0)
c.94C>A/c.124+21A>C 2 (3.4) -
Unknown 2 (3.4) -
mean Cd4 nadir ± SD 205.8 ± 152.4
carT 58 (98.3)
race, n (%)
Caucasian 47 (79.7)
Hispanic 1 (1.7)
African 4 (6.8)
Asian 5 (8.5)
Mix 2 (3.4)
mean WbC, x109/L ± SD 6.33 ± 2.05 8.69 ± 2.82 4.00–10.00 <0.001
mean rbC, x1012/L ± SD 4.67 ± 0.66 4.77 ± 0.34 4.20–6.20 0.31
mean Hb, mmol/L ± SD 10.67 ± 9.40 8.94 ± 0.70 7.50–11.00 0.20
mean Ht, L/L ± SD 0.48 ± 0.06 0.43 ± 0.03 0.36–0.51 <0.001
mean mCV, fL ± SD 102.76 ± 9.69 90.24 ± 3.66 80.00–100.00 <0.001
mean mCH, ± SD 2.03 ± 0.22 1.87 ± 0.09 1.70–2.10 <0.001
mean mCHC, g/dl ± SD 19.80 ± 1.02 20.78 ± 0.61 19.30–22.50 <0.001
mean Platelets, x1012/L ± SD 222.07 ± 68.47 248.48 ± 60.62 130.00–400.00 0.04
cART, combined Antiretroviral therapy; WBC, White blood cells; RBC, Red blood cells; Hb, Hemoglobin; Ht, 
Hematocrit; MCV, Mean corpuscular volume; MCH, Mean corpuscular hemoglobin; MCHC, Mean corpuscu-
lar hemoglobin concentration
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Quantitation of ITPase expression
ITPase expression was determined in the ITPase positive cell fraction. ITPase expression 
(expressed as median fluorescent intensity) was highest in activated monocytes and lowest 
in lymphocytes, in both HIV-infected patients and controls regardless of HIV-infection 
(Figure 2A). In HIV-infected patients, ITPase expression was lower in (activated) mono-
cytes, granulocytes, and lymphocytes compared with controls (Figure 2A, p<0.0001 for 
all). In all lymphocyte subsets, ITPase expression was significantly lower in HIV-infected 
patients compared with controls (Figure 2B, p-values <0.0001 for all).
association of ITPase expression in leukocytes with ITPA genotype
ITPA allele frequencies did not differ significantly between HIV-infected patients and the 
control group (Table 1). Wt/wt was the most prominent ITPA genotype (67.8% in HIV-
infected and 52% in controls). The ITPase expression was not associated with ITPA geno-
type (comparison between wt/wt, wt/c.124+21A>C and wt/c.94C>A + other) in monocytes, 
lymphocytes, and granulocytes (Fig. 3).
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figure 1: Comparison of percentages of ITPase positive cells in (A) white blood cell subtypes and (B) lympho-
cyte subsets between HIV-infected patients (white bars) and control patients (gray bars). Displayed are: the 
median, the 25-75% percentiles (bars), upper and lower 1,5 times interquartile range (whiskers) and outliers 
(dots). Except for (activated) monocytes, all the compared cell types showed significant decreases of ITPase 
positive cells in HIV-infected patients (p=0.002 in T-helper cells, p<0.0001 in all others).
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figure 2: Comparison of ITPase expression (expressed as Median fluorescent intensity; MFI) in white blood 
cell subtypes (A) and lymphocyte subsets (B) between HIV-infected patients (white bars) and control patients 
(gray bars). Displayed are: the median, the 25-75% percentiles (bars), upper and lower 1,5 times interquartile 
range (whiskers), outliers (dots). All the compared cell types showed significant decreases of MFI in HIV-
infected patients (p<0.0001 for all).
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0
10000
20000
30000
40000
Wt 12
4 94 Wt 9412
4
Monocytes
12
4
12
4
12
4
12
4Wt WtW
t
Wt 94 94 94 94
Lymphocytes Granulocytes
HIV-patients
Controls
ITPA genotype
NS
NS NS
NS
NS NS
NS
NS NS
NS
NS NS
NS
NS NS
NS
* NS
* p=0.046
IT
Pa
se
 e
xp
re
ss
io
n 
(M
FI
)
figure 3. Stratification of different leukocyte subtypes by ITPA genotype and the corresponding ITPase ex-
pression (expressed as Median fluorescent intensity, MFI). No association was found between ITPA genotype 
(wt=wt/wt; 124=wt/c.124+21A>C; 94=wt/c.94C>A) and ITPase expression in HIV-infected patients (white 
bars) and control patients (gray bars) in monocytes, lymphocytes and granulocytes (no significant differences 
except for the comparison between wt/wt and wt/c.124+21A>C in lymphocytes of control patients; p=0.046).
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dIsCussION
Here, we report a striking significant decrease in ITPase expression in leukocyte subtypes 
and lymphocyte subsets in HIV-infected patients compared with controls. We observed an 
overall decrease in ITPase expression in white blood cells of treated HIV-positive patients, 
regardless of genotype suggesting that the decrease in ITPase expression in leukocytes was 
because of HIV-infection or cART, albeit that the influence of nucleoside analogues is likely 
to be limited.4
Regardless of HIV status, ITPase protein expression was highest in monocytes, being 
especially high in activated monocytes. This may reflect the phagocytic activity, as the 
destruction of pathogens and infected cells either by oxygen dependent and independent 
pathways releases nucleotides and very likely also noncanonical nucleotides, such as Inosine 
triphosphate (ITP).
Competition for the intracellular nucleotide pools between the host white blood cells 
and HIV appears to be a major contributor to HIV pathogenesis. Earlier reports showed 
that pyrimidine nucleotide metabolism (both de novo and salvage) is severely impaired 
in HIV-infected lymphocytes.1–3 After mitogenic stimulation, HIV-infected lymphocytes 
were unable to extend both their purine and pyrimidine nucleotide pools to allow prolif-
eration. A major difference between HIV-infected lymphocytes and controls was that the 
former rely predominantly on purine salvage metabolism to meet the cellular requirement 
opposed to de novo synthesis of purine nucleotides being the predominant biosynthetic 
route in the latter. Sterile alpha motif and histidine-aspartic domain-containing protein 1 
(SAMHD1) is a human defense protein that inhibits the HIV-1 replication by depleting 
intracellular deoxynucleotide pools.23 In HIV-2 infection, this action is counteracted by the 
virion-packaged accessory protein.23 These findings suggest that the infected lymphocyte’s 
ultimate defense mechanism is to cause a fatal imbalance in the intracellular nucleotide pool 
to prevent HIV-integration and replication. Our observation of reduced ITPase expression 
in HIV-infected lymphocytes is in line with this hypothesis. Decreased activity of ITPase 
leads to decreased scavenging of noncanonical nucleotides, including ITP and deoxy-ITP 
which contributes to the intracellular nucleotide imbalance in HIV-infected lymphocytes 
by increasing the availability of non-canonical nucleotides for DNA and RNA replication, 
causing erroneous incorporation into nucleic acids, potentially leading to programmed cell 
death and mutagenesis.24
The decreased ITPase expression and thus possibly the decreased ITPase activity in the 
blood compartment4 may have implications for the efficacy of purine analogue reverse 
transcriptase inhibitors. It can be expected that the efficacy of nucleos(t)ide reverse tran-
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scriptase inhibitors (NRTIs) of which the nucleotide triphosphate form exerts the virostatic 
effect is enhanced, whereas the efficacy of NRTIs of which the nucleotide monophosphate 
exerts the virostatic effect is reduced. This implies treatment with purine NRTIs tenofovir, 
didanosine, and abacavir, which are active in their nucleotide triphosphate form, benefit 
from the observed decreased ITPase expression. This is in contrast to the earlier reported 
decreased phosphorylation of ziduvodine in HIV-infected lymphocytes due to decreased 
thymidine kinase 2 activity.2
ITPase protein and ITPA mRNA are likely to be ubiquitously expressed in all nucleated 
cells.25–27 With respect to erythrocytes, a clear-cut genotype–phenotype correlation exists, 
both in HIV-infected patients and in controls.28,29 According to our present findings this 
seems not to be the case in white blood cells, neither in HIV-infected patients and controls. 
Our previous results in erythrocytes may suggest decreased stability of the P32T ITPase 
protein and the wild type protein in the erythrocytes of HIV-infected individuals. Because 
no protein synthesis takes place in erythrocytes, a HIV-induced instability or reduced bio-
synthesis of the ITPase protein is readily detected. A possible explanation for the fact that 
this is not observed in our present work may be that in white blood cells ITPA is transcribed 
and the ITPase protein is synthesized continuously, despite the amount of mRNA encod-
ing the entire protein being reduced due to altered splicing of the pre-mRNA in the ITPA 
94C>A and 121+21A>C.30 Although ITPase expression appears to be generally decreased in 
blood, there may still exist pharmaco-genetic phenomena associated with ITPA genotype, 
apart from the present observation.
In conclusion, this study is the first to report that the expression of ITPase is significantly 
decreased in lymphocytes and granulocytes of treated HIV-infected patients, compared 
with a control population. Given that purine NRTIs are active in their triphosphate form, 
the present results underline their importance in the backbone of cART. Our findings cor-
roborate previous findings that control over intracellular nucleotide pools is vital for both 
HIV and its host for survival.
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absTraCT
The purine analogues tenofovir and abacavir are precursors of potential substrates for the 
enzyme Inosine 5’-triphosphate pyrophosphohydrolase (ITPase). Here, we investigated the 
association of ITPase activity and ITPA genotype with the occurrence of adverse events 
(AEs) during combination antiretroviral therapy (cART) for human immunodeficiency vi-
rus (HIV) infection. In 393 adult HIV-seropositive patients, AEs were defined as events that 
led to stop of cART regimen. ITPase activity ≥ 4 mmol IMP/mmol Hb/hour was considered 
as normal. ITPA genotype was determined by testing two ITPA polymorphisms: c.94C>A 
(p. Pro32Thr, rs1127354) and c.124+21A>C (rs7270101). Logistic regression analysis deter-
mined odds ratios for developing AEs. In tenofovir-containing regimens decreased ITPase 
activity was associated with less AEs (p=0.01) and longer regimen duration (p=0.001). In 
contrast, in abacavir-containing regimens decreased ITPase activity was associated with 
more AEs (crude p=0.02) and increased switching of medication due to AEs (p=0.03). ITPA 
genotype wt/wt was significantly associated with an increase in the occurrence of AEs in 
tenofovir-containing regimens. Decreased ITPase activity seems to be protective against 
occurrence of AEs in tenofovir-containing cART, while it is associated with an increase in 
AEs in abacavir-containing regimens.
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INTrOduCTION
Combination anti-retroviral therapy (cART) for patients infected with the human im-
munodeficiency virus (HIV) has been increasingly effective over the last years. However, 
adverse events (AEs) are still common and can be severe. Predicting whether AEs will occur 
with specific antiretroviral drugs would be a valuable tool in the choice of cART regimens. 
Although determination of HLA-B*57:01 status to predict hypersensitivity for abacavir, is 
widely used,1 no other biomarkers or genetic susceptibility traits are known that can be used 
to predict AEs associated with cART.
The enzyme Inosine 5’-triphosphate pyrophosphohydrolase (ITPase) is an enzyme which 
converts inosine 5’-triphosphate (ITP) to inosine 5’-monophosphate (IMP) and xanthosine 
5’-triphosphate (XTP) to xanthosine 5’-monophosphate (XMP). IMP and XMP are central 
metabolites in the purine metabolism, from which adenosine 5’-monophosphate (AMP) 
and guanosine 5’-monophosphate (GMP) and subsequently adenosine 5’-triphosphate 
(ATP) and guanosine 5’-triphosphate (GTP) can be formed. ITPase is encoded by the ITPA 
gene located on chromosome 20p. ITPA is a polymorphic gene and a substantial part of 
the Western population carries one of the single nucleotide polymorphisms (SNPs) ITPA 
c.94C>A or ITPA c.124+21A>C.2 The frequency of c.94C>A is highest in Asian popula-
tions (14–10%) compared to Central/South American (1–2%) and Caucasian and African 
populations (6–7%).2 The SNP c.124+21A>C is extremely rare in Asian populations.3-5 
These polymorphisms result in a decreased ITPase activity.6,7 Homozygosity for ITPA c.94 
C>A leads to a null activity solely in erythrocytes, while activity in nucleated cells remains 
detectable.8 True ITPase deficiency in humans is very rare and causes a severe form of early 
infantile encephalopathy.9 Decreased ITPase activity and the frequent ITPA SNPs are as-
sociated with a reduced risk to develop ribavirin-induced hemolytic anemia in patients 
on treatment for hepatitis C,10-12 and with an increased risk of AEs in patients treated with 
thiopurines.13-15
Our interest in the role of ITPase in the treatment of HIV-infected patients stems from the 
fact that both abacavir and tenofovir as well as didanosine are purine analogues and are 
therefore potential precursors of substrates for ITPase. Similarly to its association with AEs 
during the use of thiopurines and ribavirin, ITPase activity might influence the occurrence 
of AEs during purine analogues containing cART. Moreover, the majority of HIV-infected 
patients showed a decreased erythrocyte ITPase activity compared to healthy controls.16 
Therefore, we determined whether ITPase activity and ITPA genotype are associated with the 
occurrence of AEs during cART with purine analogues in a cohort of HIV-infected patients. 
In addition, we tested whether the active metabolites of abacavir and tenofovir (i.e. carbovir-
triphosphate and tenofovir-diphosphate resp.) are substrates for the enzyme ITPase.
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maTerIals aNd meTHOds
Patients
Consecutive HIV-infected patients attending the outpatient clinic of the Maastricht Univer-
sity Medical Center in Maastricht, The Netherlands, between March first 2009 and January 
first 2014, who were treated with cART were included in this study after providing a written 
informed consent. Demographic, laboratory and clinical data from the moment the patients 
entered medical care for the HIV-infection until January first 2014 were retrieved from 
the database of the Dutch HIV monitoring foundation (Stichting HIV Monitoring; SHM), 
also known as the AIDS Therapy Evaluation in the Netherlands (ATHENA) and if needed 
from the medical records. The SHM includes data on demographics, comorbidities, cART, 
clinical, immunological and virological parameters of individuals in HIV care since January 
1996 in any of the 26 HIV treatment centers in the Netherlands. Patients can opt-out after 
being informed by their treating physician of the purpose of collection of clinical data. The 
study was censored at January first 2014. The study was performed according to the Helsinki 
Declaration and approved by the Medical Ethical Committee of the Maastricht University 
Medical Center, Maastricht, The Netherlands.
ITPase activity
Erythrocyte ITPase activity was determined once per patient in the period of March first 
2009 until January first 2014 and determined as described previously17 and assessed by 
formation of inosine 5’-monophosphate (IMP) from inosine 5’-triphosphate (ITP). ITPase 
activity was expressed as mmoles of IMP formed from ITP in one hour per mmol hemo-
globin (mmol IMP/mmol Hb/hour). The cut-off value discriminating between normal or 
decreased ITPase activity was set at 4 mmol IMP/mmol Hb/hour, which is the lowest value 
within the 95% CI for ITPA wt/wt carriers.16,18
In order to test whether or not carbovir-triphosphate and tenofovir-diphosphate are sub-
strates for ITPase, the enzyme activity assay was carried out as described, using 1 millimolar 
of ITP, carbovir-triphosphate or tenofovir-diphosphate. Erythrocytes of a non-HIV infected 
confirmed wild type ITPA genotype carrier individual was used for this experiment. Experi-
ments were performed in triplicate. Carbovir-triphosphate and tenofovir-diphosphate were 
obtained from Toronto Research Chemicals (Toronto, Ontario, Canada).
ITPA genotype analysis
Genomic DNA was isolated from whole blood using the Wizard Genomic DNA purification 
kit (Promega, Madison, WI) and genotyped using sanger sequencing for the two ITPA poly-
morphisms; c.94C>A (p.Pro32Thr, rs1127354) and c.124+21A>C (rs7270101), as previously 
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described.16 When both polymorphisms were not detected, the genotype was considered to 
be wild type (wt/wt). All sequences were evaluated by two independent laboratory experts.
adverse events
For a uniform definition of AEs, AEs resulting in stopping or switching of the cART regi-
men and AEs that could be objectified in the laboratory were included. AEs were defined 
as stopping or switching for any reason except for the reasons virological failure, interac-
tion with other medication, simplification or intensification of the regimen, drug taken off 
the market, patient deceased, low cART blood levels. Before statistical analyses, AEs were 
categorised and their potential association with ITPase activity or ITPA genotype was de-
termined. The categorisation of the AEs was as follows: any AE (all categories of AE named 
hereafter taken together), gastro-intestinal (abdominal pain, nausea, diarrhoea, stomach 
ache, loss of appetite, pancreatitis), neurological (psychiatric complaints or dizziness, sleep-
ing disorder, headache, tremor, disorders of taste), renal (renal insufficiency, kidney stones, 
nephritis, hypophosphatemia or lactate acidosis as reported reason for stopping the cART 
regimen or MDRD <60 ml/min/1.73 m2 or phosphate <0.6 mmol/L in at least two separate 
measurements without other obvious cause), skin (rash or abscess at the site of injection) 
and liver related (liver failure as reported reason for stopping the cART regimen or alanine 
aminotransferase and/or aspartate aminotransferase >90 U/L without other obvious cause, 
in at least two separate measurements, or in one measurement in case of only two measure-
ments performed during that regimen).
statistical analysis
Results were analysed using IBM SPSS Statistics 21 (IBM Corporation, New York, USA) and 
SAS system for windows version 9.3. Pearson-chi-square-tests, Fisher’s exact test and inde-
pendent samples T-tests were used to determine significant differences. P values <0.05 were 
considered to be statistically significant. The occurrence of adverse events was analyzed 
with logistic regression with repeated statement and adjusted for cumulative total duration 
of cART therapy, cumulative duration of purine analogue therapy of all prior regimens and 
duration of the current regimen. Analysis included check for significant interaction with 
treatment and ITPase activity. When abacavir, tenofovir or didanosine were used concomi-
tantly in one cART regimen, these regimens were excluded from the analysis.
Chapter 4.
70
resulTs
Patient characteristics
Of 393 HIV infected patients, 205 (52.2%) patients had a decreased ITPase activity (Table 
1). There were no statistically significant differences with respect to age, gender, ethnicity 
and alcohol use between the groups having normal and decreased ITPase activity. Mean 
CD4 nadir did not differ significantly between the group of patients with decreased ITPase 
activity (216 ± 161 cells/μL) and normal ITPase activity (200 ± 146 cells/μL).
carT regimens
In total 393 patients accounted for 1464 prescribed regimens. The median number of 
regimens per patient was 3, with a maximum of 18 regimens in one patient (Table 1). In 
total 38.992 person months of anti-retroviral therapy were observed. 9% of the regimens 
started before 1998. Purine analogues (tenofovir, abacavir and didanosine) were frequently 
prescribed (n=601, n=244 and n=128 respectively) and the proportion of purine analogue 
containing regimens (69.3%) did not differ between the group of patients with normal 
ITPase activity and the group of patients with decreased ITPase activity (p=0.09). 17 
regimens (1.1%) contained both tenofovir and didanosine, 16 regimens (1.1%) contained 
abacavir and didanosine and 9 regimens (0.6%) contained tenofovir and abacavir. These 
regimens were excluded from further analysis, so 1422 regimens were used to assess the 
association of ITPase activity and ITPA genotype with AEs.
ITPase activity and ITPA genotype in HIV patients
ITPA genotype was determined in 386 patients. The most prominent ITPA genotype was 
wt/wt (265 patients, 67.4%). The occurrence of wt/c.124+21A>C and wt/c.94C>A ITPA 
genotype variants was 68 (17.3%) and 35 (8.9%) respectively. Other variants occurred in 
only 4.6% of the patients (homozygous c.124+21A>C n=5, homozygous c.94C>A n=2 and 
heterozygous c.124+21A>C/c.94C>A n=11). Mean ITPase activity correlated with ITPA 
genotype, with the highest ITPase activity in the wt/wt genotype. However, within the ITPA 
genotype wt/wt, 90 (34.0%) patients had decreased ITPase activity and within the ITPA 
genotype wt/c.124+-21A>C, 9 (13.2%) of the patients had normal ITPase activity. The other 
ITPA genotypes were only associated with a decreased ITPase activity.
association of ITPase activity with aes
734 regimens were prescribed in 205 patients with decreased ITPase activity and 688 in 
188 patients with normal ITPase activity (N.S., Table 1). In 6.8% of the regimens the reason 
for switching or stopping cART regimen was unknown. In total, AEs were present during 
714 regimens (50.2%) with 356 AEs in patients with decreased ITPase activity and 358 in 
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patients with normal ITPase activity (N.S.). The occurrence of AEs and the effect of the 
ITPase activity are displayed in Table 2 and Figure 1 respectively.
Table 1. Demographic and clinical characteristics of the patients (n=393) with ITPase activity <4 and ≥4 mmol 
IMP/mmol Hb/hour.
Characteristic ITPase activity P-value
<4a (n=205) ≥4a (n=188)
age, median years (range) 50.6 (20-81) 49.7 (27-84) 0.80
male Gender, n (%) 164 (80.0) 155 (82.4) 0.53
race, n (%) 0.81
White non-Hispanic 164 (80.0) 147 (78.2)
White Hispanic 5 (2.4) 4 (2.1)
African 22 (10.7) 27 (14.4)
Asian or other 14 (6.9) 10 (5.3)
mean ITPase activity ± SD 2.44 ± 1.12 5.24 ± 1.09 <0.001
ITPA genotype, n (%) <0.001
Wt/wt 90 (43.9) 175 (93.1)
Wt/c.124+21A>C 59 (28.8) 9 (4.8)
Wt/c.94C>A or otherb 53 (25.9) -
Unknown 3 (1.5) 4 (2.1)
alcohol, n (%) 0.51
<2 IU/day 157 (76.6) 133 (70.7)
≥2 IU/day 35 (17.1) 36 (19.1)
Unknown 13 (6.3) 19 (10.1)
recreational drugsc, n (%) 0.04
None 120 (58.5) 92 (48.9)
Yes 50 (24.4) 55 (29.3)
Unknown 35 (17.1) 41 (21.8)
Hepatitis b co-infection, n (%) 0.25
No / cleared 182 (88.8) 167 (88.8)
Yes 10 (4.9) 6 (3.2)
Unknown 13 (6.3) 15 (8.0)
Hepatitis C co-infection, n (%) 0.52
No 174 (84.9) 159 (84.6)
Yes 27 (13.2) 22 (11.8)
Unknown 4 (2.0) 7 (3.7)
mean Cd4 nadir ± SD 215.6 ± 160.9 200.1 ± 145.7 0.32
median year of start carT (range) 2006 (1987-2013)d 2006 (1987-2013)e 0.25
start carT < the year 1998 (%) 9.7 8.3 0.68
median number of carT regimens/patient (range) 3 (1-14) 3 (1-18) 0.74
Total number of carT regimens 734 688
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Tenofovir
Normal ITPase activity was significantly associated with AEs in regimens containing te-
nofovir (167 vs 137 respectively, Odds ratio (OR) 0.65 for decreased ITPase activity versus 
normal activity; 95% CI 0.46–0.92; p=0.01), see Figure 1. Tenofovir-containing regimens 
used with normal ITPase activity were significantly more often switched because of AEs 
than for other reasons compared to regimens used with a decreased ITPase activity (91 
of 281 vs 70 of 293 respectively (reason for switch unknown in 27 regimens), p=0.02). 
Furthermore, mean regimen duration was statistically significantly longer in patients with a 
decreased ITPase activity (29.2 vs 22.5 months; p=0.001), see Table 1.
Of all the renal AEs that occurred, 48.7% were in the group of regimens containing tenofovir 
(n=55) and of these 63.6% occurred in the patients with normal ITPase activity (p=0.04; OR 
0.51; 95% CI 0.27–0.96 for patients with decreased ITPase activity versus normal activity), 
see Figure 2.
Abacavir
In regimens containing abacavir 61.2% of all AEs occurred in the patients with decreased 
ITPase activity and 38.8% in the patients with normal ITPase activity (crude p=0.02). After 
correction using logistic regression, OR remained elevated for decreased ITPase activity 
versus normal ITPase activity (1.69) but did not reach significance (p=0.08), see Figure 1. 
Significantly more often the cART regimen was switched because of AEs instead of other 
reasons when ITPase activity was decreased compared to normal ITPase activity (50 of 124 
Table 1. Demographic and clinical characteristics of the patients (n=393) with ITPase activity <4 and ≥4 mmol 
IMP/mmol Hb/hour. (continued)
Characteristic ITPase activity P-value
<4a (n=205) ≥4a (n=188)
median duration of carT regimen, months (range) 18.0 (0-161)f 15.5 (0-160)g 0.06
Purine containing carT, n (%) 0.09
Tenofovir 306 (40.1) 295 (41.1) 
Abacavir 131 (17.2) 113 (15.8) 
Didanosine 51 (6.7) 77 (10.7) 
mean duration purine containing carT, months ± SD
Tenofovir 29.2 ± 24.7 22.5 ± 22.0 0.001 
Abacavir 34.9 ± 35.6 41.4 ± 40.8 0.19 
Didanosine 24.7 ± 27.9 19.4 ± 22.4 0.24 
a mmol IMP/mmol Hb/hour; b Other, homozygous c.124+21A>C or homozygous c.94C>A or heterozygous 
c.124+21A>C/c.94C>A; c heroin, cocaine, amphetamines, 3,4-methylenedioxymethamphetamine (MDMA), 
cannabis, lysergic acid diethylamide (LSD), ketamine, gamma-hydroxybutyric acid (GHB) and akylnitrate 
(‘poppers’); d Missing in 1 patient; e Missing in 2 patients; f Missing in 1 patient; g Missing in 3 patients
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vs 29 of 108 respectively (reason for switch unknown in 12 regimens), p=0.03). In general, 
more adverse events tended to occur in patients with decreased ITPase activity, e.g. gastro-
intestinal and skin related AEs (Figure 2). Of the cART regimens containing abacavir, 6.1% 
were stopped or changed because of skin related AEs and 73.3% of these events occurred 
in the patients with decreased ITPase activity, however this difference was not statistically 
significant.
Effect of ITPase activity on any AE
0.1 1 10
No purine
Didanosine
Abacavir
Tenofovir
Regimen containing:
←⎯⎯ ⎯⎯→
More adverse events                              More adverse events
in ITPase activity ≥4                               in ITPase activity <4
0.87 (0.57-1.31)
0.97 (0.45-2.10)
1.69 (0.93-3.08)
0.65 (0.46-0.92)
OR (95% CI)
0.50
0.94
0.08
0.01
P-values
figure 1. Effect ITPase activity on total adverse events. The effect of decreased versus normal ITPase activity on 
the occurrence of total adverse events (grouped by regimens containing tenofovir, abacavir or didanosine and 
regimens without tenofovir, abacavir or didanosine) is plotted. Odds ratio with 95% confidential interval and 
matching p-values are displayed. The analyses were conducted with repeated statement, adjusted for cumulative 
total duration of cART, cumulative duration of purine analogue therapy of all prior regimens and duration of 
the current regimen.
Effect of ITPase activity 
0.1 1 10
Skin
Gastro-intestinal
Abacavir
Renal
Tenofovir
←⎯⎯ ⎯⎯→
More adverse events                              More adverse events
in ITPase activity ≥4                               in ITPase activity <4
2.41 (0.69-8.36)
2.13 (0.56-8.13)
0.51 (0.27-0.96)
OR (95% CI)
0.84
0.86
 
0.04
P-values
figure 2. Effect ITPase activity on regimen associated adverse events. The effect of decreased ITPase activity on 
the occurrence of regimen associated adverse events (renal adverse events for tenofovir and gastro-intestinal 
and skin related adverse events for abacavir) is plotted. Odds ratio with 95% confidential interval and match-
ing p-values are displayed. The analyses were conducted with repeated statement, adjusted for cumulative total 
duration of cART, cumulative duration of purine analogue therapy of all prior regimens and duration of the 
current regimen.
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Didanosine and regimens without tenofovir, abacavir and didanosine
No statistically significant association was found for AEs occurring with use of didanosine 
or regimens without tenofovir, abacavir and didanosine and ITPase activity.
association of ITPA genotype with aes
The occurrence of AEs and the effect of the ITPA genotype are displayed in Table 3 and 
Figure 3 respectively. 960 regimens were prescribed for patients with wt/wt genotype and 
435 for patients with one or more of the SNPs. Genotype was unknown for 27 regimens.
Tenofovir
ITPA genotypes other than wt/wt, associated with decreased ITPase activity, seemed to be 
protective against AEs (p=0.04), as 72.4% of all AEs occurred in the patients with ITPA 
Table 2. Occurrence of adverse events in patients grouped by ITPase activity, percentage of adverse events and 
crude p-values per purine type.
carT
containing:
ITPase activity <4a ITPase activity ≥4a Crude p-value
aeb, n / Patients, n % of total aeb aeb, n / Patients, n % of total aeb
Tenofovir 137/306 45.1% 167/295 54.9% 0.004
Abacavir 74/131 61.2% 47/113 38.8% 0.02
Didanosine 27/51 40.3% 40/77 59.7% 0.91
No purine 118/246 53.2% 104/203 46.8% 0.49
a mmol IMP/mmol Hb/hour; b AE, adverse events
Effect of ITPA gentoype on any AE
0.1 1 10
No purine
Didanosine
Abacavir
Tenofovir
Regimen containing:
←⎯⎯ ⎯⎯→
More adverse events                              More adverse events
           in ITPA genotype wt/wt                           in ITPA genotype with SNP
0.69 (0.45-1.06)
1.20 (0.51-2.78)
1.05 (0.56-1.96)
0.66 (0.45-0.97)
  OR (95% CI)
0.09
0.68
0.87
0.04
P-values
figure 3. Effect ITPA genotype on total adverse events. The effect of ITPA genotype wt/wt versus the other 
ITPA genotypes on the occurrence of total adverse events (grouped by regimens containing tenofovir, abacavir 
or didanosine and regimens without tenofovir, abacavir or didanosine) is plotted. Other ITPA genotypes than 
wt/wt were wt/c.124+21A>C, wt/c.94C>A, c.124+21A>C/c.124+21A>C, c.94C>A/c.94C>A or c.124+21a>C/
c.94C>C. Odds ratio with 95% confidential interval and matching p-values are displayed. The analyses were 
conducted with repeated statement, adjusted for cumulative total duration of cART, cumulative duration of 
purine analogue therapy of all prior regimens and duration of the current regimen.
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genotype wt/wt and 26.3% in patients with SNPs in the genotype. 1.3% Of the regimens with 
an AE had an unknown genotype. 76.4% of all renal AEs occurred in the regimens with wt/
wt genotype, this difference was not statistically significant, see Figure 4.
Abacavir
No association was found between ITPA genotype and all AEs in patients using abacavir. 
For gastro-intestinal AEs a SNP in the ITPA genotype was associated with an increased 
number of AEs (OR 3.45 for ITPA genotypes with SNPs versus wt/wt genotype; 95% CI 
0.99–11.11; p=0.05), see Figure 4.
Table 3. Occurrence of adverse events in patients grouped by ITPA genotype, and crude p-values per purine 
type for each type of adverse event.
carT 
containing:
sNP in ITPA genotypea ITPA genotype wt/wt ITPA genotype unknown Crude 
p-valueaeb, n / 
Patients, n
% of total 
ae
aeb, n / 
Patients, n
% of total 
aeb
aeb, n / 
Patients, n
% of total 
aeb
Tenofovir 80/186 26.3% 220/409 72.4% 4/6 1.3% 0.04
Abacavir 38/75 31.4% 82/164 67.8% 1/5 0.8% 0.52
Didanosine 18/31 26.9% 48/96 71.6% 1/1 1.5% 0.54
No purine 64/143 28.8% 151/291 68.0% 7/15 3.2% 0.36
a heterozygous wt/c.124+21A>C or wt/c.94C>A, homozygous c.124+21A>C or c.94C>A or compound hetero-
zygous c.124+21A>C/c.94C>A; b AE, adverse events
Effect of ITPA gentoype
0.1 1 10
Skin
Gastro-intestinal
Abacavir
Renal
Tenofovir
←⎯⎯ ⎯⎯→
More adverse events                              More adverse events
           in ITPA genotype wt/wt                           in ITPA genotype with SNP
2.04 (0.58-7.14)
3.45 (0.99-11.11)
0.55 (0.26-1.18)
  OR (95% CI)
0.26
0.05
0.13
P-values
figure 4. Effect ITPA genotype on regimen associated adverse events. The effect of ITPA genotype wt/wt versus 
the other ITPA genotypes on the occurrence of regimen associated adverse events (renal adverse events for te-
nofovir and gastro-intestinal and skin related adverse events for abacavir) is plotted. Other ITPA genotypes than 
wt/wt were wt/c.124+21A>C, wt/c.94C>A, c.124+21A>C/c.124+21A>C, c.94C>A/c.94C>A or c.124+21a>C/
c.94C>C. Odds ratio with 95% confidential interval and matching p-values are displayed. The analyses were 
conducted with repeated statement, adjusted for cumulative total duration of cART, cumulative duration of 
purine analogue therapy of all prior regimens and duration of the current regimen.
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Didanosine and regimens without tenofovir, abacavir and didanosine
No association was found between ITPA genotype and AEs in patients using didanosine or 
regimens without tenofovir, abacavir and didanosine.
Carbovir-triphosphate and tenofovir-diphosphate are no direct substrates for 
ITPase
To test the hypothesis that carbovir-triphosphate could be a substrate for ITPase, resulting 
in higher carbovir levels when ITPase activity is decreased, and more pronounced adverse 
effects, carbovir-triphosphate was directly used as a substrate for ITPase. Carbovir-triphos-
phate was not a direct substrate for ITPase and neither was tenofovir-diphosphate.
dIsCussION
Here, we show for the first time that ITPase activity is associated with the occurrence of 
AEs in patients using cART containing the purine analogues tenofovir and abacavir. A 
significant reduction in all AEs was found in patients with decreased ITPase activity using 
tenofovir. Moreover, mean regimen duration was significantly longer indicating a better 
tolerance of tenofovir containing cART regimens in patients with decreased ITPase activity. 
On the other hand, patients with decreased ITPase activity using abacavir were more at risk 
for developing AEs. Mean regimen duration was longer in the patients with normal ITPase 
activity, indicating a better tolerance of abacavir in these patients. No clear association be-
tween AEs and regimens without tenofovir, abacavir or didanosine could be demonstrated.
These data suggest that ITPase activity may be used as a pharmacogenetic biomarker in 
patients starting cART containing tenofovir or abacavir. Up to now no other biomarkers are 
in use, apart from HLA-B*57:01 status to predict abacavir hypersensitivity syndrome. As 
tenofovir is used as a part of the regimen in the PrEP studies to prevent HIV transmission, 
we expect an increase in the use of tenofovir by indivuduals not infected with HIV. A test to 
identify individuals with increased risk of developing long term adverse effects due to teno-
fovir would be an extremely welcome asset. The present study suggest ITPase activity is a po-
tential candidate. In other diseases, results of studies using ITPA polymorphisms to predict 
AEs varied with the purine analogue used. The ITPase lowering ITPA polymorphisms were 
shown to be protective against ribavirin-induced anemia in hepatitis C on treatment.19,20 
In patients with inflammatory bowel disease using azathioprine, however, adverse events 
occurred more frequently in patients with ITPase lowering ITPA polymorphisms.7,21 In our 
study a lower ITPase activity was associated with less cART regimen switches due to AEs 
in patients using tenofovir, whereas regimens containing abacavir were more frequently 
switched. The underlying cause of the observed differences between the purine analogues 
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tenofovir and abacavir is yet unclear. Both abacavir and tenofovir are potent inhibitors 
of HIV reverse transcriptase.22-24 However, the chemical structure differs greatly between 
the two analogues (Figure 5). Whilst tenofovir is an acyclic adenine nucleotide analogue, 
abacavir is the prodrug of carbovir, which is formed by removal of the cyclopropylammonia 
moiety attached to the purine base and is a guanosine analogue. We expect that part of the 
explanation is to be found in the chemistry of these compounds. 
In our hands, both carbovir-triphosphate and tenofovir-diphosphate proved to be non-
substrates for ITPase, so the mechanism behind our observation that decreased ITPase 
activity leads to an increased occurrence of adverse events in abacavir therapy is not easily 
explained. As was hypothesized by Coelho et al,25 the use of cART may lead to an increase 
in IMP and so to an increase in cytotoxicity by an increased ITP level in patients with 
decreased ITPase activity. Interestingly, we observed cultured skin fibroblasts of patients 
with encephalopathy associated with ITPA mutations9 leading to severely reduced ITPase 
activity show increased levels of IMP rather than ITP when compared to controls, so direct 
toxicity by ITP can only explain part of the mechanism involved. Bondoc and coworkers26 
demonstrated that intra-cellular anabolism of carbovir was stimulated by adenine, adenos-
figure 5. Chemical structures. Chemical structures of tenofovir, abacavir, adenosine, carbovir, didanosine, ino-
sine and guanosine.
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ine, hypoxanthine, inosine and even dideoxy-Inosine. Their hypothesis is that increased 
intracellular levels of IMP and ATP enhanced the anabolism of carbovir by stimulating 
phosphorylation by 5’-nucleotidase. In line with this, we might hypothesize that a decreased 
ITPase activity leads to an increase in IMP and so to an increase of carbovir anabolism. In 
addition to its anti-retroviral activity, carbovir-triphosphate has been demonstrated to be a 
competitive inhibitor of soluble guanylate cyclase influencing platelet activity.27 Considering 
that carbovir-triphosphate might be increased by decreased ITPase activity, the interference 
of carbovir-triphosphate in the nitric oxide (NO) signalling pathway may be considerable, 
leading to adverse events and regimen change. This hypothesis needs further investigation 
to clarify the mechanism.
Skin reactions related to abacavir are an immunological phenomenon. In our study, most 
of the skin related adverse events occurred in the abacavir-containing regimens used by 
patients with decreased ITPase actvitiy, although this difference was not statistically signifi-
cant. The role of ITPase in immunologically induced AEs remains to be elucidated.
For tenofovir an explanation for the present results seems to be less straightforward. Tenofovir 
differs from carbovir in two essential aspects: tenofovir is a nucleoside-monophosphate and 
a adenosine analogue rather than a guanosine analogue. Tenofovir metabolites appear to be 
resistant to deamination28 making accumulation of the deaminated tenofovir-diphosphate 
metabolite due to decreased ITPase activity unlikely. At this moment we can only speculate 
that ITPase activity influences tenofovir metabolism in a yet unknown fashion. In this study 
we were not able to rule out other factors that may have influenced renal events other than 
tenofovir use, like hypertension, diabetes mellitus, age and the use of other medication, like 
non-steroidal anti-inflammatory drugs.
All previous studies evaluating the effect of ITPA genotype polymorphisms on adverse 
events assumed that the reported ITPase activity directly corresponds to a specific ITPA 
polymorphism.14,18 However, in accordance with our previous work29 we found that an 
ITPA variant such as wt/c.124+21A>C leads to a variety of ITPase activities from as low 
as 1.53 to as high as 7.70 mmol IMP/mmol Hb/hour. Moreover, in spite of wt/wt genotype, 
HIV-infected patients were found to have a decreased ITPase activity compared to control 
patients16 and therefore more often will have an ITPase activity <4 mmol IMP/mmol Hb/
hour. In HIV, the association between ITPA genotype and ITPase activity is less strict as 
has previously been assumed. This may be an explanation why ITPA genotype correlated 
less to AEs compared to ITPase activity, as we found in this study. Previously we showed 
that ITPase activity is lower in HIV-infected patients compared to control populations in 
erythrocytes16 as well as in leukocytes30 independent of ITPA genotype, which did not ap-
pear to be an effect of nucleoside analogues.16
79
ITPase activity potential biomarker for AE in cART for HIV
Some limitations of this research need to be mentioned. Because cART is, by definition, a 
combination of antiretroviral drugs, adverse events during a cART regimen might be at-
tributed to more than one drug. However, by using repeated statement and adjusting the 
statistical analysis for cumulative total duration of cART, cumulative duration of purine 
analogue therapy of all prior regimens and duration of the current regimen, we were able 
to measure the association between ITPase activity and tenofovir and abacavir containing 
regimens. More studies will be needed to confirm our findings.
The lack of more significant results analyzing specific adverse events other than gastro-
intestinal, renal and skin related adverse events in this study may be due to the relatively 
small numbers of the occurrence of these adverse events. This was probably due to the fact 
that in our definition of adverse event we only used the reasons for stopping a regimen in 
combination with retraceable laboratory values. We have chosen this strategy because in 
the SHM database reason for switching cART regimen is a mandatory question, whereas 
reporting AEs is up to the physician and not a prerequisite item in the database and there-
fore is a less reliable parameter. Still, in 7% of the regimens, the reason for switching cART 
was unknown. The number of regimens with unknown reason for switching were equally 
distributed between both ITPase activity groups. We therefore do not expect this to be af-
fecting the results of the study.
Because the data were collected retrospectively, the causality between the use of cART and 
the occurrence of AEs cannot be proven in this study. By using only the reasons for stop-
ping the cART regimen or retraceable laboratory values, we avoided some bias, however, 
prospective trials are needed to confirm our data.
In conclusion, ITPase enzyme activity <4 mmol IMP/mmol Hb/hour seems to be protec-
tive against occurrence of adverse events in cART regimens containing tenofovir, while it 
leads to an increase in adverse events in cART regimens containing abacavir. These results 
warrant further elucidation of the mechanism involved and need to be confirmed in a 
prospective trial.
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absTraCT
Objectives
Nucleotide reverse transcriptase inhibitors play a pivotal role in HIV-treatment. The enzyme 
Inosine 5’-triphosphatase (ITPase) is involved in the nucleotide metabolism and has been 
associated with adverse drug events. We studied the association between ITPase-activity 
and tenofovir disoproxil fumarate (TDF)-associated nephrotoxicity.
design
Single center 1:2 case control cohort study, including suppressed HIV-infected patients with 
(cases) and without (controls) TDF-associated nephrotoxicity.
methods
26 cases (eGFR-decline >25% and/or ≥2 proximal tubular dysfunction (PTD)-markers 
during TDF use) were matched to 55 controls. ITPase-activity and ITPA genotype were 
measured in all patients. The primary endpoint was the proportion of patients with normal 
ITPase-activity (≥4 mmol IMP/mml Hb/hour) in cases versus controls. The eGFR-improve-
ment 48 weeks after TDF-cessation was measured in cases. McNemar’s test, conditional 
logistic regression, and paired T-tests were used.
results
The eGFR in cases and controls at TDF-discontinuation was 78 and 85 ml/min. 19/26 cases 
(73.1%) versus 28/55 controls (50.9%) had normal ITPase activity, p=0.001 (OR 2.55, 95% 
CI 0.89-7.31, p=0.08). 23/26 cases (88.5%) versus 40/55 controls (72.7%) had wt/wt ITPA 
genotype, p=0.26 (OR 2.59, 95%CI 0.70-9.54, p=0.15). After TDF-cessation, the eGFR 
increased in cases with normal ITPase activity (-5.5 to +4.4 ml/min/year, p=0.008), but 
remained stable in cases with reduced activity (-4.3 to -4.0, p=0.97). In cases with wt/wt 
ITPA genotype, eGFR increased from –5.0 to +3.0 ml/min/year, p=0.021. 13/16 cases with 
PTD had normal ITPase activity. Of cases with available data, 50% with normal activity had 
PTD-recovery after TDF-cessation.
Conclusions
Normal ITPase-activity is associated with nephrotoxicity during TDF use and recovery after 
TDF-cessation. ITPase-activity might function as a screening-tool for probable occurrence 
and reversibility of TDF-toxicity.
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INTrOduCTION
Tenofovir disoproxil-fumarate (TDF) is a recommended nucleotide-analog reverse-tran-
scriptase inhibitor (NRTI) in combination antiretroviral therapy (cART) for HIV-treatment. 
Other indications for TDF-use are chronic hepatitis B virus infection and pre-exposure 
prophylaxis (PrEP).1 Use of TDF is associated with an accelerated estimated glomerular fil-
tration rate (eGFR)-decline2-4 and proximal tubular dysfunction (PTD).2,5,6 In clinical trials, 
tenofovir alafenamide (TAF), a novel tenofovir prodrug, showed comparable virological ef-
ficacy as TDF, but caused smaller eGFR-declines and renal tubular proteinuria.7,8 Therefore, 
TAF-containing cART became a recommended first-line regimen next to TDF-containing 
cART.9,10 Recently, generic TDF has become available, which might favor prescribing TDF 
over TAF for cost-effectiveness and aid in the roll out of cART in resource-limited countries. 
Additionally, the use of TDF as PrEP is increasing. Therefore, it is useful to predict in which 
patient the risk of TDF-associated nephrotoxicity is high, and whether it would recover.
DNA consists of the canonical nucleobases adenine, cytosine, guanine, and thymidine. 
However, incorporation of non-canonical nucleoside triphosphates in the DNA potentially 
causes cyto- or genotoxicity.11 The housekeeping enzyme Inosine 5’-triphosphatase (ITPase), 
encoded by the polymorphic gene ITPA (OMIM #147520), eliminates the nucleotide pool 
from non-canonical nucleoside triphosphates.12 In HIV-infected patients, ITPase activity 
and enzyme expression were decreased compared to non HIV-infected controls in erythro-
cytes and CD4+ lymphocytes,13,14 which could not be fully explained by the single nucleotide 
polymorphisms (SNPs) c.94C>A (p.Pro32Thr, NCBI rs1127354) and c.124+21A>C (NCBI 
rs7270101) in the ITPA gene. In a retrospective cross-sectional study, a normal ITPase 
activity was associated with broadly defined nephrotoxicity in HIV-infected patients on 
TDF-containing cART.15 
We evaluated whether ITPase activity or ITPA genotype could be useful biomarkers to 
predict TDF-associated nephrotoxicity, and whether they were associated with eGFR-
improvement after TDF-cessation.
meTHOds
This was a 1:2 matched case-control study in a cohort of HIV-1 infected adult patients from 
the Erasmus Medical Center, Rotterdam, the Netherlands. The study was approved by the 
local ethics committee, conducted according to the Helsinki Declaration, and participants 
provided informed consent. Participants were selected from 2 previous studies: a cohort 
study on TDF-associated nephrotoxicity and a randomized clinical trial in which TDF-
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containing cART was discontinued (DOMONO,NCT02401828).16,17 Cases were patients 
who developed TDF-associated nephrotoxicity, and controls were patients who did not. 
Matching was performed for gender, age and ethnicity. Nephrotoxicity was defined as >25% 
eGFR-decrease during TDF-use and/or presence of ≥2 PTD markers: normoglycaemic 
glucosuria, hypophosphatemia <0.8 mmol/L, urine protein:creatinine ratio (UPCR) >15.0 
mg/mmol, urine albumin:protein ratio (APR) <0.4 in patients with increased UPCR, or in-
creased fractional excretion of phosphate (>20%, or >10% in hypophosphatemic patients).18 
ITPase activity was measured as described previously.19 ITPase activity ≥4 mmol IMP/mml 
Hb/hour was considered normal.20 ITPA genotype was determined by genotyping whole 
blood for the ITPA SNPs c.94C>A (p.Pro32Thr, rs1127354) and c.124+21A>C (rs7270101). 
ITPA genotypes without these SNPs were considered wt/wt. 47 patients (15 cases and 
32 controls) were selected from the study of Rokx et al, and 34 patients (11 cases and 23 
controls) from the DOMONO-study.16,17 Data on demographics, medical history (diabetes 
mellitus, hypertension, hepatitis C virus infection, cardiovascular disease), nephrotoxic 
medications (sulphamethoxazole/trimethoprim, non-steroidal anti-inflammatory drugs, 
angiotensin converting enzyme-inhibitors, angiotensin-2 receptor-antagonists, and valacy-
clovir or ganciclovir), eGFR, and PTD markers during TDF-use were collected, as well as 
eGFR and PTD-markers 48 weeks after TDF-cessation.
The primary outcome of this study was the proportion of normal versus reduced ITPase 
activity in cases versus controls. Secondary outcomes were: 1) proportions of patients with 
wt/wt versus wt/94C>A or wt/124+21A>C ITPA-genotype in cases versus controls, and 2) 
improvement of eGFR and PTD 48 weeks after TDF-cessation in cases with normal versus 
decreased ITPase activity and wt/wt versus another ITPA genotype. A sample size of 87 
(29 cases and 58 controls) was needed to prove with a 1:2 case-control study-design that a 
significantly greater proportion of patients with nephrotoxicity had normal ITPase activity 
(π1=0.5) than patients without nephrotoxicity (π2=0.2), based on previous findings, with 
power 1-β=80% and a 2-sided α of 0.05.15 McNemar’s Test was used to compare proportions 
of patients with normal ITPase activity in cases and controls. Nephrotoxicity related to both 
ITPase activity (normal versus reduced) and ITPA genotype (wt/wt versus genotype with 
SNP) was analyzed using conditional logistic regression, resulting in an odds ratio (OR) 
with 95% confidence interval (CI). Fishers’ Exact Test, Unpaired T-tests, Chi Square Tests, 
and Mann Whitney U Tests were used for other comparisons between patients with normal 
versus reduced ITPase-activity, and paired T-tests were performed for comparisons on 
eGFR-improvement. An alfa of 0.05 was used.
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resulTs
81 Patients were included, of whom 26 patients were cases and 55 patients were controls. 
Although we intended to include 87 patients based on our sample size calculation, we did a 
preliminary analysis after including 81 patients due to repeated non-adherence to scheduled 
outpatient appointments of the remaining eligible patients. This analysis showed highly sig-
nificant results for the primary endpoint, with a calculated power of 76%. Therefore, patient 
inclusion was stopped for ethical arguments, since we considered that the supporting data 
for our assumptions for the power calculation were limited and could deviate from the true 
difference. In both groups, participants were predominantly Caucasian middle-aged males. 
The duration of TDF-use was comparable between cases and controls (83 and 84 months), 
as well as use of nephrotoxic co-medication and comorbidity. The mean (SD) eGFR in cases 
and controls at the moment of TDF-discontinuation was 78 (19) and 85 (13) ml/min. Of the 
cases, 80.8% had >25% eGFR-decline since TDF initiation, 61.5% had ≥2 PTD-markers, and 
42.3% had both. (Table 1).
Of the cases, 73.1% (19/26) had a normal ITPase activity versus 50.9% (28/55) of controls 
(p=0.001; Table 2). Wt/wt ITPA genotype was present in 88.5% of cases and 72.7% (40/55) 
of controls (p=0.26; Table 2). Conditional logistic regression showed an increased and 
nearly statistically significant risk for nephrotoxicity in patients with normal ITPase activity 
and ITPA genotype wt/wt: OR 2.56 (95%CI 0.89-7.31; p=0.08), and OR 2.59 (95%CI 0.70-
9.54; p=0.15), respectively. The eGFR-course improved from -5.5 ml/min/year during TDF 
to +4.4 ml/min/year after TDF-cessation (p=0.008) in cases with normal ITPase activity 
(N=19), whereas it remained stable in cases with reduced activity (N=4): -4.3 versus -4.0 
ml/min/year, p=0.97. (Table 2). Of 11 cases that started dolutegravir therapy after TDF-
cessation, 7 had normal ITPase activity, of whom 6 had improvement of eGFR, whereas 
4 had reduced activity, of whom 1 had improvement of eGFR. These results indicate that 
patients with a normal ITPase activity may recover from TDF-associated nephrotoxicity 
after TDF-cessation, but patients with reduced activity may not. In cases with wt/wt ITPA 
genotype (N=22), the eGFR-course improved from -5.0 to +3.0 ml/min/year, p=0.021 
(Table 2). eGFR data from only 1 patient with SNPs in the ITPA genotype were available, of 
which no conclusions can be drawn. Of the 16 cases with PTD, 3 had decreased and 13 had 
normal ITPase activity. Week 48 data were available in 9 patients, of whom the only patient 
with decreased ITPase activity had no PTD recovery, and PTD recovered in 4 of 8 patients 
with normal activity.
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Table 1. Clinical characteristics of the patients with (cases) and without (controls) TDF-associated nephrotoxic-
ity.
Characteristic Cases
(n=26)
Controls
(n=55)
p-value
male gender, n (%) 23 (88.5) 49 (89.1) 1.00 (FE)a
age, mean years ± SDb 51 ± 10 52 ± 9 0.50 (UT)c
ethnicity, n (%) 0.87 (FE)a
Caucasian 22 (84.6) 44 (80.0) 
African 2 (7.7) 3 (5.5) 
Asian 0 (0.0) 1 (1.8) 
Latino 2 (7.7) 7 (12.7) 
route of transmission, n (%) 0.77 (FE)a
MSMd 20 (76.9) 37 (67.3) 
Heterosexual 5 (19.2) 12 (21.8) 
IVDUe 1 (3.8) 3 (5.5) 
Unknown 0 (0.0) 3 (5.5) 
smoking status, n (%) 0.60 (CS)f
Current 8 (30.8) 22 (40.0) 
Previous 8 (30.8) 12 (21.8) 
Never 9 (34.6) 21 (38.2) 
Unknown 1 (3.8) 0 (0.0) 
Comorbidities, n (%)
Hypertension 5 (19.2) 10 (18.2) 1.00 (FE)a 
Diabetes mellitus 3 (11.5) 1 (1.8) 0.10 (FE)a 
Hepatitis C virus infection 2 (7.7) 5 (9.1) 1.00 (FE)a 
Cardiovascular disease 3 (11.5) 4 (7.3) 0.68 (FE)a 
Tdfg-containing carTh, n (%) 0.86 (FE)a
+ NNRTIi-containing, N (%) 24 (92.3) 49 (89.1) 
RPVj-containing 9 (34.6) 18 (32.7) 
+ bPIk-containing, N (%) 2 (7.7) 5 (9.1) 
+ INSTIl-containing, N (%) 0 (0.0) 1 (1.8) 
median duration of Tdf-usem, months (Q1,Q3) 83 (50,117) 84 (46,115) 0.72 (MWU)n
mean eGfro at discontinuation of Tdfg, ml/min, ± SDb 78.1 ± 19.2 85.2 ± 12.9 0.09 (UT)c
Comedication during Tdfg-use, n (%)
Sulfamethoxazol/trimethoprim 0 (0.0) 1 (1.8) 1.00 (FE)a 
ACEp-inhibitor 3 (11.5) 3 (5.5) 0.38 (FE)a 
AT2q-antagonist 0 (0.0) 4 (7.3) 0.30 (FE)a 
Acyclovir/gancyclovir 1 (3.8) 3 (5.5) 1.00 (FE)a 
NSAIDr 7 (26.9) 18 (32.7) 0.62 (CS)f 
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dIsCussION
In this case-control and cohort study in HIV-patients, TDF-associated nephrotoxicity was 
associated with a normal ITPase activity, and in these patients their eGFR-course amelio-
rated after TDF-cessation. Less patients with reduced ITPase activity had and accelerated 
eGFR-decline, which did not recover after TDF-cessation. ITPase activity may be used as 
biomarker to predict which patients are at high risk for developing nephrotoxicity during 
TDF-use (more pronounced in normal ITPase activity), in which patients TDF-associated 
nephrotoxicity may be irreversible (decreased activity), and in whom TDF therefore should 
Table 1. Clinical characteristics of the patients with (cases) and without (controls) TDF-associated nephrotoxic-
ity. (continued)
Characteristic Cases
(n=26)
Controls
(n=55)
p-value
Tdfg-associated nephrotoxicity, n (%)
>25% decrease in eGFRo 21 (80.8) 
≥2 markers of PTDs 16 (61.5) 
>25% decrease in eGFRo + ≥2 markers of PTDs 11 (42.3) 
a FE, Fisher’s Exact test; b SD, standard deviation; c UT, Unpaired T-test; d MSM, men who have sex with men; e 
IVDU, intravenous drug use; f CS, Chi Square test; g TDF, tenofovir disoproxil fumarate; h cART, combination 
antiretroviral therapy; i NNRTI, non-nucleoside reverse transcriptase inhibitor; j RPV, rilpivirine; k bPI, boosted 
protease inhibitor; l INSTI, integrase strand transfer inhibitor; m duration of TDF-use at inclusion and alloca-
tion to ‘case’ or ‘control’; n MWU, Mann Withney U test; o eGFR, estimated glomerular filtration rate; p ACE, 
angiotensin converting enzyme; q AT2, Angiotensine 2 antagonist; r NSAID, Non-steroidal anti-inflammatory 
drug; s PTD, proximal tubular dysfunction.
Table 2. Renal outcomes related to ITPase-activity and ITPA genotype.
Tdfa-associated 
nephrotoxicity
P-value eGfrb-changec in cases, 
mean ±sdd
P-value
yes (n=26) No (n=55) during Tdfa-
use 
after Tdfa 
discontinuation 
ITPase activitye 0.001 (MNf)
<4 7 (26.9%) 27 (49.1%) -4.3 ± 5.8 -4.0 ± 9.9 0.97 (PTg)
≥4 19 (73.1%) 28 (50.9%) -5.5 ± 4.8 +4.4 ±13.0 0.008 (PTg)
Mean ± SDd 4.41 ± 1.28 3.90 ± 1.31 0.103 (UTh)
ITPA genotype 0.256 (MNf)
Wt/94C>A 2 (7.7%) 3 (5.5%) * * *
Wt/124+21A>C 1 (3.8%) 12 (21.8%) * * *
Wt/wt 23 (88.5%) 40 (72.7%) -5.0 (4.7) +3.0 (13.0) 0.021 (PTg)
a TDF, tenofovir disoproxil fumarate; b eGFR, estimated glomerular filtration rate; c in ml/min/year, d SD, stan-
dard deviation; e mmol IMP/mmol Hb/hour; f MN, McNemar (Wt/wt versus wt/94C>A and wt/124+21A>C 
combined); g PT, Paired samples T-test; h UT, Unpaired T-test; * indicates that not enough data were available 
for analysis.
Chapter 5.
90
be discontinued when signs of TDF-associated nephrotoxicity occur. The results of the pres-
ent study confirm our previous findings that a normal ITPase activity was associated with 
nephrotoxicity during TDF-use.15 However, in this study, we were able to strictly define 
nephrotoxicity and investigate the association between ITPase activity and TDF-associated 
nephrotoxicity.16
It is unclear why a normal ITPase activity is associated with both TDF-associated neph-
rotoxicity and recovery after TDF-cessation. TDF causes mitochondrial DNA (mtDNA) 
toxicity in tubular cells.21-23 Imbalanced mitochondrial nucleotide pools can cause mtDNA 
depletion, resulting in mitochondrial dysfunction.24,25 Furthermore, TDF leads to increased 
oxidative stress in mitochondria of renal tubular cells.26 In cells with oxidative stress, the 
enzyme xanthine oxidase (XO) activity is relatively increased27 and XO is a source of free 
radicals28. A normal ITPase activity, compared to decreased activity, may lead to more 
availability of hypoxanthine (formed from inosine), a substrate for XO. Eventually, the com-
bination of a normal ITPase activity and TDF-use may lead to increasing oxidative stress, 
resulting in nephrotoxicity. Further research is warranted to clarify whether erythrocyte 
ITPase activity is an adequate surrogate for ITPase activity in renal cells, and what the effect 
of ITPase on the nucleotide pools in renal mitochondria is. Differences in ITPase activity in 
mitochondria, the effect of the ITPase activity on mitochondrial TDF-metabolism, and the 
role of TDF in oxidative stress should be studied.
This study has some limitations. First, the sample size of the study was based on previous 
findings,15 but data on ITPase activity related to TDF-associated nephrotoxicity are scarce 
and difficult to translate to assumptions for our sample size. As the results of a preliminary 
analysis in the first 81 included patients were already highly significant, the final 6 patients 
were not included. Second, we cannot exclude that the nephrotoxicity observed in our cases 
was due to other, unidentified, factors, although patient characteristics were comparable 
between the cases and controls. Besides, data on longer follow-up were not available, and 
therefore we cannot exclude that patients who are included as controls, could have de-
veloped nephrotoxicity with longer use of TDF. Third, recovery of nephrotoxicity may be 
underestimated in patients using DTG. DTG is known for its inhibitory effect on tubular 
creatinine clearance, leading to an increase in serum creatinine, which decreases the eGFR 
without impairment of actual glomerular or tubular function.29 11 of the 26 cases were 
former DOMONO-participants, and switched to DTG monotherapy. Indeed, in some of 
our patients using DTG the eGFR further decreased, but this was in only 1 of 7 patients 
with normal ITPase activity, versus in 2/4 cases with reduced activity. So even after a switch 
from TDF to DTG, the distinct between normal versus reduced ITPase activity in relation 
to eGFR-improvement remains. Given the low numbers of patients with follow-up of PTD-
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markers after 48 weeks, importantly due to the observational nature of the study of Rokx et 
al, we were not able to provide data on recovery of PTD.
In conclusion, ITPase activity is associated with nephrotoxicity during TDF-use for HIV-
infection and could be used to predict eGFR-recovery, but the underlying mechanism needs 
to be elucidated. ITPase activity may be used in the decision to initiate and discontinue TDF 
in an individual patient, and this recommendation should be confirmed in a prospective 
trial.
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absTraCT
Objectives
Abacavir use has been associated with an increased risk of cardiovascular disease (CVD) and 
metabolic events in HIV-infected patients, although this finding was not consistently found. 
It is unclear whether abacavir only increases this risk in subpopulations of HIV-infected pa-
tients. It may be hypothesized that inosine 5’-triphosphate pyrophosphohydrolase (ITPase), 
an enzyme involved in the metabolism of purine analogues used in HIV treatment, plays a 
role in the risk of CVD and metabolic events in HIV-infected patients.
methods
ITPase activity and ITPA genotype were determined in 393 HIV-infected patients. ITPase 
activity <4 mmol IMP/mmol Hb/h was considered decreased. ITPA polymorphisms tested 
were: c.94C>A (rs1127354) and c.124+21A>C (rs7270101). ORs were determined using 
generalized estimating equation models for developing CVD in patients who had ever 
been exposed to abacavir, tenofovir or didanosine and for developing metabolic events in 
patients currently using these drugs.
results
In patients using abacavir, metabolic events were associated with ITPase activity. No as-
sociation was demonstrated for tenofovir or didanosine. The OR for metabolic events was 
3.11 in patients using abacavir with normal ITPase activity (95% CI 1.34–7.21; p=0.008) 
compared with patients with decreased ITPase activity (adjusted for age, BMI, cumulative 
duration of combination antiretroviral therapy (cART) use and the use of PI and NNRTI). 
CVD was not associated with ITPase activity or ITPA genotype.
Conclusions
This study shows, for the first time, that ITPase activity is associated with the occurrence 
of metabolic events in patients using abacavir. Further studies are needed to confirm this 
association and to elucidate the possible mechanism.
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INTrOduCTION
The life expectancy of patients infected with HIV has improved substantially in recent 
decades1 and in developed countries has been approaching that of the non-HIV-infected 
general population.2 In the Netherlands, currently, 42% of HIV patients are older than 50 
years of age3 and in the USA, at year-end in 2015, the group of patients aged 50–54 years 
made up the largest percentage of persons living with HIV (18%).4 With increasing age, 
non-communicable comorbidities such as cardiovascular disease (CVD) increase, espe-
cially among HIV-infected patients using combination antiretroviral therapy (cART).5–7 For 
CVD it is unclear what the contribution of the HIV infection itself is compared with the 
drugs that are part of the cART regimens. In a meta-analysis the pooled relative risk of 
CVD among HIV-infected patients without treatment was 1.61 compared with people not 
infected with HIV.8 The pooled relative risk for HIV-infected patients on treatment was 
2.00 compared with non-HIV-infected people.8 Different antiretroviral medication classes 
have been associated with a higher risk of CVD. The relative risk of CVD was 1.41 (95% 
CI 1.2–1.65) for patients on PI-based cART compared with those on non-PI-based cART.8 
An increased rate of myocardial infarction in patients recently treated with abacavir and 
didanosine was first reported in the D:A:D study.9 Since then, several cohort studies and 
randomized clinical trials have confirmed the association of abacavir use and increased 
risk for CVD10–12 and in a meta-analysis the pooled relative risk was 1.8 (95% CI 1.43–2.26; 
p<0.001) for patients treated with abacavir.8 Currently this association is still debated, as 
other studies have found either no effect or no significant effect of abacavir use on the risk 
of CVD.13,14
The pathogenic mechanism of the potential association between abacavir use and CVD 
is not clear. Which factors predispose patients using abacavir to a higher risk of CVD, 
apart from the classic risk factors such as dyslipidaemia, hypertension (HT) and smoking, 
has not yet been elucidated. It may be hypothesized that differences in the metabolism of 
abacavir predispose to a higher risk for CVD. The active metabolite of abacavir is carbovir 
triphosphate, which is a guanosine analogue. Guanosine 5’-triphosphate (GTP) is a low-
affinity substrate for the enzyme inosine 5’-triphosphate pyrophosphohydrolase (ITPase) 
compared with the natural substrate inosine 5’-triphosphate (ITP).15 ITPase is one of 
the scavenger enzymes eliminating the potentially cytotoxic or genotoxic non-canonical 
nucleoside triphosphates from the nucleotide pool16 and is encoded by the ITPA gene on 
chromosome 20p (OMIM #147520). The SNPs c.94C>A (p.Pro32Thr, NCBI rs1127354) and 
c.124+21A>C (NCBI rs7270101) in the ITPA gene can cause a decrease in ITPase activity.17 
In HIV-infected patients, ITPase was found to have decreased expression in leukocytes, 
which was not associated with ITPA genotype,18 and decreased activity in erythrocytes in 
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patients with ITPA genotype wt/wt or c.94C>A compared with a control population with 
the same genotype.19
The natural role of ITPase, the different ITPase activity in HIV-infected patients and the 
potential role of ITPase in the metabolism of the purine analogues used in HIV treatment, 
suggest that ITPase activity may play a role in the risk of CVD in patients using abacavir.
We therefore determined whether ITPase activity and ITPA genotype are associated with 
the occurrence of CVD and with risk factors such as HT, hypercholesterolaemia and diabe-
tes mellitus (DM) during abacavir use in a cohort of HIV-infected patients.
PaTIeNTs aNd meTHOds
Patients
HIV-infected patients at the outpatient clinic of the Maastricht University Medical Center 
in Maastricht, The Netherlands, who were treated with cART, were included in this study 
after providing written informed consent. The data used for this study were collected as 
described previously.20 The study was performed according to the Helsinki Declaration and 
approved by the Medical Ethics Committee of the Maastricht University Medical Center, 
Maastricht, The Netherlands.
endpoints
The endpoints of the study were CVD and metabolic events. CVD was defined as: reported 
cerebrovascular accident (CVA) (transient ischaemic attack, haemorrhagic/ischaemic/
unspecified CVA), arterial occlusion, peripheral stent or bypass, coronary event (coronary 
artery bypass graft, percutaneous intervention or myocardial infarction) or anamnestic 
complaints of peripheral claudication, during the use of cART. Metabolic events were de-
fined as: dyslipidaemia as the reported reason for stopping the cART regimen, laboratory-
confirmed dyslipidaemia (total cholesterol >6.5 mM, triglycerides >2.3 mM, LDL >4.5 
mM), use of lipid-lowering therapy (statins and/or fibrates), DM or HT. DM was defined 
as fasting glucose ≥7 mM (126 mg/dL) measured on two or more consecutive occasions 
within 3 months, or glucose ≥11.1 mM (200 mg/dL) measured once and in combination 
with symptoms of hyperglycaemia, or if the patient was reported as being diabetic, or if 
the patient had glucose-lowering therapy.21 HT was defined as mean systolic pressure >140 
mmHg, mean diastolic pressure >90 mmHg or if the patient used anti-hypertensive medica-
tion.22
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ITPase activity
Erythrocyte ITPase activity was determined as described previously23 and assessed by 
formation of inosine 5’-monophosphate (IMP) from ITP. ITPase activity was expressed as 
millimoles (mmol) of IMP formed from ITP in 1 h per mmol hemoglobin (mmol IMP/
mmol Hb/h). ITPase activity of ≥4 mmol IMP/mmol Hb/h was considered normal, which 
is the lowest value within the 95% CI for ITPA wild-type (wt/wt) carriers.19,24
ITPA genotype analysis
ITPA genotype was analysed as described previously by Bierau et al.19 The Wizard Genomic 
DNA purification kit (Promega, Madison, WI, USA) was used to isolate genomic DNA 
from whole blood. The DNA was genotyped using Sanger sequencing for the two ITPA 
polymorphisms; c.94C>A (p.Pro32Thr, rs1127354) and c.124+21A>C (rs7270101). The 
genotype was considered to be wild-type (wt/wt) when neither of the polymorphisms was 
detected. All sequences were evaluated by two independent laboratory experts.
statistical analysis
All analyses were performed with IBM SPSS Statistics 21 (IBM Corporation, NY, USA) 
and the statistical software package R (free download from www.rproject.org) version 3.4.3. 
Pearson’s χ2 tests, Fisher’s exact test, independent samples T-tests and Mann–Whitney U 
tests were used to determine significant differences.
The occurrence of CVD was analysed using generalized estimating equation models to 
account for repeated statement and adjusted for differences in CVD risk profile: age at the 
time of changing the cART regimen, the last measured BMI, smoking status (current or 
former smoker), pre-existing CVD before the start of cART, HT, DM, dyslipidaemia and 
gender. Further adjustment for cumulative total duration of cART and use of a PI or an 
NNRTI at the time of the event was performed. Numerical variables were standardized in 
order to have the same scale.
The occurrence of a metabolic event was analysed using generalized estimating equation 
models to account for repeated statement and adjusted for cumulative total duration of 
cART, age at the time of changing the cART regimen, the last BMI measured, use of a PI and 
use of an NNRTI at the time of the event. Numerical variables were standardized in order 
to have the same scale.
Since tenofovir disoproxil fumarate (further referred to as tenofovir) and didanosine are 
also purine analogues, their active metabolites being adenine nucleotide analogues instead 
of guanosine nucleotide analogues such as carbovir, the association of ITPase activity, ITPA 
genotype and CVD in patients using these drugs in their cART regimen was determined in 
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addition. For exposure to either abacavir, tenofovir or didanosine, in the analysis of CVD 
we used current (which means use at the time of the event) and past exposure. Only current 
exposure was used in the analysis of metabolic events.
When abacavir, tenofovir or didanosine were used concomitantly in one cART regimen, this 
regimen was excluded from the analysis. P-values <0.05 were considered to be statistically sig-
nificant. We did not correct for multiple testing because our analyses were hypothesis driven.
resulTs
Patient characteristics
After excluding regimens containing a combination of didanosine, tenofovir or abacavir, 1422 
regimens in 393 patients were used in the analysis.20 Of these patients, 52.2% had an ITPase ac-
tivity of <4 mmol IMP/mmol Hb/h (Table 1). No statistically significant difference was found 
between patients with decreased ITPase activity and with normal ITPase activity with regard 
to age, gender, race, CD4 nadir counts and PI and NNRTI use. In 60.1% of regimens containing 
no purine, a PI was part of the cART regimen; this was, respectively, 34.5%, 22.9% and 60.2% 
in regimens containing tenofovir, abacavir or didanosine. Current exposure to the purine 
analogues tenofovir, abacavir and didanosine was frequent (n=601 (42.3%), n=244 (17.2%) 
and n=128 (9.0%) respectively). The number of regimens with current plus past exposure to a 
purine analogue was 699 (49.2%) for tenofovir, 465 (32.7%) for abacavir and 365 (25.7%) for 
didanosine. CVD was present in 12.5% of the patients (n=49) and reported to be CVA (n=15), 
arterial occlusion (n=2), peripheral stent or bypass (n=6), coronary arterial bypass graft (n=6), 
percutaneous intervention (n=12), myocardial infarction (n=7) or anamnestic complaints of 
peripheral claudication (n=1). In patients with current or past exposure to abacavir, 24 CVD 
events occurred; CVA (n=7), coronary artery bypass grafting (n=3), percutaneous coronary 
intervention (n=7), myocardial infarction (n=2), arterial occlusion (n=2) and peripheral stent 
or bypass (n=3). In 749 regimens (52.7%) a metabolic event was found. An overview of differ-
ent components of the combined endpoint metabolic event is presented in Table 2.
effect of ITPase activity and ITPA genotype on CVd
No significant difference in CVD between the regimens used in patients with decreased 
versus normal ITPase activity was found, irrespective of cART regimen used (22 versus 
27 events, respectively; crude p=0.34). ITPase activity in combination with current or past 
exposure to abacavir was not associated with a higher number of CVD events compared 
with tenofovir or didanosine exposure in our cohort (Table 3).
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Table 1. Demographic and clinical characteristics of the patients (n=393) with ITPase activity <4 and ≥4 mmol 
IMP/mmol Hb/hour.
Characteristic ITPase activitya P-value
<4 (n=205) ≥4 (n=188)
age*; mean years ± SDb 50.1 ± 11.1 49.7 ± 11.9 0.78
male gender,* n (%) 164 (80.0%) 155 (82.4%) 0.53
race, n (%)* 0.81
Caucasian 164 (80.0%) 147 (78.2%)
Hispanic 5 (2.4%) 4 (2.1%)
African 22 (10.7%) 27 (14.4%)
Asian or other 14 (6.9%) 10 (5.3%)
mean ITPase activity* ± SD 2.44 ± 1.12 5.24 ± 1.09 <0.001
ITPA genotype,* n (%) <0.001
Wt/wt 90 (43.9%) 175 (93.1%)
Wt/c.124+21A>C 59 (28.8%) 9 (4.8%)
Wt/c.94C>A or otherc 53 (25.9%) -
Unknown 3 (1.5%) 4 (2.1%)
alcohol use*, n (%) 0.51
<2 (IU/day) 157 (76.6%) 133 (70.7%)
≥2 (IU/day) 35 (17.1%) 36 (19.1%)
Unknown 13 (6.3%) 19 (10.1%)
smoking, n (%) 0.65
Never 18 (8.8%) 21 (11.2%)
Current or former 130 (63.4%) 116 (61.7%)
Not current, unknown if ever 55 (26.8%) 46 (24.5%)
Unknown 2 (1.0%) 5 (2.7%)
body mass index, n (%) 0.09
Underweight (<18.5) 14 (6.8%) 3 (1.6%)
Normal (≥18.5-<25) 102 (49.8%) 95 (50.5%)
Mild/Moderate obesity (≥25-<30) 59 (28.8%) 52 (27.7%)
Severe obesity (≥30) 10 (4.9%) 15 (8.0%)
Unknown 20 (9.8%) 23 (12.2%)
median Cd4 nadir*, x106 cells/L (range) 207 (1-1022) 209 (3-612) 0.40
median year of start carT* (range) 2006 (1987-2013)c 2006 (1987-2013)d 0.25
Total number of carT regimens* 734 688
Type carT, n (%) 0.09
NNRTId 342 (46.6%) 295 (42.9%) 
PIe 239 (32.6%) 267 (38.8%) 
NNRTId and PIe 59 (8.0%) 45 (6.5%) 
Other 94 (12.8%) 81 (11.8%) 
* previously published; a mmol IMP/mmol Hb/hour; b SD, standard deviation; c Other = homozygous 
c.124+21A>C or homozygous c.94C>A or heterozygous c.124+21A>C/c.94C>A; d NNRTI, nucleoside/nucleo-
tide analog reverse-transcriptase inhibitor; e PI, Protease inhibitor
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Table 2. Diabetes mellitus, dyslipidemia and use of blood pressure medication or cholesterol lowering therapy 
for regimens used in patients with decreased and normal ITPase activity.
all regimens P-values regimens currently 
containing abacavir
P-values
ITPase activitya ITPase activitya
<4 (n=734) ≥4 (n=688) <4 (n=131) ≥4 (n=113)
diabetes, n (%) 0.03 0.04
Yes 28 (3.8) 45 (6.5) 3 (2.3) 11 (9.7) 
Unknown - 18 (2.6) - - 
Hypertension, n (%) 0.03 0.16
Yes 146 (19.9) 171 (24.9) 26 (19.8) 31 (27.4) 
Unknown - - - - 
dyslipaemia, n (%) 0.01 0.17
Yes 195 (26.6) 226 (32.8) 40 (30.5) 44 (38.9) 
Unknown - - - - 
Cholesterol lowering therapy, n (%) 0.014 0.68
Yes 86 (11.7) 117 (17.1) 20 (15.3) 23 (20.4)
Unknown 10 (1.4) 9 (1.3) 1 (0.8) 1 (0.9)
a mmol IMP/mmol Hb/hour
Table 3. CVD and metabolic events for regimens used in patients with decreased and normal ITPase activity 
and different ITPA genotypes.
ITPase activitya Crude p adjusted p ITPA genotype Crude p adjusted p
<4 ≥4 Otherb wt/wt
n /
regimens
n /
regimens
n /
regimens
n /
regimens
CVd
Totalc n=1422 22/734 27/688 0.34 0.82 13/435 35/960 0.72 0.86
Tenofovird n=699 12/354 17/345 0.31 0.50 7/211 21/478 0.35 0.77
Abacavire n=465 11/245 13/220 0.49 0.40 6/132 18/328 0.86 0.41
Didanosinef n=365 2/165 6/200 0.30 0.45 0/91 8/272 0.24 n.a.
metabolic events
Totalc n=1422 356/734 393/688 0.001 0.12 202/435 537/960 0.001 0.14
Tenofovirg n=601 155/306 168/295 0.12 0.55 89/186 231/409 0.13 0.53
Abacavire n=244 63/131 82/113 <0.0001 0.008 39/75 106/164 0.003 0.24
Didanosineh n=128 25/51 37/77 0.92 0.75 12/31 49/96 0.26 0.61
a mmol IMP/mmol Hb/hour; b heterozygous wt/c.124+21A>C or wt/c.94C>A or homozygous c.124+21A>C 
or homozygous c.94C>A or compound heterozygous c.124+21A>C/c.94C>A; c Genotype unknown in 27 regi-
mens; d Genotype unknown in 10 regimens; e Genotype unknown in 5 regimens; f Genotype unknown in 2 
regimens; g Genotype unknown in 6 regimens; h Genotype unknown in 1 regimen
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Regardless of cART regimen, CVD more often occurred in patients with ITPA genotype wt/
wt versus the other ITPA genotypes [CVD: n=35 (71.4%) versus n=13 (26.5%) respectively; 
although this difference was not statistically significant (p=0.72)] (Table 3). One CVD oc-
Effect of ITPase activity on metabolic events
0.1 1 10
No purine
Didanosine
Abacavir
Tenofovir
Total
1.14 (0.64-2.03)
0.86 (0.36-2.07)
3.11 (1.34-7.21)
1.17 (0.70-1.95)
1.34 (0.93-1.94)
OR (95% CI)
0.66  
0.75
0.008
0.55
0.12
P-values
←⎯⎯ ⎯⎯→
 More adverse events                             More adverse events
in ITPase activity <4*                             in ITPase activity ≥4*
(A)
0.1 1 10
No purine
Didanosine
Abacavir
Tenofovir
Total
1.42 (0.75-2.69)
1.27 (0.51-3.18)
1.68 (0.71-3.99)
1.18 (0.70-2.01)
1.35 (0.90-2.01)
OR (95% CI)
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P-values
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More adverse events                              More adverse events
in other ITPA gentoypes                         in ITPA genotype wt/wt
Effect of ITPA genotype on metabolic events(B)
figure 1: Effect ITPase activity (A) and ITPA genotype (B) on metabolic events. The effect of decreased versus 
normal ITPase activity (A) and of other ITPA genotypes versus ITPA genotype wt/wt (B) on the occurrence of 
metabolic events are plotted for all regimens (Total), and for regimens containing tenofovir, abacavir, didano-
sine or no purine. Odds ratio (OR) with 95% confidential interval and matching p-values are displayed. * mmol 
IMP/mmol Hb/hour
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curred in a patient with unknown ITPA genotype. Adjusting the data for CVD risk profiles, 
cumulative cART use and PI and NNRTI use did not change the outcome for CVD.
effect of ITPase activity and ITPA genotype on metabolic events
Of all the metabolic events, 52.5% occurred during regimens prescribed to patients with 
normal ITPase activity (crude p=0.001) (Table 3). In 72.6% of the regimens currently 
containing abacavir used by patients with normal ITPase activity, a metabolic event oc-
curred, compared with 48.5% in patients with decreased ITPase activity (p<0.0001; Table 
3). After adjusting for age, BMI, cumulative duration of cART use and the use of PI and 
NNRTI, the OR for developing a metabolic event was statistically significantly higher in 
patients with normal versus decreased ITPase activity (3.11, 95% CI 1.34–7.21; p=0.008) in 
abacavir-containing regimens. In regimens containing tenofovir or didanosine, no associa-
tion between ITPase activity and the occurrence of metabolic events could be demonstrated 
(Figure 1a). Also in regimens without a purine analogue but in 60% containing a PI no 
association was found (Figure 1a).
In regimens prescribed in patients with wt/wt genotype, metabolic events were more 
frequently found compared with the other genotypes (537/960 regimens versus 202/435 
regimens; p=0.001) (Table 3). Metabolic events occurred more frequently in patients using 
abacavir and having the wt/wt genotype (p=0.003). This increase could not be found in 
patients using tenofovir or didanosine (Table 3). However, after adjusting for age, BMI, 
cumulative cART use and the use of PI or NNRTI, no significant difference in metabolic 
events between patients using abacavir with wt/wt genotype and the other ITPA genotypes 
could be demonstrated (Figure 1b).
dIsCussION
In this study we show, for the first time, that ITPase activity may play a role in the as-
sociation of abacavir use and the occurrence of metabolic events in HIV-infected patients 
using cART. In regimens containing abacavir decreased ITPase activity was associated with 
fewer metabolic adverse events. We could not confirm the hypothesis that decreased ITPase 
activity decreased the risk of CVD. No association between ITPA genotype and CVD or 
metabolic events was found after adjustment for other CVD risk factors.
In multiple studies it was reported that the use of abacavir increased the risk of developing 
CVD or myocardial infarction.9–11 Other studies, however, could not confirm this associa-
tion.14,25 We found no association between abacavir use, ITPase activity and CVD events, 
possibly owing to the relatively small number of CVD events found in our study. Like oth-
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ers, we found that metabolic events were associated with abacavir, but not with tenofovir 
use.26–30 A possible explanation may be the difference in chemical structure since tenofovir 
is an adenosine analogue and abacavir is a guanosine analogue.
How ITPase might be involved in the occurrence of metabolic events during abacavir use 
is not known. Carbovir triphosphate was found not to be a direct substrate for ITPase.20 
Potentially the answer lies in cellular signal transduction. Guanosine 3’,5’-cyclic mono-
phosphate (cGMP) is an important secondary messenger that modulates multiple cellular 
processes, such as platelet aggregation, neurotransmission, blood pressure, lipolysis and 
gut peristalsis.31,32 cGMP is produced from GTP by the enzyme soluble guanylate cyclase 
(sGC)33,34 and stimulation of sGC was found to be protective against obesity.35 However, in 
the presence of nitric oxide (NO) and magnesium ions (Mg2+) sGC shifts its substrate speci-
ficity to ITP to form inosine 3’,5’-cyclic monophosphate (cIMP) and also, in the absence of 
hypoxaemia, addition of exogenous ITP to intact porcine arteries led to higher cIMP lev-
els.36,37 In contrast to cGMP, which induces vasodilatation, cIMP induces vasoconstriction.36 
This vasoconstriction has been well studied by measurement of flow-mediated dilatation 
(FMD) of the brachial artery and is strongly associated with the risk of CVD.38–40 Patients 
using abacavir were found to have lower FMD than patients not using abacavir,41 whereas 
didanosine and tenofovir use were not associated with lower FMD. Support for the hypoth-
esis that abacavir shifts sGC to use ITP instead of GTP, leading to higher cIMP levels, can be 
found in the study by Baum et al.42 Formation of cGMP was decreased in human platelets 
incubated with carbovir triphosphate (the active metabolite of abacavir) and the authors 
concluded that carbovir triphosphate inhibited sGC. The question remains whether sGC 
was inhibited, carbovir triphosphate competed with GTP or a shift in substrate specificity of 
sGC occurred. New research is warranted to investigate under which circumstances ITP is 
a substrate for sGC, what the consequences of this shift in substrate specificity are and what 
the impact of carbovir triphosphate is on sGC activity in human cells.
In 2010 Fellay et al.17 showed that the SNPs 94C>A and 124+21A>C in the ITPA genotype 
were associated with the protection against hemolytic anemia during treatment with riba-
virin for hepatitis C infection. We found ITPase might be a more accurate predictor of the 
development of hemolytic anemia in these patients than ITPA genotype.43 In HIV-infected 
patients both ITPase activity and ITPA genotype were associated with adverse events; how-
ever, ITPA genotype correlated less well with adverse events compared with ITPase activ-
ity.20 In the present study again, we found ITPA genotype and ITPase activity were both 
crudely associated with adverse events; however, after adjusting with the logistic mixed 
effects model, only ITPase activity remained statistically significant. The difference in the 
effect of ITPase activity versus ITPA genotype in HIV-infected patients may be explained 
by the finding that in these patients the wt/wt and the c.94C>A carriers have decreased 
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erythrocyte ITPase activity compared with non-HIV-infected patients carrying the same 
genotypes.19
Here, we report a lower risk of metabolic events in HIV-infected patients that use abacavir 
and have decreased ITPase activity. In a previous study, in tenofovir-containing regimens, 
decreased ITPase activity was also associated with a lower risk of adverse events.20 In con-
trast, the use of abacavir in this previous study was crudely associated with an increase in 
adverse events in patients having decreased ITPase activity. The adverse events in that study 
were different from the current study and included gastro-intestinal, neurological, renal, 
skin and liver-related adverse events, and potentially this explains why decreased ITPase 
activity may lead to an increase in adverse events in one study, but a decrease in adverse 
events in the other study. In other studies the association between decreased ITPase activity 
or a SNP in the ITPA genotype and adverse events was shown to be dependent on the kind 
of adverse event and the drug that was used, leading to, for instance, an increase in hepatic 
toxicity (during azathioprine or 6-mercaptopurine use) but a decrease in hemolytic anemia 
(during ribavirin use).44–47 We hypothesize that the effect of ITPase activity in patients using 
abacavir is also dependent on the nature of the adverse events.
There are limitations that need to be mentioned. Our study was retrospective with all the 
possible caveats of retrospective studies. For example, factors other than the cART regimen 
could have contributed to alterations in metabolic events. This is, however, not different for 
patients with decreased or patients with normal ITPase activities, and thus the influence of 
this factor seems limited. Although our results could be mechanistically made plausible, 
further prospective studies are still warranted to confirm our results. Owing to the number 
of patients included, a low frequency of cardiovascular events was found. This may explain 
the lack of association of CVD with ITPase activity. Also, the clinical relevance of our find-
ings is to be further established by larger prospective trials.
In conclusion, we showed that ITPase activity may be associated with a risk of metabolic 
events in HIV-infected patients using abacavir. Using ITPase activity as a potential bio-
marker to predict adverse metabolic events may be a further step towards more patient-
tailored medicine in the future. However, elucidation of the pathogenic mechanism needs 
further studies and our results need to be confirmed in a prospective trial.
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absTraCT
The HIV-human metabolic relationship is a complex interaction convoluted even more by 
antiretroviral therapy (cART) and comorbidities. The ability of cART to undo the HIV in-
duced metabolic dysregulation is unclear and under-investigated. Using targeted metabolo-
mics and multiplex immune biomarker analysis, we characterized plasma samples obtained 
from 18 untreated HIV-1-infected adult patients and compared these to a non-HIV infected 
(n = 23) control population. The biogenic amine perturbations during an untreated HIV 
infection implicated altered tryptophan- nitrogen- and muscle metabolism. Furthermore, 
the lipid profiles of untreated patients were also significantly altered compared to controls. 
In untreated HIV infection, the sphingomyelins and phospholipids correlated negatively 
to markers of infection IP-10 and sIL-2R whereas a strong association was found between 
triglycerides and MCP-1. In a second cohort, we characterized plasma samples obtained 
from 28 HIV-1-infected adult patients before and 12 months after the start of cART, to 
investigate the immune-metabolic changes associated with cART. The identified altered 
immune-metabolic pathways of an untreated HIV infection showed minimal change after 
12 months of cART. In conclusion, 12 months of cART impacts only mildly on the meta-
bolic dysregulation underlying an untreated HIV infection and provides insights into the 
comorbidities present in virally suppressed HIV patients.
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INTrOduCTION
The interaction of the Human immunodeficiency virus (HIV) with its host is a complex 
process with a growing body of literature revealing the capacity of HIV to induce a plethora 
of metabolic changes in the human body.1-5 Hypertriglyceridemia was identified as one of the 
first metabolic consequences of HIV infection.6 Since then, studies using Mass Spectrometry 
(MS) and Nuclear Magnetic Resonance (NMR) applied to biofluids of HIV-infected indi-
viduals have confirmed the presence of HIV induced metabolic alterations.1,7-9 Investigating 
in vitro models of HIV infection using primary macrophages and CD4+ T-cells had differ-
ent metabolic outcomes during HIV infection. CD4+ T-cells infected with HIV exhibited 
increased glucose uptake and upregulated glycolytic intermediates compared to reduced 
glucose uptake and steady-state glycolytic intermediates in HIV-infected macrophages.10 
While, in vivo models using rhesus macaques infected with simian immunodeficiency virus 
(SIV) revealed increased fatty acids, phospholipids, and acyl-carnitines, suggesting an im-
paired mitochondrial fatty acid oxidation.11 Comparatively, serum and plasma derived from 
HIV infected individuals revealed altered metabolites of lipid and mitochondrial pathways 
as well as organic acids and fatty acids.1,5 Moreover, the saliva from HIV-infected patients 
versus healthy controls revealed alterations in carbohydrate biosynthesis and degradation.2
Infection with HIV causes a progressive malfunctioning of the human immune system. 
HIV infection depletes CD4+ T-cells, while also inducing functionally exhausted CD8+ 
T-cells and impaired NK cells, leaving the host vulnerable to opportunistic infections.12 
Furthermore, the metabolic and immunological changes in untreated HIV patients increase 
the risk of developing comorbidities, including cardiovascular disease (CVD), insulin resis-
tance and HIV-associated neurocognitive disorders (HAND).13,14
The advent of combination antiretroviral therapy (cART) provided an important lifeline for 
HIV patients, since cART effectively inhibits HIV replication to undetectable levels, while 
also enabling the restoration of the immune system with increasing CD4+ T-cell counts. 
Nevertheless, important metabolic-related side-effects of cART are reported in patient pop-
ulations, mainly lipodystrophy and insulin resistance, which may further predispose virally 
suppressed patients to increased CVD, diabetes, and kidney damage.15-17 Also, studies have 
shown that although cART dramatically decreased the incidence of the most severe clinical 
phenotype of HAND (HIV associated neurocognitive disorder) – HIV-associated dementia 
– in virally suppressed patients the milder forms of HAND – asymptomatic neurocognitive 
impairment and mild neurocognitive disorders – have become more prevalent.18,19 One as-
pect of the pathogenesis of CVD or HAND in successfully treated HIV patients is that while 
cART effectively suppresses HIV replication and activity, low levels of immune activation 
are sustained.20-22 The ability of cART to rectify the HIV-induced metabolic dysregulation 
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is unclear and under-investigated. However, this may be highly relevant since persistent 
metabolic stress could be an underlying pathogenic mechanism in the comorbidities of 
untreated HIV patients as well as cART suppressed HIV patients. Robust characterization 
of the metabolic alterations experienced during HIV infection is needed to determine the 
effect of cART on these pathways, in cART suppressed HIV patients.
To study this, we used comprehensive targeted metabolomics techniques integrated with 
classical immunological assays and compared changes in plasma of untreated HIV-1 patients 
to non-HIV infected individuals, and paired plasma of untreated HIV-1 patients at baseline 
to their plasma after 12 months of cART in the HIV-suppressed state, to assess whether 
profiles normalized to the situation in healthy individuals or remained perturbed. We found 
dysregulated biogenic amine and lipid metabolism in untreated HIV-infected patients, 
conditions that have been independently associated with the pathophysiology of CVD and 
HAND. After 12 months of cART, metabolic changes were found for some biogenic amines, 
while the lipid metabolites revealed increasing levels in the virally suppressed patients.
meTHOds
Patients and sample collection
Untreated HIV versus non-HIV-infected controls, population A
For the comparison of metabolic profiles of untreated HIV-1-infected patients to a non-
HIV infected control population, 18 HIV-1-infected, cART naïve patients were selected 
from the outpatient clinic of the Erasmus Medical Center in Rotterdam, The Netherlands, 
archived sample bank. The plasma was stored at −80°C. Inclusion criteria were age over 
18 years and no previous treatment for HIV. Exclusion criteria were severe comorbidity 
(e.g. diabetes mellitus, cardiovascular disease, opportunistic infection), coinfection with 
hepatitis B or C, use of alcohol > 2 IU/day and use of co-medication. All patients had given 
written informed consent for inclusion in the database of the Dutch HIV monitoring foun-
dation (Stichting HIV Monitoring; SHM) also known as the AIDS Therapy Evaluation in 
the Netherlands (ATHENA) cohort, and collection of demographic, laboratory and clinical 
data from the medical records and storage and future use for scientific research of biological 
material. Their plasma samples were compared to a non-HIV infected control population 
from volunteers (n = 23), without comorbidity or co-medication, which had all given their 
written informed consent.
Untreated HIV versus HIV-suppressed (12 months of cART), population B
For the comparison of metabolic profiles of untreated HIV-1-infected patients to the HIV-
suppressed situation, plasma samples of 28 HIV-1-infected patients from the outpatient 
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clinic of the Maastricht University Medical Center in Maastricht, The Netherlands were 
selected in the archived sample bank. The plasma was stored at −80°C. All patients had 
given written informed consent for inclusion in the database of the Dutch HIV monitoring 
foundation and collection of demographic, laboratory and clinical data from the medical 
records and storage and future use for scientific research of biological material. From each 
included patient, a plasma sample was selected from before the start of cART and at 12 
months after the start of cART. All patients were older than 18 years at the start of cART 
and had not received any previous ART therapy. All patients started with a cART regimen 
containing Abacavir. The patients had no diabetes mellitus and no diagnosed autoimmune 
diseases. We retrieved information regarding dyslipidaemia from the earlier laboratory 
results prior to the 12 months samples after the start of cART. Because the patients were 
generally not in care prior to the HIV diagnosis, no values were available from the blood 
sample prior to the start of cART. The study was performed according to the Helsinki Decla-
ration and approved by the Ethical Committee of the Maastricht University Medical Center.
Targeted lC-ms metabolomics
Targeted metabolomics analyses were performed using standard operating procedures 
derived from previously published methods.23-26 Detailed procedures and target lists are 
provided in the Additional file 1 - Methods with a brief overview of the four platforms used 
given in Table 1. After LC-MS analyses, peak integration was done using the instrumental 
software, and the relative ratios between metabolites and their corresponding internal 
standards were determined.
metabolomics quality controls
Quality control (QC) samples consisted of equal aliquots of a QC pool made by combining 
equal volumes (±25 µL) of all study samples. A set of QC samples was then included dur-
ing the analyses of the experimental groups on the individual metabolomic platforms and 
evenly distributed across the randomized samples prior to LC-MS analyses. In addition, 
independent duplicate samples (10–15%) were randomly selected. Using the QC samples 
and duplicate samples, a double-QC approach was applied to include metabolites that were 
reliably measured by the individual metabolomics platforms by reporting and using only 
those metabolites for which both duplicate samples and QC samples showed an RSD < 30%.
multiplex immunoassays to assess plasma biomarkers
The levels of cytokines, chemokines, growth factors and other proteins were determined us-
ing the Procarta Plex human Immune Monitoring Panel (Affymetrix, Vienna, Austria). The 
panel measured 14 proteins simultaneously and consisted of IP-10, IL-10, IL-6, D-dimer, 
sIL-2R, IL-21, IL-18, MCP-1, sPD-L1, sPD-L2, sTIM-3, sPD1, CRP, and sTNF-RII. The as-
say was conducted according to the manufacturer’s instructions, identical to the procedures 
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used in our previous studies.27-29 The concentrations of analytes were measured using the 
microsphere-based multiplex Luminex-100 (Luminex Corporation, Austin, TX, USA). 
Samples to compare untreated HIV with non-HIV controls were analyzed in a different 
run than paired samples of untreated and HIV-suppressed patients. Data were analyzed 
using ProcartaPlexAnalyst 1.0 (www.ebioscience.com/resources/procartaplex-analyst-1.0-
software.htm).
statistical analyses
SPSS 21.0 (SPSS Inc., Chicago, IL, USA) was used for Fisher’s exact tests on the patient 
cohort characteristics presented as frequencies, and ANOVA on the continuous values. 
A combination of univariate and multivariate bioinformatics approaches was performed 
using the R script‒based online tool Metaboanalyst 3.0, a comprehensive tool suitable for 
analysing metabolomics data.30 The metabolomics datasets were log transformed and auto-
scaled prior to bioinformatics analyses. For the analyses between controls and untreated 
HIV patients, significant metabolites were identified per metabolomics platform based on 
the following criteria: i. a p-value < 0.05 using the unpaired student t-test, and ii. a fold 
change (FC) ≥ 1.30 or ≤0.70, indicating a 30% increase or decrease. The False discovery 
Table 1. Metabolomics platforms. A brief overview of the platforms detailing volumes, sample preparation and 
analytical instruments.
Targeted 
metabolomics 
platform
Volume
serum
used
sample 
preparation 
method
analytical 
platform
metabolite class coverage Platform targets, n
Total Quality
control
passed
%
missing
data
Biogenic 
amine24
5 µL Protein 
precipitation 
& AccQ-Tag 
derivatization
UPLCa-TQMSb Amino acids, 
catecholamines & 
polyamines 100 62 0%
Positive lipid23 10 µL Isopropyl 
alcohol 
extraction
UPLCa-QToFc Lysophospholipids, 
phospholipids, cholesterol 
esters, di/triglycerides & 
spingomyelins
250 147 0.02%
Oxylipins25 250 µL Oasis 
HLB SPE 
extraction
HPLCd-MS/
MSe
Hydroxylated fatty 
acids, prostaglandins & 
thromboxanes
120 68 7.7%
Oxidative 
stress26 150 µL
Butanol:Ethyl 
acetate 
liquid-liquid 
extraction
UHPLCf-MS/
MSe Low pH 
run
Isoprostanes, nitro-fatty 
acids, sphingosine & 
sphinganine
46 36 6.6%
UHPLCf-MS/
MSe High pH 
run
Sphingosine-1-phosphate 
& lysophosphatidic acids 
species
a UPLC, Ultra Pressure Liquid-Chromatography; b TQMS, Triple quadrupole mass spectrometer; c QToF, Quad 
Time of Flight; d HPLC, High-Pressure Liquid-Chromatography; e MS/MS, Triple quadrupole Mass Spectrom-
eter; f UHPLC, Ultra High-Pressure Liquid-Chromatography.
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rate’s q-values are reported for every reported p-value. For the analyses between the paired 
untreated HIV patients and 12 months cART follow up, significant metabolites were iden-
tified per metabolomics platform based on a False discovery rate adjusted p-value < 0.05 
using a paired student t-test. Plasma protein biomarkers were analysed using the unpaired 
student t-test for comparing controls and untreated HIV patients, and the paired student 
t-tests across the paired patients’ samples at baseline and 12 months. GraphPad Prism 7 
software was used in the rendering of graphs and figures.
Two types of immune-metabolic correlation networks were done. Firstly, for the control 
group and the untreated HIV patient group, independent Spearman correlation analyses 
were done using the absolute metabolite and cytokine levels. Next, per group cytokine levels 
were correlated with each other to form the network skeleton. The second type of correla-
tion network was based on Spearman correlations of the levels of metabolites to cytokines 
in HIV-suppressed patients after 12 months of cART relative to the levels at baseline from 
paired patient samples (relative change = 12 months cART – baseline). Next, we corre-
lated the relative change in cytokine levels to form the network skeleton. For both types of 
immune-metabolic correlations significant correlations were defined using a cut-off p-value 
(two-tailed) < 0.01 and were visualized as a network using the Metscape application within 
Cytoscape (v3.4.0).
ethics approval and consent to participate
This study was conducted in accordance with the guidelines of the Declaration of Helsinki 
and the principles of Good Clinical Practice. The ethical review board of the Erasmus MC 
has approved the study, and informed consent was obtained from all patients who were 
asked to donate blood.
resulTs
untreated HIV versus non-HIV-infected controls
Patient population A
Most of the individuals in both the patient and the control populations listed in Table 2 
were male and Caucasians. Mean age did not differ between both groups. The mean CD4+ 
T-cell count of the HIV-1 patients was 441 × 106 cells/L with an interquartile range (IQR) of 
367.5 × 106. The untreated HIV patients had a large heterogeneity in viral load with a median 
of 1.11 × 105 viral copies and an IQR of 2.64 × 105 especially when taking the minimum and 
maximum values as listed in Table 2 into account.
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Altered plasma metabolic profiles in untreated HIV-infected patients
To characterized metabolic alterations experienced during an untreated HIV-1 infection, 
we compared 18 untreated HIV-1-infected patients (population A) with 23 controls through 
profiling their biogenic amines, lipids, and signalling lipid metabolites. As shown in the 
volcano plot in Fig. 1a, 18 biogenic amines were differently affected in HIV patients versus 
controls, with reduced levels in all (see Supplementary Table S1). Reduced levels of anti-
oxidants, including total glutathione and taurine, together with lipid headgroup moieties 
o-phosphoethanolamine and the choline metabolite sarcosine were identified as the most 
significantly altered amine metabolites during an untreated HIV infection. Furthermore, 
untreated HIV patients had decreased levels of tryptophan and serotonin compared to 
controls. The plasma kynurenine/tryptophan (K/T) ratio, as a readout for indoleamine 
2,3-dioxygenase (IDO) activity, showed upregulated IDO activity during untreated HIV 
infection compared to controls (p = 0.0003) (see Supplementary Fig.  S1A). Concurrently 
investigating the plasma serotonin/tryptophan ratio reflected the consequences of increased 
IDO activity for serotonin synthesis during untreated HIV infection compared to controls 
(p < 0.0001) (see Supplementary Fig. S1B). Decreased levels of the branch chain amino acids 
leucine and isoleucine as well as carnosine reflected impaired muscle metabolism during an 
untreated HIV infection. The significantly decreased levels of ornithine and putrescine in 
untreated HIV patients also hints at a reduced urea cycle and thus ammonia clearance in 
these patients compared to controls. Additionally, decreased levels of alanine, asparagine, 
α-aminobutyric acid, tyrosine, and methionine were also detected in untreated HIV patients 
compared to controls. Evaluation of the levels of plasma lipids, which included the differ-
ent lysophospholipids classes, phospholipids, di/triglycerides, sphingomyelins, ceramides, 
and cholesterol esters, revealed 44 modulated metabolites with a p < 0.05 and a fold-change 
(FC) ≥ 1.30 or ≤0.70 (Fig.  1b and Supplementary Table  S2). The lysophospholipids class 
presented with 6 lysophosphatidic acid (LPA) species having increased plasma levels in 
untreated HIV-infected patients versus controls, and one lysophosphatidylcholine (LPC) 
metabolite which was reduced compared to controls. Furthermore, two monounsaturated 
sphingomyelin (SM) species, two PUFA cholesterol ester (CE), and two long-chain saturated 
Table 2. Characteristics of the untreated HIV-infected patients (Population A) and the non-HIV infected con-
trol population
Characteristics Patients (n=18) Controls (n=23) P-value
age; mean years ± SDa 40 ± 10 36 ± 10 0.18
male Gender, n (%) 16 (88.9) 14 (60.9) 0.08
Caucasian, n (%) 14 (77.8) 17 (73.9) 0.90
mean Cd4+ T-cell count; x106/L ± SDa 441 ± 265 - -
HIV viral load; median copies/mL (range) 1.1 x105 (60-1x107) - -
a SD, Standard deviation
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figure 1. Plasma metabolic characterization of untreated HIV vs controls. Volcano plot of (a) the biogenic 
amine profile, (b) the lipid profile and (c) the signalling lipid profile. Volcano plots are representative of the 
-log10 (Mann-Whitney p-value) on the y-axis with the x-axis showing the log2 (Fold change) of the metabolite, 
between the controls and the untreated HIV patients (population A) respectively. Dashed lines represent the 
respective significance thresholds, with the significant metabolites identifiable by coloured symbols with either 
a name or corresponding class colour identifier. CE, Cholesterol esters; CER, Ceramides; PC, Phosphatidylcho-
lines; PC-O, Plasmalogen PCs; PE, Phosphatidylethanolamines; PE-O, Plasmalogens PEs; SM, Sphingomyelins; 
TG, Triglycerides; LPA, Lysophosphatidic acid; COX, Cyclooxygenase; CYP450, Cytochrome P450; LOX, Li-
poxygenase; RNS, Reactive nitrogen species; ROS, Reactive oxygen species.
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ceramides (CER) metabolites all had reduced levels in untreated HIV patients. The triglyc-
erides (TG) profile presented with 14 mostly polyunsaturated triglycerides species showing 
significantly increased levels during untreated HIV infection. The phospholipids presented 
with seven phosphatidylcholines (PC), four plasmalogen phosphatidylcholines (PC-O), two 
phosphatidylethanolamines (PE) and two plasmalogen phosphatidylethanolamines (PE-O) 
all having decreased levels during untreated HIV.
The third subclass of metabolites that were evaluated for differences between untreated HIV 
patients and controls was the class of signalling lipid mediators, derived from the enzymatic 
or free radical oxidized polyunsaturated fatty acids, which includes the prostaglandins, 
thromboxanes, hydroxy-fatty acids, leukotrienes, resolvins, epoxy-fatty acids, isoprostanes 
and nitro fatty acids. During the untreated HIV infection 22 significantly affected signalling 
lipid metabolites were identified of which 8 had reduced levels and 14 had increased levels 
in the untreated HIV patients compared to controls. (Fig.  1c, Supplementary Table  S3). 
The four signalling mediators: 5,6-DiHETrE, 8,9-DiHETrE, 11,12-DiHETrE, and 14,15-Di-
HETrE all derived from arachidonic acid and synthesised by cytochrome P450 isozymes 
showed the most significant increased levels in the untreated HIV patients compared to 
the controls. Furthermore, untreated HIV patients had increased levels of dihydrosphingo-
sine but decreased levels of three different Sphingosine-1-phosphate species compared to 
controls. The metabolites 5-HETE, 12-HETE and 15-HETE derived from the Lipoxygenase 
activity on Arachidonic acid, also had increased levels compared to the controls. Oxidized 
lipids due to the activity of ROS and RNS showed differential responses with increased 
levels of 8-iso-PGE2, 2,3-dinor-PGF2a and 20 HETE and decreased levels of 11-HDoHE 
and 8,12-iPF2α-IV in untreated HIV patients compared to controls.
untreated HIV versus HIV-suppressed (12 months of carT)
Patient population B
The characteristics of the HIV-1-infected patients selected to compare baseline metabolic 
profile to the HIV-suppressed profile after 12 months of therapy (population B) are presented 
in Table 3. This is an independent population from the untreated HIV-infected population 
A introduced in Table 2. Most of the patients had a male gender. Mean CD4+ T-cell count 
at the start of cART was of 267 × 106 cells/L with an IQR of 224 × 106. There was a large 
heterogenicity in viral load with a median of 5.5 × 104 copies/ml and an IQR of 2.7 × 105. 
89% of the patients were of European descent. Four patients had a blip in their viral load at 
12 months on cART: their viral loads were 53, 73, 103 and 130 copies/ml. Most patients used 
Abacavir in combination with Lamivudine as the backbone in cART (n = 25). The patients 
who only used NRTI’s all used the combination Abacavir with Lamivudine and Zidovudine 
(n = 8) except for one patient who used Abacavir/Lamivudine with Stavudine. The protease 
inhibitors (PI) used were Lopinavir (in combination with ritonavir) (n = 4), Atazanavir 
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(n = 1) and Darunavir (n = 1). The NNRTI’s used were Efavirenz (n = 8), Nevirapine (n = 4) 
and Rilpivirine (n = 1). Five patients used a statin. The incidence of dyslipidaemia or the use 
of lipid-lowering therapy (statins and/or fibrates) remained stable during the first year of 
cART.
Metabolic consequences following cART treatment of HIV patients
Next, we evaluated the metabolic changes associated with 12 months of cART treatment, 
as well as HIV suppression in the longitudinal patient population B. cART treatment of 
the HIV patients resulted in viral suppression with undetectable plasma HIV RNA levels 
and partial restoration of CD4+ T-cell counts in the blood (Table 3). Eight HIV infected 
Table 3. Characteristics of 28 HIV-infected patients (Population B) at baseline and after 12 months of cART
Characteristics at baseline 12 months of carTa
age; mean years ± SDb 40 ± 10
male Gender, n (%) 21 (75.0)
european region of origin, n (%) 25 (89.3)
statin use, n (%) 4 (14.3) 5 (17.9)
mean Cholesterolc >6.5d, n (%) unknown 6 (21.4)
mean ldl >4.5d, n (%) unknown 4 (14.2)
mean Triglycerides >2.3d, n (%) unknown 8 (28.6)
mean bmIe, kg/m2 ± SDb 22.7 (3.1) 23.1 (3.3)
Hepatitis b coinfection, n (%) 1 (3.6%)
Hepatitis C coinfection, n (%) 8 (28.6%)
alcohol ≥5 IE/day, n (%) 1 (3.6%)
Hard drugsf/methadone use, n (%) 8 (28.6%)
mean Cd4+ T-cell counth, x106/L ± SDb 267.4 (158.9) 489.0 (209.4)
mean time on carT, months ± SDb n.a. 12.5 (1.2)
HIV viral load <102 h, n (%) 0 (0%) 26 (93.6%)
HIV viral load >102 h, n (%) 28 (100%) 2 (7.2%)
median HIV viral loadh (range) 5.5x104 (1.6x103 – 8.1x105)
carT regimen
NRTIi + NNRTIj, n (%) n.a. 13 (46.4%)l
NRTIi + PIk, n (%) n.a. 6 (21.4%)l
NRTIi only (n/%) n.a. 9 (32.1%)l
a cART, combination Anti-retroviral therapy; b SD, Standard deviation; c mean value of 6 months prior to sample 
used; d mmol/L; e BMI, Body mass index; f cocaine, heroin and/or MDMA (3,4-methylenedioxymethamphet-
amine); g x106/L; h copies/ml; i NRTI, Nucleoside reverse transcriptase inhibitor; j NNRTI, Non-nucleoside 
reverse transcriptase; k PI = Protease inhibitor; l Three patients used a different cART regimen at 6 months 
versus 12 months of cART. Because of one patient switching from a protease inhibitor (PI) based regimen to a 
non-nucleoside reverse transcriptase inhibitor (NNRTI) or nucleoside reverse transcriptase inhibitor (NRTI) 
only regimen and vice versa, the proportion of PI-based, NNRTI based or NRTI the only regimen remained 
unchanged in the entire group.
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patients were HCV positive, but were untreated for HCV during the 12-month period and 
were not excluded from the analyses. The untreated HCV infection had minimal impact on 
the metabolic findings as can be seen in see Supplementary Fig. S2. Evaluation of biogenic 
amine levels in paired plasma samples showed significantly increased methionine sulfone, 
histidine and tryptophan levels during the therapy period as compared to the baseline 
samples (untreated HIV), whereas pipecolic acid, 3-aminoisobutyric acid, and kynurenine 
showed significantly decreased levels during the therapy period as compared to the baseline 
(Fig. 2a, Supplementary Table S4). Significant metabolites were identified by having a false 
discovery rate adjusted p-value < 0.05 using a paired t-test approach. The K/T ratio revealed 
significantly decreased IDO activation after 12 months of cART (see Supplementary Fig. S3), 
however, the ratio between tryptophan and serotonin showed no significant changes. The 
neurotransmitter dopamine and metabolite α-aminobutyric acid correlated with CD4+ T-
cell counts during 12 months of therapy (see Supplementary Fig. S4A).
The lipid profile showed an overall increasing trend reflecting higher levels after the 
12-month cART period compared to their baseline levels, as can be seen in Fig. 2b. Predom-
inantly it was the phosphatidylcholine metabolism responding to cART with significantly 
increased levels of 9 phosphatidylcholine species, 8 plasmalogen phosphatidylcholine, and 
3 lysophosphatidylcholine species after 12 months of cART compared to baseline values 
prior to starting of cART. Furthermore, 7 sphingomyelin metabolites, together with one 
phosphatidylethanolamine species, two plasmalogen phosphatidylethanolamine, and a 
cholesterol ester were also increased after 12 months of cART compared to their baseline 
values. Furthermore, the phosphatidylcholines also revealed a positive association with 
CD4+ T-cell counts of the patients (see Supplementary Fig. S4B).
Finally, we compared changes in the signalling lipid profiles in patient plasma after 12 
months of cART to their untreated HIV levels and found no significant changes.
Plasma immune-metabolic networks of HIV infection and therapy
Plasma levels of cytokines and immune mediators are a commonly used readout reflect-
ing systemic immune activity.31,32 To correlate metabolite profiles in plasma with immune 
activity, we determined in subsequent plasma samples of the same patients the levels of the 
infection markers IP-10, sIL-2R, and D-dimer, the inflammation markers IL-6, IL-10, IL-21, 
IL-18, and MCP-1, and the soluble exhaustion markers sPD1, sPD-L1, sPD-L2, and sTIM-3. 
Significantly enhanced plasma levels of D-Dimer, IL-18, MCP-1, sPD-L2, sTIM-3, IP-10, 
sIL-2R, CRP, and sTNF-RII were observed in patients with untreated HIV as compared to 
non-HIV infected controls (Population A), and are shown in Supplementary Fig. S5. The 
other mediators tested were below the limit of detection of the assay, which included IL-6, 
IL-10, IL-21, sPD1, and sPD-L1.
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Evaluating the changes in the immunological parameters in population B after the 12 
months cART period revealed an immunological picture of effective therapy shown in 
Supplementary Fig.  S6. Markers of infection revealed that after the initiation of cART, 
both plasma IP-10 and sIL-2R levels were reduced significantly. Furthermore, initiation of 
cART reduced the levels of the inflammation marker IL-18 whereas MCP-1 levels remained 
unchanged when comparing baseline to 12 months of cART. An improvement in markers 
of exhaustion was found with reducing levels of both sPD-L2 and sTIM-3 after 12 months 
of cART.
figure 2. Plasma metabolic characterization of response to 12 months’ cART. Modified volcano plots showing 
(a) the biogenic amine profile, and (b) the lipid profile. The modified volcano plots are representative of the 
-log10 (FDR adjusted paired T-test p-value) on the y-axis with the x-axis showing the scaled mean of the paired 
differences per metabolite, between the baseline and 12 months cART follow-up sample (patient population B). 
The horizontal dashed line represents a false discovery rate adjusted q-value <0.05. Significant metabolites are 
identifiable by coloured symbols with either a name or corresponding class colour identifier. CE, Cholesterol 
esters; LPC, Lysophosphatidylcholines; PC, Phosphatidylcholines; PC-O, Plasmalogen PCs; PE, Phosphatidyl-
ethanolamines; PE-O, Plasmalogens PEs; SM, Sphingomyelins.
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Next, we constructed immune-metabolic correlation networks respectively for the controls 
and the patients with an untreated HIV infection from population B using the absolute of 
levels of metabolites and immune mediators. Figure 3 presents these three immune-meta-
bolic correlation networks showing all correlations with a strict p-value cut-off of p < 0.01. 
Comparing Fig. 3a (the control network) to Fig. 3b (the untreated HIV network) difference 
is seen in the interactions between the two networks. The control network revealed isolated 
clusters with IP-10 and IL-18 correlating to different lipid classes, sIL-2R and sTNF-RII 
correlated together and D-Dimer, sTIM-3 and MCP-1 showing correlation. Comparatively 
the untreated HIV shows positive correlations between sTIM-3, sIL-2R, IP-10 and sPD-L2 
with D-Dimer connecting the network through sTIM-3, revealing correlations between 
markers of infection and exhaustion. In both networks, sTIM-3 and D-Dimer revealed 
strong positive correlations, while in the untreated HIV patients sTIM-2 also showed strong 
interactions with phospholipids as well as lysophospholipids. Furthermore, in untreated 
HIV patients MCP-1 correlated strongly to several triglyceride species compared to the con-
trol network where MCP-1 correlate only to D-Dimer. Interestingly, in the control network, 
IL-18 showed strong interactions with triglyceride species, whereas IL-18 was correlated to 
only 5,6-DiHETrE in the untreated HIV patients.
Next, for the influence of cART on HIV infection, we constructed immune-metabolic corre-
lation network based on the relative change in levels of metabolites and immune mediators 
in the paired plasma of the patients on 12 months cART versus their untreated HIV levels. 
As shown in Fig. 3c, the correlation network revealed distinct immune-metabolic interac-
tions. Firstly, changes in sTIM-3, sIL-2R, IP-10, sPD-L2 and IL-18 positively correlated with 
each other, with D-dimer becoming disconnected from the core network. Again, MCP-1 
showed minimal interactions to other immune mediators in the panel: changes in triglyc-
eride levels correlated strongly to changes in MCP-1 levels as did some amine metabolites, 
while changes in two cholesterol-esters showed negative correlations. Furthermore, cART 
diminished the interaction of sTIM-3 with the phospholipids and lysophospholipids which 
were found in untreated HIV-patients.
dIsCussION
The data presented in this study provide some insight into the distinct effects of HIV and 
cART have on metabolism. Through identifying immune-metabolic pathways altered dur-
ing untreated HIV infection, we can follow these pathways during the first 12 months after 
commencing cART in the same patients, monitoring their responses. In line with earlier 
research, we found decreased glutathione, taurine and tryptophan levels as well as upregu-
lated IDO activity in untreated HIV patients compared to HIV-seronegative controls.8,33,34 
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Also, increased levels of highly unsaturated long-chain triglycerides35 and decreased levels 
of sphingomyelin species characterized an untreated HIV infection compared to controls. 
After the initiation of cART, changes in the lipid metabolism were primarily found within 
the phospholipids while the highly unsaturated triglyceride species remained elevated. A 
noteworthy metabolic finding is the unresponsive signalling lipid profile, showing minimal 
changes after the first 12-month cART period. Signalling lipids including eicosanoids are 
metabolically derived immunological mediators and might represent a metabolic reflec-
tion of the immune competence of HIV-infected patients.36,37 The unresponsive signalling 
lipid metabolism could result from the sequestering of their polyunsaturated fatty acid 
precursors into triglyceride species. Cassol et al. reported decreased eicosanoid levels spe-
cifically 5-hydroxyeicosatetraenoic acid (5-HETE), prostaglandin B2, prostaglandin E2 and 
thromboxane B2 in cART-treated HIV-positive individuals compared to controls.1 Since 
eicosanoids also play an essential role in immunological crosstalk38 it could help to explain 
the dysregulated immune surveillance and exhausted phenotype persisting in virally sup-
pressed patients.39
Studying the immune-metabolic networks revealed that the initiation of cART discon-
nected the interactions between kynurenine and sIL-2R as well as sTIM-3’s interactions 
with phospholipids and lysophospholipids. Thus, HIV suppression through cART attenu-
ates the pro-inflammatory sIL-2R and IDO pathways differently, since it has been reported 
that IDO activity remains significantly increased compared to controls even after 24 months 
of cART.40 Secondly, cART might contribute to an exhausted immune phenotype through 
dysregulating the phospholipids (increased during the first 12 months of cART) and their 
interactions with sTIM-3 interactions. Further, IL-18, a pro-inflammatory cytokine found 
elevated in advanced stages of HIV infection,41 showed strong correlations to triglycer-
ide levels in the control population. The role of IL-18 in cardiovascular disease and the 
metabolic syndrome, as well as its association with triglyceride levels, has been previously 
described.42,43 Comparatively, in the untreated HIV infected population, the triglyceride 
species showed a strong correlation to MCP-1 levels and not to IL-18. Initiating 12 months 
of cART was unable to nullify this interaction, revealing that changes in triglyceride levels 
still strongly correlated to those of MCP-1 in the paired patient samples. Mihăilescu et al., 
found that the prevalence of insulin resistance and metabolic syndrome was higher in HIV 
suppressed patients compared to virally active patients, and that the levels of MCP-1 cor-
related to both these co-morbidities,44 supporting our findings.
Disentangling the mechanism behind the observed metabolic changes during an HIV 
infection and therapy is a complex task. However, the importance of this task is stressed 
by the findings in this study that even 12 months of cART does not attenuate metabolic 
dysregulation. This is opposed to the finding that immune activation in HIV-infected pa-
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tients is normalized during treatment with cART for this same period, as we also previously 
showed.41 Sustained immune activation thus is not the complete answer to what causes 
co-morbidity in HIV-infected patients, like neurocognitive disorders and cardiovascular 
disease. Although cART has become increasingly effective over the last years, but as we 
show here, is not enough to fully restore the metabolic profile of HIV-suppressed patients 
to normal.
This finding warrants further research, to contribute to unravelling the metabolic patho-
physiological pathways in HIV comorbidities, with multiple findings in this study able 
to generate testable hypothesis regarding HAND and CVD. With respect to HAND, the 
following questions arise applicable to both untreated HIV and cART-treated HIV patients. 
(1) How does the sustained elevated Indoleamine-2,3-dioxygenase (IDO) activity (the rate-
limiting enzyme catabolizing L-tryptophan into neurotoxic metabolites and not serotonin) 
contribute to neurological disorders? (2) What is the pathological mechanism underlying a 
dysregulated urea cycle during an untreated HIV infection? Since disorders of the urea cycle 
are known to manifest with neurological implications due to hyperammonemia.45 Similarly 
to HAND, questions relating to CVD, an important cause of morbidity and mortality in 
untreated and suppressed HIV-infected patients, arises.46,47 (3) Do the significant correla-
tions between changes in triglycerides and MCP-1 levels, expose an alternative mechanism 
contributing to the development of CVD, independent of IL-18? (4) How does an unrespon-
sive eicosanoid metabolism contribute to CVD, since they play an important role in normal 
cardiovascular function?48-50 Potentially with the answer to these questions, morbidity, and 
mortality in HIV-infected patients because of the non-communicable disease can be further 
diminished.
It is important to note that in our study the time of follow-up of these patients was too 
short to draw conclusions about causality. The use of targeted metabolomics platforms in 
conjunction with other omics technologies would provide a unique opportunity to study 
HIV pathogenic mechanisms, as well as to identify biomarkers relevant to co-morbidities 
relating to both HIV and the use of ARVs. Studies investigating the metabolic dysregulation 
of HIV infections and exposure of antiretrovirals can be further strengthened by investigat-
ing paired longitudinal samples with a known outcome. Furthermore, these techniques 
could also proof complementary to antiretrovirals pharmacokinetic studies currently in 
clinical trials.
It is important to mention that due to the retrospective nature of the part of our study in 
which we compared cART naive HIV-infected patients with their samples after 12 months 
of therapy, it is difficult to ascertain whether all blood samples were processed identically, 
thereby introducing some variation in outcome parameters. Further, the duration of the 
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HIV infection prior to starting cART is not known of these patients. Apart from the HIV 
infection, other factors might play a role in metabolic changes, for instance, smoking habits, 
aging, and timing of sampling of the material. Also, we have no data on the fasting state 
of both the patient as well as the control population, however, because the samples of the 
included patients were taken during routine outpatient visits and blood donors, in general, 
are instructed not to donate blood in the fasted state, it is safe to assume that both groups 
were in a post-prandial state. Food intake can affect metabolites and phospholipid levels,51,52 
but also multiple large population studies have shown that changes in plasma lipids and 
lipoproteins change only modestly during the day, in response to habitual food intake.53,54 
Further, although sub-analysis of 12 months cART according to PI or NNRTI used did 
not show differences in lipid profiles, the choice of the specific components of the cART 
regimen might be a significant factor or influence on the metabolic profile of a patient in the 
long run. For instance, abacavir use, which is associated in the literature with an increase of 
CVD.55,56 Population A and B differed significantly from each other regarding mean CD4+ 
T-cell counts and cytokine profiles, probably due to the fact that Population A was selected 
to be compared to a non-HIV infected, healthy control population and therefor selection 
criteria was more strictly defined than those for population B, where the patients were their 
own controls. In population B, five patients were using statins during the first year of cART, 
of which four were already receiving statin therapy prior to the start of cART. We were 
unable to identify any trends in the data indicating that lipid profiles were skewed based 
on the use of statins. Eight patients were coinfected with HCV, which may have had an 
effect on the comparison of the untreated patients compared to controls. However, during 
this study, none of the patients was treated for HCV, thus this was a stable factor in the 
comparison between untreated HIV and 12 months of cART. A sub-analysis leaving out the 
HCV coinfected patients showed minimal impact on the outcome. In this study, we were 
not able to include a sample of the control patients after one year. However, to determine 
the baseline stability of the metabolic/immune network, further studies are needed with 
follow-up samples of a control population.
In conclusion, in our study, we found significant changes in the metabolism relevant of 
untreated HIV infected patients and after 12 months cART. Additional to this finding, 
and potentially even more important is the finding that cART alone does not restore these 
changes. Further insight into the metabolic changes caused by HIV infection is warranted 
to optimize therapy in addition to cART for this patient population.
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figure s1: Tryptophan pathway and Indoleamine 2,3-dioxygenase (IDO) activity during an untreated HIV 
infection. (A) IDO activity during an untreated HIV infection (population A). The kynurenine and tryptophan 
(K/T) ratio representative of IDO activity are plotted for the controls (Closed dots) and untreated HIV group 
(Open circles). (B) The serotonin and tryptophan (S/T) ratio showing the altered tryptophan utilization during 
untreated HIV infection, with the controls (Closed dots) and untreated HIV group (Open circles). Unpaired 
T-test, *** p< 0.001 with **** p< 0.0001.
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figure s4: Significant correlations between the CD4+ T-cell count and metabolite levels during 12 months of 
cART (population B). (A) Amine (green) metabolites correlated significantly (p<0.05) to CD4+ T-cell counts. 
(B) Phospholipid (red) metabolites correlated significantly (p<0.05) to CD4+ T-cell counts. All correlations were 
done using Spearman.
figure s3: Tryptophan and Indoleamine 2,3-dioxygenase (IDO) activity during cART. (A) IDO activity de-
creased during 12 months of cART (population B). The kynurenine and tryptophan (K/T) ratio representative 
of IDO activity are plotted for the paired untreated HIV and 12 months cART samples. (B) The serotonin and 
tryptophan (S/T) ratio showed nonsignificant changes during the first 12months of cART in the same patients. 
Paired T-test with ** p< 0.01.
Chapter 7.
138
D -Dim er
H C H I
V
0
5 00 0
1 00 00
1 50 00
2 00 00
2 50 00
L LOQ
***
p
g/
m
l
IL- 18
H C H I
V
0
1 00
2 00
3 00
4 00
L LOQ
***
p
g/
m
l
M CP -1
H C H I
V
0
1 00
2 00
3 00
4 00
L LOQ
***
p
g/
m
l
P D- L2
H C H I
V
0
1 00 0
2 00 0
3 00 0
L LOQ
***
p
g/
m
l
T im-3
H C H I
V
0
5 00
1 00 0
1 50 0
2 00 0
L LOQ
***
p
g/
m
l
IP- 10
H C H I
V
0
5 0
1 00
1 50
L LOQ
**
p
g/
m
l
s IL-2 R
HC H I
V
0
2
4
6
8
1 0 ***
L LOQ
C RP
HC H I
V
0
1 00 00 00
2 00 00 00
3 00 00 00 ***
L LOQ
p
g/
m
l
s TN F- RI I
H C H I
V
0
1 00 0
2 00 0
3 00 0
4 00 0 *
L LOQ
p
g/
m
l
figure s5: Plasma levels of the detected immunological markers in untreated HIV patients vs controls of popu-
lation A. Increased levels of all markers were found during an untreated HIV infection. Unpaired T-test with 
p-values: * <0.05, ** <0.01, and *** <0.001
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figure s6: Plasma levels of the detected immunological markers in paired patient samples of population B. 
Decreasing levels of most markers were found during the first 12 months of cART. Paired T-test with p-values: 
+ < 0.05, ++ < 0.01, +++ <0.001.
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Table s1: Descriptive statistics of the biogenic amines comparing the untreated HIV patients to the controls in 
patient population A.
metabolite
T-test false discovery rate fold change Controls untreated HIV
p-value q-value (fC) mean ± sda mean ± sda
Glutathione 1.22E-11 3.88E-10 0.43017 0.12 ± 0.03 0.050 ± 0.01
O-Phosphoethanolamine 1.38E-11 3.88E-10 0.38745 3.71 ± 1.20 1.44 ± 0.53
Sarcosine 1.72E-10 3.21E-09 0.53698 0.13 ± 0.03 0.071 ± 0.02
Serotonin 4.05E-10 5.67E-09 0.24411 0.006 ± 0.00 0.002 ± 0.00
Taurine 6.14E-08 6.88E-07 0.50741 0.66 ± 0.26 0.33 ± 0.11
L-Tryptophan 1.59E-05 0.000149 0.76073 3.25 ± 0.51 2.47 ± 0.46
L-Alanine 0.000179 0.001432 0.76731 3.88 ± 0.79 2.98 ± 0.54
L-Histidineb 0.000396 0.002773 0.81706 0.037 ± 0.01 0.030 ± 0.01
L-Asparagine 0.000463 0.002882 0.77301 0.80 ± 0.18 0.62 ± 0.11
L-Alpha-aminobutyric acid 0.000848 0.004749 0.6884 0.27 ± 0.09 0.19 ± 0.04
L-Carnosine 0.000948 0.004826 0.63414 0.000 ± 0.00 0.000 ± 0.00
Ethanolamineb 0.002506 0.011693 0.85843 0.27 ± 0.03 0.23 ± 0.05
L-Leucine 0.002953 0.012719 0.7675 1.36 ± 0.36 1.04 ± 0.22
Gamma-L-glutamyl-L-alanine 0.004387 0.017546 0.73374 0.008 ± 0.00 0.006 ± 0.00
L-Methionine 0.005782 0.020692 0.75999 1.43 ± 0.45 1.09 ± 0.24
Putrescine 0.005912 0.020692 0.64703 0.001 ± 0.00 0.001 ± 0.00
L-Tyrosine 0.006596 0.021727 0.76809 9.06 ± 2.63 6.96 ± 1.61
L-Valineb 0.011206 0.034862 0.82117 7.46 ± 1.68 6.12 ± 1.20
Ornithinec 0.017497 0.051569 0.79523 1.63 ± 0.49 1.29 ± 0.37
S-Methylcysteinec 0.023788 0.066607 0.65039 0.13 ± 0.09 0.083 ± 0.03
L-Isoleucinec 0.025046 0.066789 0.78844 3.62 ± 1.16 2.86 ± 0.69
Gamma-Glutamylglutamineb,c 0.028906 0.07358 0.8311 0.007 ± 0.00 0.006 ± 0.00
L-Lysineb,c 0.035184 0.085666 0.83576 2.04 ± 0.55 1.71 ± 0.33
a SD, Standard Deviation; b Metabolites adhering to p-value<0.05 but not a FC of 30% (FC>1.3 or FC<0.7); c 
Metabolites having a FDR q-value>0.05
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Table s2: Descriptive statistics of the lipid profiling comparing the untreated HIV patients to the controls in 
patient population A.
metabolite T-test false discovery rate fold change Controls untreated HIV
p-value q-value (fC) mean ± sda mean ± sda
CE205b 0.0250 0.123 0.774 0.03 ± 0.01 0.02 ± 0.01
CE226b 0.0106 0.073 0.808 0.034 ± 0.01 0.027 ± 0.01
Cerd180_220b 0.0451 0.179 0.769 0.033 ± 0.01 0.025 ± 0.01
Cerd180_240b 0.0226 0.118 0.685 0.041 ± 0.02 0.028 ± 0.01
Cerd181_160b 0.0114 0.073 1.490 0.01 ± 0.00 0.02 ± 0.01
LPA-160 0.0003 0.002 2.005 0.09 ± 0.04 0.18 ± 0.13
LPA-161 0.0021 0.013 1.992 0.01 ± 0.01 0.03 ± 0.02
LPA-181 0.0017 0.011 1.847 0.10 ± 0.04 0.19 ± 0.15
LPA-182b 0.0256 0.083 1.515 0.56 ± 0.19 0.85 ± 0.57
LPA-203 0.0003 0.002 2.165 0.02 ± 0.01 0.04 ± 0.02
LPA-204 0.0000 0.000 2.047 0.15 ± 0.05 0.30 ± 0.16
LPC182b 0.0104 0.073 0.753 3.97 ± 1.30 2.99 ± 0.97
PC322b 0.0449 0.179 0.734 0.22 ± 0.09 0.16 ± 0.08
PC342b,c 0.0109 0.073 0.829 24.63 ± 5.54 20.42 ± 3.54
PC362c 0.0017 0.028 0.837 18.11 ± 2.80 15.16 ± 3.02
PC365b 0.0405 0.169 0.657 1.25 ± 0.73 0.82 ± 0.52
PC366b 0.0103 0.073 0.661 0.04 ± 0.02 0.02 ± 0.01
PC386 0.0003 0.012 0.702 5.56 ± 1.68 3.90 ± 1.17
PC404 0.0007 0.016 1.323 0.12 ± 0.04 0.16 ± 0.03
PC406 0.0014 0.026 0.712 1.64 ± 0.54 1.17 ± 0.45
PC407 0.0001 0.008 0.685 0.35 ± 0.10 0.24 ± 0.07
PC408 0.0001 0.008 0.653 0.08 ± 0.03 0.05 ± 0.02
PCO-341b,c 0.0081 0.072 0.833 0.40 ± 0.08 0.33 ± 0.08
PCO-342 0.0001 0.008 0.707 0.54 ± 0.13 0.38 ± 0.10
PCO-343 0.0008 0.016 0.690 0.52 ± 0.16 0.36 ± 0.13
PCO-363 0.0003 0.012 0.747 0.13 ± 0.03 0.10 ± 0.02
PCO-386b 0.0143 0.085 0.779 0.06 ± 0.04 0.05 ± 0.03
PCO-387b,c 0.0162 0.090 0.813 0.10 ± 0.02 0.08 ± 0.03
PE342b 0.0386 0.169 0.705 0.41 ± 0.20 0.29 ± 0.09
PE382 0.0045 0.050 0.703 3.13 ± 1.22 2.20 ± 0.70
PEO-385b 0.0200 0.108 0.777 0.67 ± 0.24 0.52 ± 0.18
PEO-387 0.0004 0.012 0.636 0.24 ± 0.09 0.16 ± 0.05
SMd181_180b,c 0.0406 0.169 0.839 1.00 ± 0.25 0.84 ± 0.22
SMd181_181b 0.0243 0.123 0.796 0.40 ± 0.12 0.32 ± 0.11
SMd181_201 0.0019 0.028 0.750 0.28 ± 0.08 0.21 ± 0.06
TG501b 0.0156 0.090 1.346 7.59 ± 4.97 10.22 ± 4.24
TG502b 0.0099 0.073 1.360 10.73 ± 5.05 14.59 ± 5.60
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Table s2: Descriptive statistics of the lipid profiling comparing the untreated HIV patients to the controls in 
patient population A. (continued)
metabolite T-test false discovery rate fold change Controls untreated HIV
p-value q-value (fC) mean ± sda mean ± sda
TG503b 0.0364 0.169 1.359 5.54 ± 2.88 7.52 ± 3.54
TG511b 0.0114 0.073 1.526 0.57 ± 0.51 0.86 ± 0.45
TG512b 0.0075 0.069 1.589 0.97 ± 0.64 1.55 ± 0.82
TG513b 0.0067 0.066 1.414 0.70 ± 0.28 0.99 ± 0.38
TG514b 0.0469 0.182 1.281 0.30 ± 0.12 0.38 ± 0.14
TG522b 0.0125 0.077 1.296 30.19 ± 7.26 39.13 ± 12.24
TG531b 0.0393 0.169 1.375 0.13 ± 0.08 0.18 ± 0.08
TG552b 0.0277 0.132 1.284 0.09 ± 0.03 0.12 ± 0.04
TG565 0.0036 0.043 1.593 2.00 ± 0.52 3.19 ± 1.54
TG566b 0.0052 0.054 1.573 2.73 ± 0.74 4.29 ± 1.96
TG585 0.0034 0.043 1.535 0.14 ± 0.04 0.22 ± 0.12
TG586 0.0020 0.028 1.514 0.28 ± 0.06 0.42 ± 0.19
a SD, Standard Deviation; b Metabolites having a FDR q-value>0.05; c Metabolites adhering to p< 0.05 but not a 
FC of 30% (FC>1.3 or FC<0.7).
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Table s3: Descriptive statistics of the signalling lipid profiling. Comparing the untreated HIV patients to the 
controls in patient population A.
metabolite T-test false discovery 
rate
fold 
change
Controls untreated HIV
p-value q-value (fC) mean ± sda mean ± sda
PGF2ab,c 0.01302 0.0509 1.15220 0.029 ± 0.004 0.033 ± 0.0065
PGE2c 0.03223 0.0904 2.10360 0.015 ± 0.005 0.028 ± 0.0255
12S-HHTrEc 0.03437 0.0943 1.48530 0.460 ± 1.018 0.684 ± 0.6429
5,6-DiHETrE 0.00000 0.0000 2.13540 0.006 ± 0.003 0.013 ± 0.0060
14,15-DiHETrE 0.00000 0.0000 1.55070 0.047 ± 0.009 0.073 ± 0.0212
11,12-DiHETrE 0.00000 0.0001 1.57940 0.036 ± 0.008 0.057 ± 0.0183
8,9-DiHETrE 0.00001 0.0002 1.64400 0.006 ± 0.002 0.010 ± 0.0033
5-HETE 0.00007 0.0008 1.86770 0.061 ± 0.024 0.114 ± 0.0457
15-HETE 0.00079 0.0060 1.61210 0.088 ± 0.040 0.143 ± 0.0593
15S-HETrE 0.00256 0.0138 1.68570 0.037 ± 0.023 0.062 ± 0.0319
12-HETE 0.00566 0.0252 2.26500 0.779 ± 0.298 1.765 ± 1.1447
12S-HEPEc 0.01717 0.0633 0.61502 0.263 ± 0.176 0.161 ± 0.1160
9/10-NO2-OA 0.00058 0.0047 0.49727 0.145 ± 0.117 0.072 ± 0.0477
11-HDoHE 0.00000 0.0000 0.25878 0.172 ± 0.074 0.045 ± 0.0180
2,3-dinor-8-iso-PGF2a 0.00000 0.0001 2.21740 0.086 ± 0.027 0.191 ± 0.0817
20-HETE 0.00223 0.0131 1.55120 0.071 ± 0.020 0.110 ± 0.0497
8,12-iPF2a-IV 0.00250 0.0138 0.80572 0.032 ± 0.006 0.025 ± 0.0087
8-iso-PGF2a 0.00533 0.0245 0.74017 0.133 ± 0.039 0.098 ± 0.0384
8-iso-PGE2c 0.04270 0.1102 2.61560 0.009 ± 0.006 0.024 ± 0.0188
SPHA-C180 0.00394 0.0195 1.66750 0.074 ± 0.023 0.123 ± 0.0825
S-1-P-161 0.00454 0.0217 0.74230 0.220 ± 0.069 0.163 ± 0.0450
S-1-P-182 0.00746 0.0321 0.77115 0.951 ± 0.250 0.734 ± 0.2526
S-1-P-181c 0.02076 0.0724 0.79819 2.914 ± 0.783 2.326 ± 0.7220
a SD, Standard Deviation; b Metabolites adhering to p<0.05 but not a FC of 30 % (FC>1.3 or FC<0.7); c Metabo-
lites having a FDR q-value >0.05
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Table s4: Descriptive statistics of the biogenic Amine and lipid profiling. Comparing the untreated HIV pa-
tients to their paired 12 months cART follow samples in patient population B.
metabolite Paired 
T-test
false discovery 
rate
T-stata untreated HIV 
(baseline)
12 months carT
p-value q-value mean ± sdb mean ± sdb
Platform: biogenic amines
Methionine sulfone 2.0E-06 1E-04 6.14 0.008 ± 0.003 0.014 ± 0.007
L-Pipecolic acid 0.0014 3E-02 -3.59 0.046 ± 0.015 0.040 ± 0.016
DL-3-aminoisobutyric acid 0.0032 4E-02 -3.26 0.023 ± 0.011 0.018 ± 0.008
L-Histidine 0.0034 4E-02 3.23 0.022 ± 0.003 0.025 ± 0.004
L-Tryptophan 0.0047 5E-02 3.10 2.715 ± 0.891 3.243 ± 0.487
L-Kynurenine 0.0051 5E-02 -3.07 0.021 ± 0.006 0.017 ± 0.004
Platform: lipid profiling
CE181 0.0086 5E-02 2.86 0.039 ± 0.011 0.047 ± 0.009
LPC181 0.0079 5E-02 2.90 2.372 ± 0.681 2.751 ± 0.558
LPC183 0.0030 4E-02 3.30 0.054 ± 0.020 0.077 ± 0.029
LPC203 0.0065 5E-02 2.98 0.291 ± 0.103 0.369 ± 0.116
PC322c 0.0127 6E-02 2.69 0.149 ± 0.061 0.192 ± 0.068
PC341 0.0011 3E-02 3.71 12.278 ± 2.382 14.096 ± 2.540
PC343 0.0009 3E-02 3.80 0.658 ± 0.195 0.886 ± 0.269
PC344c 0.0115 6E-02 2.74 0.047 ± 0.031 0.070 ± 0.039
PC361 0.0003 2E-02 4.25 2.712 ± 0.891 3.663 ± 1.115
PC362 0.0012 3E-02 3.66 15.778 ± 3.018 18.441 ± 3.238
PC363 0.0018 4E-02 3.51 10.626 ± 2.977 13.234 ± 2.799
PC364c 0.0121 6E-02 2.71 11.041 ± 2.766 12.950 ± 2.812
PC382 0.0013 3E-02 3.64 0.322 ± 0.102 0.432 ± 0.124
PC383c 0.0165 7E-02 2.58 2.514 ± 1.250 3.699 ± 1.838
PC384c 0.0141 6E-02 2.65 7.179 ± 2.238 9.006 ± 2.590
PC385c 0.0141 6E-02 2.65 3.437 ± 1.338 4.544 ± 1.349
PC404c 0.0102 5E-02 2.79 0.169 ± 0.065 0.223 ± 0.083
PC405 0.0052 4E-02 3.07 0.605 ± 0.200 0.876 ± 0.292
PC406c 0.0226 8E-02 2.44 1.231 ± 0.415 1.821 ± 0.866
PC407 0.0083 5E-02 2.88 0.311 ± 0.115 0.418 ± 0.146
PC408 0.0033 4E-02 3.27 0.058 ± 0.022 0.077 ± 0.024
PCO-341 0.0039 4E-02 3.20 0.358 ± 0.068 0.398 ± 0.075
PCO-342 0.0001 2E-02 4.68 0.532 ± 0.123 0.669 ± 0.140
PCO-343 0.0033 4E-02 3.26 0.391 ± 0.129 0.466 ± 0.101
PCO-362 0.0026 4E-02 3.36 0.188 ± 0.033 0.212 ± 0.035
PCO-363 0.0022 4E-02 3.43 0.128 ± 0.028 0.152 ± 0.028
PCO-385 0.0048 4E-02 3.11 0.861 ± 0.162 0.986 ± 0.192
PCO-406 0.0062 5E-02 3.00 0.143 ± 0.021 0.169 ± 0.029
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Table s4: Descriptive statistics of the biogenic Amine and lipid profiling. Comparing the untreated HIV pa-
tients to their paired 12 months cART follow samples in patient population B. (continued)
metabolite Paired 
T-test
false discovery 
rate
T-stata untreated HIV 
(baseline)
12 months carT
p-value q-value mean ± sdb mean ± sdb
PE382 0.0010 3E-02 3.73 3.248 ± 0.995 4.343 ± 1.346
PE384c 0.0180 7E-02 2.54 0.203 ± 0.073 0.286 ± 0.146
PEO-365 0.0042 4E-02 3.16 0.300 ± 0.109 0.370 ± 0.144
PEO-385 0.0079 5E-02 2.90 0.460 ± 0.169 0.580 ± 0.243
SMd181/161c 0.0276 9E-02 2.35 1.033 ± 0.275 1.161 ± 0.248
SMd181/181c 0.0289 1E-01 2.32 0.706 ± 0.225 0.821 ± 0.244
SMd181/200 0.0033 4E-02 3.26 1.210 ± 0.274 1.470 ± 0.351
SMd181/201 0.0020 4E-02 3.47 0.403 ± 0.112 0.490 ± 0.142
SMd181/210c 0.0123 6E-02 2.71 0.367 ± 0.107 0.441 ± 0.128
SMd181/220 0.0067 5E-02 2.97 2.761 ± 0.647 3.173 ± 0.649
SMd181/221 0.0037 4E-02 3.21 1.866 ± 0.395 2.159 ± 0.393
SMd181/230 0.0084 5E-02 2.87 1.028 ± 0.250 1.176 ± 0.267
SMd181/231 0.0060 5E-02 3.01 0.758 ± 0.137 0.872 ± 0.170
SMd181/240c 0.0099 5E-02 2.80 1.827 ± 0.457 2.090 ± 0.431
SMd181/241c 0.0135 6E-02 2.67 6.005 ± 1.019 6.506 ± 1.023
SMd181/242 0.0084 5E-02 2.87 2.506 ± 0.575 2.751 ± 0.529
TG505c 0.0155 6E-02 2.61 0.178 ± 0.232 0.248 ± 0.223
TG525c 0.0257 9E-02 2.38 2.160 ± 2.715 2.727 ± 1.860
TG545c 0.0278 9E-02 2.34 7.446 ± 6.853 9.387 ± 5.391
TG546c 0.0223 8E-02 2.44 2.985 ± 3.473 3.687 ± 2.546
TG547c 0.0261 9E-02 2.37 0.688 ± 0.895 0.844 ± 0.650
TG563c 0.0192 7E-02 2.51 0.596 ± 0.582 0.756 ± 0.489
a For T-stat positive values: increased in 12 months cART vs untreated HIV. For T-stat negative values: de-
creased in 12 months cART vs untreated HIV; b SD, Standard Deviation; c Metabolites adhering to p<0.05 but 
not a FDR q-value of q<0.05
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INTrOduCTION
From an untreatable deadly illness HIV has become a chronic disease in less than 40 years, 
due to tremendous progress in treatment effectivity and tolerability. Nowadays, most patients 
are treated with only one combination tablet a day, whereas previously up to 16 pills were 
sometimes necessary. However, since HIV infection can still not be cured, HIV-infected 
patients need lifelong treatment and are at risk for treatment related adverse events. Some 
adverse events occur within the first months after the start of combination antiretroviral 
therapy (cART), such as gastro-intestinal complaints like nausea or abdominal pain, dizzi-
ness or headache and skin rashes. Other adverse events may only become evident years or 
even decades after the start of a cART regimen, such as nephrotoxicity, diabetes mellitus and 
bone mineral density loss. Apart from determining the genotype HLA-B*57:01 to predict a 
hypersensitivity reaction to abacavir, it is currently still not possible to predict which patient 
will suffer from adverse events due to cART. New biomarkers to predict adverse events 
would be valuable tools in the treatment of HIV.
Recent studies have given insight in the possible role of the ITPA genotype as a biomarker to 
predict adverse events during purine analogue therapy for hepatitis C (HCV). SNPs in the 
ITPA gene, leading to a decreased ITPase activity, were found to be protective against the 
development of hemolytic anemia during treatment with ribavirin.1-7 Purine analogues are 
also used in the vast majority of cART regimens for HIV, these are abacavir and tenofovir. 
Thus, it can be hypothesized that the ITPA genotype is a potential genetic biomarker for 
adverse events associated with these drugs. However, the use of genetic biomarkers has 
disadvantages such as lack of sufficient evidence for consistent phenotype-genotype asso-
ciations, significant overlap between genotype and influence of polygenic factors. These dis-
advantages may potentially be overcome by using a protein instead of a genetic biomarker. 
For the ITPA gene the translated protein is ITPase, an ubiquitous enzyme in humans. In 
this thesis, the influence of ITPA genotype and ITPase activity on the occurrence of adverse 
events during the use of purine analogue drugs for HIV and HCV was investigated and the 
correlation between ITPA genotype and ITPase activity was determined.
The current chapter summarizes and discusses the main findings of this thesis with empha-
sis on the difference between ITPA genotype and ITPase activity as biomarker and their role 
in the prediction of adverse events. Additionally, metabolomics after initiation of cART are 
discussed, as are recommendations for future research.
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maIN fINdINGs aNd dIsCussION
ITPA genotype versus ITPase activity
ITPA genotype was assumed to be directly associated with ITPase activity and the current 
literature has mainly focussed on SNPs in the ITPA gene as biomarkers for adverse events 
related to drugs targeting purine metabolism. However, ITPA genotype does not always 
directly correspond to ITPase activity. For instance, in HIV-infected patients, ITPase activ-
ity in erythrocytes is decreased compared to a HIV-negative control population, despite 
a similar allele frequency.8 Therefore ITPase expression and activity were investigated in 
correlation with ITPA genotype for both HIV and HCV infected patients.
In Chapter 2 it is described that in patients infected with HCV, ITPA genotype is not di-
rectly associated with ITPase activity. While the ITPA genotype wt/c.94C>A resulted in a 
decreased ITPase activity in all HCV-infected patients, the ITPA genotype wt/c.124+21A>C 
was associated with a wide variety of ITPase activities, ranging from 0.67 to as high as 5.47 
mmol IMP/mmol Hb/hr (reference values measured in Caucasian populations are 4.0-10.0 
mmol IMP/mmol Hb/hour).9 Moreover, 38% of patients with this SNP had a normal ITPase 
activity. On the other hand, one of the patients with wt/wt ITPA genotype, presumed to 
have a normal ITPase activity, had a decreased activity. An explanation may be that in our 
study only part of the ITPA gene was sequenced to determine the prominent ITPA polymor-
phisms 94C>A and 124+21A>C only. However, more ITPA SNPs have become known10-12 
and we cannot exclude the possibility that the decreased ITPase activity in the patient with 
wt/wt genotype was due to another genetic variant in the ITPA gene. Because of the low 
prevalence of the other genetic variants, it was chosen not to determine these in the studies 
of this thesis.
In Chapter 3, presence of ITPase in leukocytes was determined using monoclonal 
anti-ITPase antibodies and the ITPase expression was quantitated by measuring median 
fluorescent intensity for the ITPase positive cell fraction. In all the leukocyte subtypes, 
except monocytes, of the HIV-infected patients ITPase presence was significantly decreased 
compared to the control population. Also, median fluorescent intensity was lower in HIV-
infected patients in all cell types. No correlation of ITPA genotype with ITPase expression 
in leukocytes was observed.
Why ITPase expression and activity are decreased in erythrocytes and leukocytes of HIV-
infected patients is yet unknown. A direct effect of nucleoside analogues on ITPase activity 
was excluded previously in vitro.8 It is intriguing to think of HIV infection as a struggle for 
dominance over intracellular nucleotide pools. As such, decreased ITPase expression may 
be a defensive mechanism of the host cell. There is evidence that human leukocytes can 
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mount an offence against HIV-1 infection by decreasing their cytoplasmic deoxynucleotide 
triphosphate pools by increasing sterile alpha motif and histidine-apartic domain-contain-
ing protein 1 (SAMHD1) expression thus impeding DNA replication and repair, in turn 
inhibiting viral replication.13 Earlier reports showed that HIV-infected T-lymphocytes were 
severely affected in both purine and pyrimidine nucleotide metabolism.14-16 After exog-
enous mitogenic stimulation, intracellular adenosine 5’-triphosphate (ATP) and guanosine 
5’-triphosphate (GTP) pools declined dramatically rather than expanded as is required 
for proliferation.16 In line with these observations, decreased ITPase activity may be the 
consequence of HIV targeting host cell nucleotide metabolism as well as another suicidal 
defense mechanism. By increasing non-canonical nucleotide pools, incorporation of these 
nucleotides into DNA and RNA is stimulated, leading to mutagenesis and, more impor-
tantly, programmed cell death, thus hindering HIV replication.17
A direct intracellular effect of HIV infection cannot be the only explanation for a decrease 
in ITPase activity. Also in erythrocytes and B-cells ITPase activity was found to be de-
creased, whereas these cells are not infected by HIV. An intracellular pathway activated 
by extracellular HIV particles may be hypothesized, because for B-cells, there is strong 
evidence that HIV binds to the CD21 receptor.18 The influence of other factors secondary to 
HIV infection, such as chronic inflammation is unclear.
Taken together, decreased ITPase expression might be part of the host cell’s response in 
defense to HIV-infection, or a consequence of HIV infection itself. On top of that there may 
be additional yet unidentified causes.
ITPase activity as a biomarker in predicting adverse events
There are several arguments in favor of preferring ITPase activity in erythrocytes as a bio-
marker over ITPA genotype to be used in clinical practice: 1) ITPA genotype is less strictly 
associated with ITPase activity than previously assumed,8,19 2) HIV-infection most prob-
ably influences ITPase activity,8,20 3) ITPA genotype did not influence ITPase expression in 
leukocytes,20 (in both HIV-infected as well as control patients), and finally 4) unknown and 
rare SNPs not detected by routine screening for the most prevalent genetic variants may 
cause a decrease in ITPase activity. Therefore, the role of ITPase activity as biomarker for 
adverse events was evaluated and compared to ITPA genotype in the viral infections HCV 
and HIV.
Before ITPase can be used to predict adverse events during therapy with purine analogues, 
there are several issues that need to be addressed. First, the intra individual variability of the 
ITPase activity. In order to use a test as a biomarker, one has to know that the value found 
is reproducible, when measured at a different time. For ITPase the intra individual vari-
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ability was found to be low (mean variation 15.2% within each subject)21 and within- and 
between-day imprecision in ITPase activity measurement was 3.8% and 7.5% respectively.10 
Thus, under stable conditions, ITPase activity is a reproducible parameter, with a proper 
test available.
Further, the effect of other parameters (as age, sex and drugs) on ITPase activity is important 
to assess before using it as a biomarker. In several studies age had no effect on ITPase activ-
ity21,22 nor had sex.21-23 Multiple drugs were tested and found to have no inhibitory effect on 
ITPase activity: corticosteroids, infliximab, mesalazine, adalimumab,21 azathioprine22 and 
multiple nucleoside analogues (among which abacavir and TDF).8 Cytarabine and gem-
citabine were found to decrease ITPase activity in MOLT-3 cells after 18 hr of incubation,8 
but this effect is probably due to death of this cell population. Only ribavirin was thought to 
increase ITPase activity,24 this topic will be discussed more in depth below.
Hepatitis C
In Chapter 2 it was found that ITPase activity is a better biomarker than ITPA genotype to 
predict the development of anemia during ribavirin treatment for HCV infection. ITPase 
activity had a higher negative predicting value for the onset of anemia at both 4 weeks 
after the start of ribavirin and at the time of the lowest measured hemoglobin value during 
treatment. Therapy success rate, defined as sustained virological response (SVR), was not 
associated with either ITPase activity or ITPA genotype. During the time this study was 
done, standard treatment for HCV consisted of pegylated interferon alpha in combina-
tion with ribavirin. Nowadays, NS5A inhibitor, NS5B RNA-dependent RNA polymerase 
inhibitor and NS3/4A protease inhibitor combinations are the mainstay of HCV therapy, 
with cure rates above 95%. Ribavirin is now only used to reduce treatment duration in 
well-defined clinical scenarios or for patients with specific HCV genotypes or unfavour-
able patient characteristics (like cirrhosis) with known low rates of SVR.25 By using ITPase 
activity as a predictor, adverse events may potentially be prevented during treatment with 
ribavirin in a more tailor-made treatment model for these hard to treat patients.
How and why low ITPase activity and or ITPA variants are associated with less anemia dur-
ing treatment with ribavirin remains somewhat enigmatic and contradictory phenomena 
are observed. Previously it has been assumed that low ITPase activity would decrease ribavi-
rin metabolite levels in erythrocytes, while quite obviously the opposite seems to be true.26,27 
This makes sense as ribavirin triphosphate makes an excellent substrate for ITPase.28 Riba-
virin was found to induce ITPase activity,24 but there was no effect on ITP levels.29 This also 
makes sense as ITP only accumulates to detectable levels in the erythrocytes when ITPase 
activity is completely lacking.11,30 It is known that ribavirin depletes erythrocytes of ATP.29,31 
ATP is thought to play an important role in erythrocyte membrane stability. The effect of 
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ITPA genotypes on ribavirin-induced ATP depletion has been a focus of research, but the 
data are conflicting. An in vitro study showed a reduced ATP loss in erythrocytes from 
patients with ITPase activity lowering SNPs,32 and an in vivo study showed a larger ATP 
decrease in individuals with these SNPs compared to individuals with wt/wt genotype.29 
The question rises whether ITP can function as an alternative energy source in erythro-
cytes as ITP was found not to be a substrate for ATPases keeping membrane stability in 
erythrocytes.32 However, ITP was found to be a substitute for GTP as an energy source for 
adenylosuccinate synthethase (ADSS), which is the only known enzyme in erythrocytes to 
generate an adenine nucleotide from IMP.32 Whereas in older literature it was described 
that ADSS is lacking in human erythrocytes,33 a recent study showed traces of it with a 
deep proteomic analysis technique.34 Thus potentially a decreased ITPase may lead to more 
availability of ITP (yet undetectable with present day techniques) in the erythrocytes, lead-
ing to generation of AMP from IMP via ADSS, restoring ATP depletion and protecting the 
erythrocyte from hemolysis.
In conclusion, although the mechanism is unclear, ITPase activity and ITPA genotype are 
biomarkers to predict hemolytic anemia during ribavirin therapy for HCV infection.
HIV
In HIV-infected patients, ITPase activity was also found to be a better predictor than 
ITPA genotype for adverse events during treatment with purine analogues, as described in 
Chapter 4, 5 and 6. An activity of ≥4 mmol IMP/mmol Hb/h was chosen as normal, being 
the lowest value within the 95% confidence interval for ITPA wild type carriers.8,10 Teno-
fovir and abacavir are purine analogues frequently used in the backbone of the currently 
recommended cART regimens for HIV. Tenofovir disoproxil fumarate (TDF, referred to as 
tenofovir in this thesis) is a prodrug, which is phosphorylated inside the cells to tenofovir-
diphosphate, which is the active metabolite and a non-canonical nucleotide 5’-triphosphate. 
Tenofovir-diphosphate will compete with the natural purine ATP for incorporation into the 
HIV DNA during its replication cycle. Abacavir is a guanosine analogue, and this prodrug 
is phosphorylated inside the cells to carbovir-triphosphate, the active metabolite competing 
with GTP. After incorporation of either tenofovir-diphosphate or carbovir-triphosphate 
into the growing HIV DNA-strand, further DNA synthesis is terminated because of the 
missing 3’-hydroxyl group in carbovir-triphosphate and tenofovir-diphosphate. Because 
didanosine, although being a guanosine nucleotide purine analogue, is no longer recom-
mended in the treatment of HIV and no association was found between ITPase activity or 
ITPA genotype and adverse events during therapy with didanosine (Chapter 4 and 6), the 
focus in this discussion will be on abacavir and tenofovir.
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Tenofovir
A decreased ITPase activity is associated with less occurrence of adverse events during the 
use of tenofovir in the cART regimen as is described in Chapter 4. In this retrospective 
study in 393 HIV-infected patients, all adverse events that led to stop of the cART regimen 
were analysed. Nephrotoxicity was less frequently found in patients with a decreased ITPase 
activity using tenofovir. This finding was confirmed in a retrospective cohort study (Chap-
ter 5). Compared to the endpoints in Chapter 4, the endpoints in the latter study were more 
strictly defined. Nephrotoxicity was defined as >25% decrease in estimated glomerular 
filtration rate (eGFR) from the start of tenofovir use and/or the presence of ≥2 markers 
of proximal tubular dysfunction (PTD).35 HIV-infected patients with (cases) and without 
(controls) tenofovir-associated nephrotoxicity were matched for age, gender and ethnicity. 
ITPase activity, ITPA genotype and the improvement of eGFR and PTD after tenofovir ces-
sation were compared between both groups. 73% of the cases had a normal ITPase activity, 
compared to 50% of the controls (p=0.001). Remarkably, ITPase activity was also associated 
with recovery of renal function after stopping tenofovir. In patients with normal ITPase 
activity, the recovery of eGFR was significantly better than in the patients with decreased 
ITPase activity. ITPA genotype wt/wt was also associated with more renal adverse events 
compared to patients carrying 124+21A>C or 94C>A (Chapter 4). In Chapter 5 the odds 
ratio for developing nephrotoxicity was not statistically significantly increased for patients 
with wt/wt genotype; 2.56 (95% CI 0.89-7.31). However, eGFR improvement after cessation 
of tenofovir was significantly better for wt/wt genotype.
It is an intriguing question what mechanism might be causing the protective effect of a 
decreased ITPase activity against nephrotoxicity. In tubular cells, tenofovir causes mito-
chondrial DNA (mtDNA) toxicity.36-38 Imbalanced nucleotide pools may cause mtDNA 
depletion, potentially influenced by ITPase, thereby leading to mitochondrial dysfunc-
tion.39,40 Hypothetically decreased ITPase activity could lead to an increase in ITP. Structur-
ally, ITP and ATP are very similar and it is not unthinkable that ITP can substitute for ATP 
in reactions that are driven by ATP’s high-energy phosphate esters.41,42 Tenofovir is found 
to decrease the production of ATP in proximal tubular mitochondria.43 Therefore, ITP may 
serve as an alternative high-energy donor during ATP depletion caused by tenofovir.
Tenofovir causes increased oxidative stress in mitochondria of renal tubular cells.44 Oxida-
tive stress leads to a relative increase of xanthine oxidase (XO) activity,45 a source of free 
radicals.46 With respect to ITPase activity and oxidative stress two scenarios can be envi-
sioned. Fist, a relatively high, i.e. normal, activity drives the flux from ITP via IMP towards 
the production of hypoxanthine. Hypoxanthine is a substrate for XO, thereby a source of 
free radicals. Reasoning along this line, individuals with a normal ITPase activity may have 
higher levels of oxidative stress because of more availability XO substrates than individuals 
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with a low ITPase activity. The second scenario considers the assumed primary function 
of ITPase, which is the elimination of non-canonical purine nucleoside triphosphates. 
Oxidative stress leads to oxidized (damaged), thus non-canonical, nucleotides.47 A high 
ITPase activity provides better protection against accumulation of rogue nucleotides than 
a low activity. Perhaps this is why individuals with normal ITPase activity experience more 
nephrotoxicity on tenofovir but also quickly recover once tenofovir is discontinued.
Abacavir
The results of the studies investigating ITPase activity as a potential biomarker to predict 
adverse events during abacavir use, are shown in Chapter 4 and 6. As opposed to regimens 
containing tenofovir, in regimens containing abacavir, significantly more adverse events 
occurred in patients with decreased ITPase activity: 61% versus 39% in patients with 
normal activity. This difference did not reach significance in the linear regression analysis, 
adjusting for confounding factors. On the other hand, metabolic adverse events (defined 
as dyslipidemia, use of lipid lowering therapy, diabetes mellitus or hypertension) occurred 
more frequently in patients with a normal ITPase activity, as is shown in Chapter 6 (odds 
ratio 3.11, 95% CI 1.34-7.21, p = 0.008). Although wt/wt ITPA genotype was crudely as-
sociated with an increase in metabolic events, after adjusting for confounding factors this 
association disappeared. For cardiovascular diseases, no association with either ITPase or 
ITPA genotype could be demonstrated, probably due to the low incidence of these diseases.
As ribavirin-triphosphate proved to be a substrate for ITPase,28 in Chapter 4, both carbovir-
triphosphate and tenofovir-diphosphate were studied for their ability to function as a 
substrate for ITPase. Both proved not to be substrates for ITPase. The explanation for the 
association between ITPase activity and adverse events is thus not a simple effect of ITPase 
causing accumulation of toxic metabolites. Changes in cellular signal transduction may be 
hypothesized to play a role.
Vasorelaxation, smooth muscle proliferation and platelet aggregation are processes medi-
ated by guanosine 3’, 5’-cyclic monophosphate (cGMP). cGMP is synthesised from GTP 
by the enzyme soluble guanylate cyclase (sGC) and has a wide range of effects within 
human cells. One of these effects is vasodilatation by vasorelaxation in vascular smooth 
muscle48-51 and expression of sGC in endothelial cells reduces hypertension.52,53 cGMP is 
being studied as a target for pharmacological therapy in cardiovascular disease. Under 
hypoxic conditions, however, sGC was found to shift its substrate specificity from GTP to 
ITP, causing increased inosine 3’, 5’-cyclic monophosphate (cIMP) instead of cGMP.54,55 As 
opposed to cGMP, cIMP induces vasoconstriction and it was also found to be formed when 
intact porcine arteries were incubated with exogenous ITP.54 In human platelets, formation 
of cGMP was decreased when they were incubated with carbovir-triphosphate.56 Patients 
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using abacavir were found to have lower flow-mediated dilatation57 (FMD; a non-invasive 
technique to assess endothelial function),58 which significantly correlates with invasive test-
ing of coronary endothelial function and coronary atherosclerosis.59-61 In these studies ITP 
and cIMP were not measured, but since the effect of cIMP is vasoconstriction, it may be 
hypothesized that carbovir-triphosphate made sGC substrate specificity shift from GTP to 
ITP, forming cIMP. It would also explain a link between varying ITPase activity, potentially 
leading to more or less availability of ITP in cells, abacavir use and metabolic adverse events 
during treatment for HIV. To further test this theory, experiments need to be conducted to 
determine whether carbovir-triphosphate inhibits sGC, if sGC substrate specificity shifts 
to ITP instead of GTP by carbovir-triphosphate or if carbovir-triphosphate competes with 
GTP for sGC. The effect of a decreased ITPase activity on the substrate availability for sGC 
and the mechanism behind its protective effect against metabolic events also needs further 
evaluation.
metabolic changes in HIV-infection and carT containing abacavir
The patients with a normal ITPase activity seem to have an increased risk for metabolic 
events during abacavir use compared to patients with decreased ITPase activity (Chapter 
6). The life expectancy of HIV-infected patients increases, and nowadays patients aged 
50-54 years make up the largest subpopulation of people living with HIV in the USA.62 
Consequently, cardiovascular diseases (CVD) and metabolic events will also increase in the 
HIV-infected population. It is still unclear to what extend HIV-infection causes an increase 
in CVD and metabolic risk and which part of the increased risk can be attributed to the use 
of cART. Use of some drugs in cART has been associated with an increased risk for CVD. 
Patients using protease inhibitors (PIs) were found to have an increased relative risk of CVD 
compared to patients using cART not containing PIs.63 Abacavir use has been associated 
with an increased risk of CVD compared to regimens without abacavir,63-65 however, other 
studies could not confirm this increased risk.66,67 Lipid parameters were found to improve 
when cART containing abacavir was switched to a regimen containing tenofovir.68 On the 
other hand, it is unknown whether HIV-infection itself induces changes that increase risk 
of CVD and whether, if so, if it can be undone by the use of cART. To further investigate the 
influence of cART on metabolic events, plasma metabolites of a HIV-infected population 
before start of cART were compared to a non-HIV infected control population (Chapter 
7). Additionally, plasma metabolites of untreated HIV-infected patients were compared to 
those after 12 months of cART. The comparison of the biogenic amines, lipids and signalling 
lipid metabolites between untreated, active HIV-infection, and non-HIV infected control 
patients showed a profile of mainly decreased biogenic amines in untreated HIV-infection. 
The decreased concentrations of leucine, isoleucine and carnosine might point to an im-
paired muscle metabolism, whereas reduced levels of ornithine could suggest an affected 
ureum cycle and a potentially decreased ammonia clearance. After 12 months of abacavir 
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containing cART, only 3 amines (methionine sulfone, histidine and tryptophan) showed a 
significant increase versus the baseline measurement. The lipid profile showed an overall 
increasing trend after 12 months of cART, however the most striking finding was that 12 
months of cART had no significant effect on the signalling lipids, the group including 
amongst others prostaglandins, thromboxanes and leukotrienes. The signalling lipids are 
metabolites that play an essential role in immunological crosstalk.69 Thus although cART 
successfully suppresses HIV-RNA in blood and restores the number of CD4+ lymphocytes, 
it seems to be unable to restore all the metabolic changes caused by the infection. This may 
be an explanation for the persistently increased occurrence of CVD in the HIV-infected 
population, next to a potential direct effect of cART on CVD.
fuTure PersPeCTIVes
ITPase activity in patients with viral infectious diseases
The results of this thesis show that ITPase activity may serve as a biomarker to predict 
adverse events during therapy with purine analogues for the chronic infections HCV and 
HIV. More specifically, during use of the purine analogues ribavirin (HCV), tenofovir and 
abacavir (HIV), ITPase activity was found to be associated with specific adverse events: ane-
mia and hemoglobin decline, nephrotoxicity and metabolic adverse events, respectively. As 
currently many non-HIV infected individuals start with tenofovir as pre-exposure prophy-
laxis (PrEP) against HIV, a prospective study determining ITPase activity in relation to the 
occurrence of nephrotoxicity is warranted in order to determine the value as biomarker for 
this adverse event in a non-HIV infected population. Nephrotoxicity can also be prevented 
by using tenofovir alafenamide (TAF) instead of tenofovir, as this was found to be equally 
effective in suppressing HIV in cART, but with significantly less nephrotoxicity. However, 
TAF has not yet been studied as PrEP. A model using tenofovir in one arm and TAF in the 
other can give information on both the efficacy of TAF as PrEP and the association between 
ITPase activity and ITPA genotype and adverse events during TAF or tenofovir use in the 
absence of HIV-infection.
Apart from nephrotoxicity, osteoporosis during tenofovir use is another interesting topic 
to investigate since ITPase plays a role in the formation of pyrophosphate, an inhibitor 
of bone mineralization.70,71 In a preliminary study, bone mineral density (measured by 
Dual Energy X-ray Absorptiometry (DEXA) scanning) of 10 HIV-infected patients with 
decreased ITPase activity was compared to 22 patients with normal ITPase activity at 2 
time points: just before switching off tenofovir-containing cART and 48 weeks thereafter. 
Bone mineral density of the lumbar spine was found to significantly increase after cessa-
tion of tenofovir in the patients with decreased ITPase activity, but not in the patients with 
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normal ITPase activity. In the hip, bone mineral density increased more in the patients with 
decreased ITPase activity than in the patients with normal activity, but these results did not 
reach significance. A larger, preferably prospective study, following HIV-infected patients 
on tenofovir containing cART compared to patients on cART not containing tenofovir, 
measuring bone mineral density through DEXA scanning after 24, 48 and 72 weeks and 
comparing outcome for patients with decreased versus normal ITPase activity, may give 
more insight in the association of ITPase activity and bone toxicity during tenofovir use in 
cART for HIV-infection.
While CVD and metabolic events are expected to increase in the HIV-infected population 
due to increasing age, more research, preferably large and prospective studies, should be 
done to further elucidate the role of ITPase activity and ITPA genotype in the occurrence of 
these events. Other adverse events that are known to occur during use of abacavir, such as 
gastro-intestinal adverse events, should be the scope of further research as well, as these are 
among the most frequent reasons for stopping this drug during cART.
An intriguing question is whether the headache and depression seen during triumeq use 
(a combination drug containing abacavir, dolutegravir and lamivudine) is associated with 
ITPase activity. The potential link between ITPase activity and these adverse events may be 
hypothesized by the findings that inosine has an inhibitory effect on Purkinje cerebral cells 
in rats,72 inosine is an endogenous agonistic ligand for the benzodiazepine receptors in pig 
brains,73 and pathogenic ITPA mutations cause an encephalopathy.12,74 
Potentially a decreased ITPase activity may lead to an increase of the risk for malignancies. 
Studies have shown that both genetically engineered knock-out of ITPase expression in 
mice and naturally occurring genetic variants in the human population cause genetic insta-
bility. ITPA knock-out mice incorporated more deoxyinosine residues into embryonic DNA 
than controls.75 In fibroblasts cultured from these embryos an increase in chromosomal 
aberrations and single-strand DNA breaks was observed.75 In addition, in humans the SNP 
94C>A in the ITPA gene was associated with a higher number of DNA mutations.17 These 
observations are in line with the mutagenic properties of dITP76 and the role of ITPase in the 
sanitation of the nucleotide pool.77 The incidence of malignancies is increased in the HIV-
infected patient population and certain malignancies are considered AIDS-defining cancers 
(Kaposi sarcoma, non-Hodgkin lymphoma and invasive cervical cancer).78 Although cART 
has reduced the incidence of these AIDS-defining cancers,79,80 still, the occurrence of cancer 
(both AIDS-defining and non-AIDS-defining) is higher compared to the general popula-
tion.79-82 Investigating the association between ITPase activity and the risk for malignancies 
is an important subject to investigate in the HIV-infected population.
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In other virus infections purine analogues are also being used. For instance tenofovir is used 
to treat hepatitis B (HBV) infection, ribavirin is sometimes used as a treatment option for 
Respiratory syncytial virus (RSV), ganciclovir can be used to treat Cytomegalovirus (CMV) 
and acyclovir to treat Herpes simplex virus (HSV). If ITPase activity or ITPA genotype 
could be used as a biomarker prior to treatment for these infections, potentially adverse 
events like nephrotoxicity and hemolytic anemia can be prevented.
The findings in Chapter 7 on changes in metabolites during untreated HIV-infection, not 
fully restored by cART may function as a starting point for further unravelling the metabolic 
pathways affected by HIV. New insight in these pathways is important for cardiovascular 
risk management and prevention of malignancies.
ITPase activity in other populations
As was mentioned before, in other populations than patients with HIV- and HCV-infection, 
purine analogues are being used, like azathioprine in patients with multiple autoimmune 
diseases and 6-mercaptopurine in patients with acute lymphoblastic leukemia. The question 
rises in what patient population using ITPase activity as a biomarker for adverse events 
during purine analogue based therapy will be most rewarding. In the Asian populations the 
SNP 94C>A, and thus a decrease in ITPase activity, was the most prevalent compared to 
other populations.83 Perhaps screening should therefore concentrate on these Asian popu-
lations. A larger trial that includes mainly Asian HIV-infected patients would be helpful 
to investigate the use of ITPase activity and ITPA genotype as a biomarker for predicting 
adverse events during cART in this population.
More studies are needed to obtain more insight in the role of non-canonical nucleotides 
(like inosine) in human cells. Besides from having deleterious effects, the other, potentially 
beneficial effects could gain insight in the basic cell metabolism, as well as have potential 
implications for future treatment of human disease. Inosine was found to be cardioprotec-
tive,84 and is currently under investigation to slow down Parkinson’s disease and amyo-
trophic lateral sclerosis (ALS),85,86 via neuroprotective mechanisms of hypoxanthine. In the 
form of inosine pranobex, inosine is under research to alleviate influenza-like symptoms via 
immunomodulatory routes.87 Further, purine metabolism is under the attention in the anti-
cancer field where, among other things, inosine monophosphate dehydrogenase (IMPDH) 
inhibitors have shown anti-leukemic effects in a variety of acute myelogenous leukemia 
(AML) cell lines.88 Under what conditions is inosine a substrate for sGC? What happens to 
intracellular nucleotide pools in cells under stress (like hypoxemia or due to certain drugs)? 
And what role does the variability in ITPase activity between patients play in these mecha-
nisms? Could ITPase activity be used in predicting cardiovascular or neurological disease 
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in patients other than HIV-infected patients? These questions need to be answered in order 
to gain more insight in human metabolism, towards tailor-made therapy for every patient.
CONClusIONs Of THIs THesIs
In the leukocytes of HIV-infected patients the presence and expression of the enzyme 
ITPase is significantly decreased compared to non-HIV infected individuals. Further, 
the ITPA genotype c.124+21A>C is less strictly associated with ITPase activity than has 
previously been assumed. ITPase activity is a more accurate biomarker than ITPA genotype 
for predicting 1) anemia and hemoglobin-decrease during HCV therapy with ribavirin, 2) 
adverse events in general and nephrotoxicity during HIV therapy with tenofovir and 3) 
metabolic events during HIV therapy with abacavir, and an ITPase activity <4 mmol IMP/
mmol Hb/hour was associated with a decrease in these adverse events. The situations in 
which a normal ITPase activity seemed to be more favourable than a decreased activity were 
limited to adverse events in general during HIV therapy with abacavir (however no longer 
significant logistic regression analysis) and the recovery of nephrotoxicity after tenofovir 
cessation. Metabolites changed by HIV-infection are not all fully restored to the levels of 
non-HIV infected patients in spite of successful suppression of the HIV-replication by 
cART.
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HumaaN ImmuNOdefICIëNTIeVIrus
Het Humaan immunodeficiëntievirus (HIV) is een enkelstrengs ribonucleïnezuur (RNA)-
virus dat specifiek CD4+ T-helper lymfocyten, macrofagen en dendritische cellen infecteert. 
Na binding van een oppervlakte-eiwit op de HIV celmembraan met de CD4 receptor en één 
van de co-receptoren CCR5 of CXCR4 op deze gastheercellen, fuseren beide celmembranen 
met elkaar en komt de inhoud van de HIV-cel in het cytoplasma van de gastheercel. Het 
HIV gebruikt daar het enzym ‘reverse transcriptase’ en de nucleotiden van de gastheercel 
om van de enkele RNA-streng een dubbele deoxyribonucleïnezuur (DNA)-streng te maken. 
Dit DNA wordt via het HIV-enzym ‘integrase’ in het DNA van de gastheer ingebouwd. Via 
het nucleotide-metabolisme van de gastheer worden vervolgens van dit ingebouwde DNA 
nieuwe RNA-moleculen afgeschreven, welke na translatie nieuwe HIV-eiwitten leveren. 
Deze HIV-eiwitten worden in een deel van de celwand van de gastheercel weer verpakt 
tot nieuwe HIV-partikels, die nieuwe gastheercellen kunnen infecteren. Onbehandelde 
HIV-infectie leidt tot een vermindering van CD4+ T-cel lymfocyten en uiteindelijk tot 
immuundeficiëntie, Acquired Immune Deficiency Syndrome; AIDS genoemd. Zonder 
behandeling leidt dit ziektebeeld tot het overlijden van de patiënt. De medicatie die wordt 
gebruikt om HIV te remmen, combinatie anti-retrovirale therapie (cART) genoemd, is in 
de laatste tientallen jaren steeds effectiever geworden. cART kan de virusreplicatie onder-
drukken en zorgen voor (gedeeltelijk) herstel van het immuunsysteem. Er zijn meerdere 
stappen in de HIV-replicatie cyclus die een aangrijpingspunt vormen voor de medicatie. In 
een cART regime zitten altijd meerdere middelen uit verschillende klassen medicatie die op 
verschillende van deze aangrijpingspunten werken. De huidige richtlijnen schrijven allen 
een combinatie van minimaal 3 middelen voor, waarin twee NRTIs worden gecombineerd 
met of een niet-nucleoside reverse-transcriptase remmer (NNRTI), een protease remmer 
(PI) of een integrase remmer. Hoewel de huidige therapie de laatste jaren zeer sterk verbe-
terd is qua effectiviteit, kunnen we HIV nog altijd niet genezen en moet een patiënt de rest 
van zijn leven cART blijven gebruiken. Zoals bij vrijwel alle medicatie treden ook bij cART 
gebruik frequent bijwerkingen op, waarvan we, behoudens middels de genetische marker 
HLA-B*57:01 voor abacavir, niet kunnen voorspellen welke patiënt ze krijgt en hoe ernstig 
deze zullen zijn.
ITPase
De replicatie van HIV en de werking van de NRTIs zijn afhankelijk van het nucleotide 
metabolisme van de gastheercel. De nucleotiden, adenine en guanine (purines) en cytosine 
en thymine (pyrimidines), zijn de bouwstenen van DNA. Deze nucleotiden zijn uitgebreid 
onderzocht en van hun nucleotide-5’-trifosfaat vorm is bekend dat ze betrokken zijn bij 
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de energielevering voor verschillende processen in de menselijke cel, signalen doorgeven 
binnen de cellen, betrokken zijn bij de vorming van polysachariden en onderdelen zijn 
van verschillende co-enzymen die belangrijk zijn voor oxidatie-reductie reacties. Naast 
deze 4 nucleotiden, zijn er nog andere nucleobasen, zoals xanthine en hypoxanthine, waar-
van de laatste de base is om de nucleoside inosine te vormen. Deze nucleobasen worden 
gevormd binnen de metabole paden van het purine nucleotide mechanisme, maar ook 
bij oxidatieve stress en deaminatie. De rol van xanthine en hypoxanthine, ook wel ‘non-
canonische’ nucleosiden genoemd, is minder uitgebreid onderzocht dan van de ‘canonische’ 
nucleosiden. Wel is bekend dat ze zowel gunstige als schadelijke effecten kunnen hebben. 
Inosine trifosfaat pyrofosfohydratase (ITPase) is een enzym dat inosine-5’-trifosfaat (ITP) 
defosforyleert naar inosine-5’-monofosfaat (IMP). Dit enzym wordt gecodeerd door het 
gen ITPA. Verschillende single nucleotide polymorfismen (SNPs) zijn bekend binnen dit 
gen, waarvan meerdere SNPs leiden tot een verminderde activiteit van het enzym ITPase. 
Zo leidt homozygoot dragerschap voor SNP 94C>A tot nagenoeg volledige ITPase defici-
entie, terwijl heterozygote dragers van deze SNP nog 23% restactiviteit hebben. De SNP 
124+21A>C leidt in homozygote dragers tot 30% en in heterozygote dragers tot 60% ITPase 
restactiviteit. Deze verschillende SNPs komen wereldwijd in wisselende frequenties voor bij 
verschillende populaties. Er is uitgebreid onderzoek gedaan naar de invloed van deze SNPs 
op bijwerkingen van purine analogen zoals azathioprine dat gebruikt wordt in de behande-
ling van inflammatoire darmziekten, mercaptopurine voor acute lymfoblastaire leukemie 
en ribavirine voor hepatitis C (HCV). Voor de eerstgenoemde middelen zijn de uitkomsten 
van de onderzoeken niet eenduidig. Voor ribavirine is echter aangetoond dat dragerschap 
van een SNP in het ITPA gen, leidend tot een vermindering van de activiteit van ITPase, 
beschermt tegen de bijwerking hemolytische anemie. In cART voor HIV worden purine 
analogen gebruikt als nucleoside/nucleotide reverse-transciptase remmers (NRTIs) zoals 
abacavir, tenofovir en didanosine.
Dit proefschrift beschrijft de resultaten van onderzoek naar het enzym ITPase als mogelijke 
biomarker voor het voorspellen van bijwerkingen tijdens de behandeling met ribavirine 
voor HCV en cART voor HIV en wordt hierin vergeleken met het ITPA gen.
ITPase als bIOmarker VOOr bIjWerkINGeN
In hoofdstuk 2 wordt beschreven dat de ITPase activiteit een betere biomarker is dan het 
ITPA genotype voor het voorspellen van anemie en hemoglobine daling tijdens de behande-
ling van HCV met ribavirine. In alle in dit proefschrift beschreven onderzoeken wordt een 
verlaagde ITPase activiteit gedefinieerd als <4 mmol IMP vorming per mmol hemoglo-
bine per uur (<4 mmol IMP/mmol Hb/uur), omdat dit de laagste waarde is van het 95% 
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betrouwbaarheidsinterval van de waarde van ITPase activiteit bij mensen met een ITPA 
genotype zonder SNPs (die geacht worden een normale ITPase activiteit te hebben). Uit 
deze studie, die 106 patiënten bevat, blijkt dat een verlaagde ITPase activiteit geassocieerd 
is met een minder laag hemoglobine, minder grote hemoglobine daling en minder frequent 
voor komen van anemie (bloedarmoede). Ook patiënten met een van beide hierboven 
genoemde SNPs in het ITPA gen blijken een significant minder laag hemoglobine en een 
mindere hemoglobine daling te hebben, maar het voorkomen van anemie is alleen ver-
minderd in de patiënten met de SNP 94C>A vergeleken met patiënten zonder SNP in hun 
genotype (wildtype; wt/wt). Een mogelijke verklaring hiervoor is dat de SNP 124+21A>C 
in het ITPA gen minder strikt geassocieerd is met een verminderde ITPase activiteit dan 
eerder werd aangenomen. De patiënten met deze SNP hebben namelijk ITPase activiteiten 
variërend van sterk verlaagde tot normale waarden; 38% heeft een normale ITPase activiteit. 
Tot slot blijkt dat zowel de ITPase activiteit als het ITPA genotype geen invloed hebben op 
de effectiviteit van de HCV behandeling.
In hoofdstuk 3 worden de resultaten beschreven van het onderzoek naar de aanwezigheid 
van het enzym ITPase in witte bloedcellen (leukocyten) van 59 HIV-patiënten vergeleken 
met een controle groep van 50 niet-HIV geïnfecteerde mensen. Het enzym ITPase blijkt in 
alle leukocyten subsets van HIV-patiënten, behalve de monocyten, minder vaak aanwezig 
te zijn dan in de leukocyten subsets van de controle groep. De cellen die wel ITPase bevat-
ten, hebben bij de HIV-patiënten een minder sterke mate van expressie vergeleken met de 
cellen van de individuen in de controle groep. Deze verlaging van de aanwezigheid van 
ITPase is niet gerelateerd aan het ITPA genotype, want de verdeling van de genotypes is 
in HIV-patiënten hetzelfde als in de niet-HIV geïnfecteerde mensen. De resultaten van dit 
onderzoek sluiten aan bij eerder onderzoek, waarin ook in rode bloedcellen (erythrocyten) 
van HIV-patiënten een verlaagde ITPase activiteit werd gevonden ten opzichte van een 
controle populatie.
Naar aanleiding van bovenstaande bevindingen (1] ITPase activiteit lijkt een betere voor-
speller te zijn van bijwerkingen tijdens therapie met een purine analoog voor HCV en 2] 
de ITPase activiteit is verlaagd in zowel erythrocyten als leukocyten van HIV-patiënten), 
werden de studies gedaan die worden beschreven in hoofdstukken 4, 5 en 6. In analogie 
van HCV, blijkt voor het voorspellen van bijwerkingen tijdens behandeling met de purine 
analogen abacavir en tenofovir in cART voor HIV de ITPase activiteit ook een betere maat 
dan het ITPA genotype. Didanosine is ook een purine analoog, maar omdat bij het gebruik 
hiervan geen relatie met ITPase activiteit en ITPA genotype is gevonden en dit middel tegen-
woordig bijna niet meer gebruikt wordt, worden deze resultaten hier niet apart besproken.
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Tenofovir
In hoofdstuk 4 worden de resultaten beschreven van een retrospectieve studie in een 
populatie van 393 HIV-geïnfecteerde patiënten die behandeld werden met cART. De bijwer-
kingen worden gegroepeerd in de categorieën maag/darmklachten, neurologische klachten, 
nefrotoxiciteit, huidafwijkingen en leverproblemen. Bijwerkingen ten tijde van het gebruik 
van de verschillende cART regimes worden vergeleken tussen patiënten met een verlaagde 
en patiënten met een normale ITPase activiteit. Ook wordt deze vergelijking gemaakt tussen 
patiënten met een of meerdere van de SNPs c.94C>A en c.124+21A>C in het ITPA gen en de 
patiënten zonder SNPs in dit gen (wt/wt). De patiënten met een verlaagde ITPase activiteit 
hebben minder bijwerkingen dan de patiënten met een normale ITPase activiteit tijdens 
de behandeling met een cART regime dat tenofovir bevat. Dit geldt ook voor patiënten 
met SNPs in het ITPA gen (c.94C>A en/of c.124+21A>C) vergeleken met patiënten met 
het wildtype (wt/wt) ITPA genotype. Maar als gekeken wordt naar afzonderlijke bijwer-
kingen, dan is een verlaagde ITPase activiteit alleen geassocieerd met minder nierschade 
(nefrotoxiciteit) tijdens behandeling met tenofovir en kan deze associatie niet worden 
aangetoond voor het ITPA genotype. In het vervolgonderzoek (beschreven in hoofdstuk 5), 
vergelijken we HIV-patiënten die tenofovir gebruikten met nefrotoxiciteit tijdens therapie 
(26 patiënten) met 55 gematchte patiënten zonder nefrotoxiciteit. In deze studie worden 
de resultaten uit hoofdstuk 4 bevestigd. Patiënten met nefrotoxiciteit hebben significant 
vaker een normale ITPase activiteit dan patiënten zonder nefrotoxiciteit. Dit verschil wordt 
niet gevonden als de verschillende ITPA genotypes met elkaar worden vergeleken. Wel is 
het hebben van een normale ITPase activiteit geassocieerd met een beter herstel van de 
nierfunctie na het staken van tenofovir.
abacavir
Voor abacavir zijn de resultaten, beschreven in hoofdstuk 4 en 6 minder eenduidig dan 
voor tenofovir. De bijwerkingen waarvoor een verminderde ITPase activiteit bij tenofovir 
beschermend lijkt te zijn (maag/darmklachten, neurologische klachten, nefrotoxiciteit, 
huidafwijkingen en leverproblemen), komen juist vaker voor bij de patiënten met een 
verminderde ITPase activiteit tijdens therapie met abacavir. Echter na correctie voor de 
factoren: duur van cART, duur van purine therapie en duur van het huidige cART regime, 
is dit verschil niet significant meer. Het ITPA genotype is niet geassocieerd met deze bijwer-
kingen tijdens therapie met abacavir.
In hoofdstuk 6 blijkt dat het hebben van een verlaagde ITPase activiteit ook voor HIV-
patiënten die abacavir gebruiken op een andere wijze gunstiger is, omdat zij minder vaak 
een metabole bijwerking (diabetes mellitus, hypertensie en dyslipidemie) blijken te hebben 
dan de patiënten met een normale ITPase activiteit. Hoewel ook in ITPA genotypes die een 
SNP bevatten minder metabole bijwerkingen lijken voor te komen, is deze associatie niet 
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langer significant na correctie voor leeftijd, body mass index (BMI), cumulatief gebruik van 
cART en het gebruik van een PI of NNRTI. Het eindpunt hart- en vaatziekten (cardiovascu-
laire ziekten) is in dit onderzoek niet geassocieerd met ITPase activiteit of ITPA genotype, 
waarschijnlijk door het lage aantal gevallen dat voorkwam in de onderzochte populatie.
meCHaNIsme
De ITPase activiteit is geassocieerd met bijwerkingen ten tijde van therapie met tenofovir 
(algemene bijwerkingen en nefrotoxiciteit) en abacavir (metabole bijwerkingen) voor HIV 
en zou daarom mogelijk in de toekomst in kunnen worden gezet als biomarker voor het 
voorspellen van bijwerkingen. De ITPase activiteit lijkt in de studies beschreven in dit 
proefschrift een betere biomarker te zijn dan het ITPA genotype. Een voor de hand lig-
gende verklaring voor de gevonden associatie zou kunnen zijn dat de actieve metabolieten 
van tenofovir en abacavir een substraat zijn voor het ITPase enzym en dat zo de activiteit 
van ITPase de vorming van toxische metabolieten beïnvloedt. Dit is echter getest en beide 
blijken geen direct substraat te zijn, waardoor deze hypothese moet worden verworpen 
(hoofdstuk 4). In de discussie (hoofdstuk 8) van dit proefschrift worden enkele hypothesen 
besproken over de mogelijke mechanistische verklaring achter de gevonden associaties. 
Mogelijk spelen verschuivingen in intracellulaire nucleotide voorraden of het ontstaan van 
zuurstofradicalen een rol, maar ook een veranderde cellulaire signaal transductie waarin 
mogelijk ITP een substraat is voor cyclisch guanosine-3’,5’-monofosfaat (cGMP) behoort 
theoretisch tot de mogelijkheden. Duidelijk is dat er nog veel aanvullend onderzoek nodig 
is om het mechanisme achter de gevonden associaties in zijn geheel te verklaren.
VeraNderINGeN VerOOrzaakT dOOr VIrus Of medICaTIe?
Een normale ITPase activiteit tijdens het gebruik van abacavir voor HIV-infectie zou dus 
ongunstig kunnen zijn voor onder andere het ontwikkelen van risicofactoren voor car-
diovasculaire ziekten. Voor HIV-patiënten is gebleken dat het risico op cardiovasculaire 
ziekten verhoogd is, maar onbekend is in hoeverre dit risico wordt veroorzaakt door de 
infectie zelf of door de cART. Om meer inzicht te krijgen in de metabole veranderingen 
tijdens een actieve, onbehandelde HIV-infectie, worden in hoofdstuk 7 metabolieten in het 
plasma van 18 HIV-patiënten vergeleken met dat van 23 niet-HIV geïnfecteerde personen. 
In de onbehandelde HIV-patiënten worden meerdere verschillen gezien ten opzichte van de 
controle groep in de biogene amines, waarvan alle amines die verschilden, verlaagd zijn bij 
HIV-patiënten. Ook het lipidenprofiel verschilt tussen beide groepen met een toename van 
meervoudig onverzadigde triglyceride soorten in HIV, maar een afname van fosfolipiden. 
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Binnen de groep signaallipiden, met name van belang voor het doorgeven van signalen 
tussen immuuncellen, is een groot deel van de lipiden verhoogd, waaronder de lipiden 
afkomstig van de vorming van oxidatieve zuurstofradicalen. Concluderend bestaan er grote 
verschillen tussen HIV-patiënten en niet-HIV geïnfecteerde personen in zowel biogene 
amines als lipiden en signaallipiden. De resultaten van dit onderzoek kunnen bijdragen aan 
toekomstig onderzoek dat noodzakelijk is voor het beantwoorden van meerdere vragen, 
zoals waarom HIV-patiënten een verhoogd cardiovasculair risico hebben, of waarom er 
meer maligniteiten voorkomen bij HIV-patiënten. De meest opvallende bevinding van het 
onderzoek dat wordt beschreven in hoofdstuk 7 is dat 12 maanden behandeling met abaca-
vir bevattende cART in HIV-geïnfecteerde patiënten met succesvolle onderdrukking van de 
virale replicatie toch niet leidt tot herstel van de gevonden verschillen tussen onbehandelde 
HIV-patiënten en de controle populatie. Slechts enkele verlaagde amines nemen significant 
toe na 12 maanden cART en alle signaallipiden blijven verlaagd, ondanks de therapie. De 
overige lipiden laten wel veranderingen zien en blijken over het algemeen toe te nemen 
tijdens therapie. Samenvattend betekent dit dat de metabole veranderingen die ontstaan 
tijdens actieve HIV-infectie, niet compleet ongedaan worden gemaakt met een jaar lang 
succesvolle abacavir bevattende therapie tegen HIV.
CONClusIes
In hoofdstuk 8 worden alle resultaten samengevat en wordt de balans opgemaakt tussen 
ITPase activiteit en ITPA genotype als biomarker voor bijwerkingen tijdens de behandeling 
met de purine analogen ribavirine voor hepatitis C en abacavir en tenofovir voor HIV. Ook 
de mogelijkheden voor toekomstig onderzoek worden hier besproken. De belangrijkste 
conclusies van dit proefschrift zijn: 
1) In de leukocyten van HIV-patiënten is het enzym ITPase minder vaak aanwezig en is de 
expressie minder sterk dan in de leukocyten van niet-HIV geïnfecteerde mensen.
2) Het voorkomen van de SNP c.124+21A>C is minder sterk geassocieerd met een vermin-
derde ITPase activiteit dan voorheen werd aangenomen.
3) ITPase activiteit is een betere biomarker dan ITPA genotype voor het voorspellen van: 
 a)  anemie en hemoglobine-daling ten tijde van behandeling met ribavirine voor hepa-
titis C,
 b)  bijwerkingen in het algemeen en nefrotoxiciteit in het bijzonder ten tijde van behan-
deling met tenofovir voor HIV,
 c)  metabole bijwerkingen ten tijde van behandeling met abacavir voor HIV.
4) Bij alle bovengenoemde associaties is een verlaagde ITPase activiteit (<4 mmol IMP/
mmol Hb/uur) gunstiger dan een normale ITPase activiteit.
5) Een verlaagde ITPase activiteit is echter mogelijk geassocieerd met 
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 a)  een slechter herstel van nefrotoxiciteit na het staken van tenofovir voor HIV,
 b)  het vaker voorkomen van algemene bijwerkingen tijdens gebruik van abacavir voor 
HIV.
6) De verandering in metabolieten bij patiënten met onbehandelde HIV-infectie, wordt 
niet volledig hersteld door een jaar succesvolle onderdrukking van de virale replicatie 
van HIV door gebruik van abacavir bevattende cART.
Toekomstig onderzoek zal uit moeten wijzen of ITPase ook bij andere indicaties voor teno-
fovir geassocieerd is met bijwerkingen en of het ook met andere bijwerkingen dan anemie, 
nefrotoxiciteit en metabole effecten geassocieerd is tijdens therapie met purine analogen. 
Verder zal onderzocht moeten worden in welke populaties de biomarker het best inzetbaar 
zal zijn. Ook algemeen onderzoek naar ITPase en de non-canonische nucleotiden is nodig 
om zowel hun gunstige als schadelijke effecten beter in kaart te brengen. Hopelijk zal dit 
leiden tot ‘therapie op maat’ voor elke patiënt.
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En opeens zit het er bijna op en kan ik gaan schrijven aan het dankwoord, dat ik in gedach-
ten al zo vaak heb geschreven. Toch blijkt het in de praktijk lastiger dan ik dacht, want wat 
hebben er veel mensen geholpen, op allerlei verschillende manieren. Van het bedenken en 
uitvoeren van onderzoeken, het redigeren en corrigeren van manuscripten tot het aanhoren 
van oefen-presentaties, het bieden van een troostende schouder als het eens tegen zat of 
gewoon even afleiding van het hele promotietraject. Al die mensen, die me de afgelopen 
jaren hebben gesteund, wil ik hier graag bedanken.
Allereerst mijn promotor, prof. dr. A. Verbon, beste Annelies, wat heb ik toch ontzettend 
veel aan je te danken. Zonder jou was deze promotie nooit gelukt. Je maakte altijd tijd voor 
me vrij en nooit hoefde ik lang te wachten op antwoord als ik een manuscript bij je inle-
verde. Het ene aspect wat beter uitlichten, het andere net op een andere manier verwoorden, 
altijd wist je het weer duidelijk beter te maken. Je bent een voorbeeld voor mij op gebied van 
wetenschap en organisatie. Heel erg bedankt voor al jouw hulp en begeleiding de afgelopen 
jaren, die zeker niet alleen met het promotietraject te maken hebben gehad. 
Mijn co-promotor, dr. J. Bierau, beste Jörgen, het is wel duidelijk dat artsen en klinisch ge-
netisch laboratorium specialisten op een andere manier denken: waar jij altijd de chemische 
structuren voor je ziet, zie ik de patiënten erachter. Wat bleken deze verschillende visies op 
hetzelfde onderwerp een goede combinatie te zijn voor dit proefschrift. Jouw mooie schrijf-
stijl maakte alle teksten beter. Ik ben je zo dankbaar voor het feit dat je altijd bereikbaar voor 
me was, en dat je me al die jaren zo fijn hebt begeleid. Ik heb het gevoel dat ik er een vriend 
bij heb gekregen, dank je wel. 
Mijn co-promotor, dr. J.A. Bakker, beste Jaap, net als Jörgen, was jij er al die jaren altijd om 
me te helpen, mee te brainstormen en de stukken beter te maken door ze kritisch na te lezen 
en met goede aanvullingen te komen. Je altijd weer vriendelijke woorden en e-mails hebben 
me vaak opgebeurd en gemaakt dat ik dit proefschrift heb kunnen maken. Dank je, Jaap, 
zonder jou was het niet gelukt.
De mogelijkheid om überhaupt te starten aan dit proefschrift, is gegeven door Martin Jaekel, 
toentertijd werkend bij Janssen pharmaceutical companies Nederland. Doordat u aan Prof. 
dr. Verbon een unrestricted scientific grant toekende, kreeg ik tijd en ruimte om dit traject 
te realiseren. Bedankt daarvoor.
Dan de leden van de leescommissie, prof. dr. E.J.G. Sijbrands, beste Eric, ik voel me vereerd 
dat je secretaris in de leescommissie wilde zijn. Jouw vriendelijkheid en de gesprekken aan 
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jouw bijzondere tafel in de D-gang, hebben mijn enthousiasme voor wetenschappelijk on-
derzoek verder aangewakkerd en er mede voor gezorgd dat ik me altijd welkom heb gevoeld 
als collega in het Erasmus MC. Prof. dr. A.T. van der Ploeg, beste Ans, hoewel we op het ge-
bied van de metabole ziekten nog maar kort met elkaar samenwerken, heb ik al erg veel van 
je geleerd. Bedankt dat je in de leescommissie heb willen plaatsnemen. Prof. dr. M.E. Rubio 
Gozalbo, beste Estela, heel erg bedankt dat je de tijd hebt willen nemen dit proefschrift te 
lezen en je mooie woorden over het proefschrift in je antwoord naar Annelies. 
Dan de leden van de grote commissie, bedankt voor jullie bereidheid in de oppositie plaats 
te nemen. Dr. A. Oude Lashof, beste Astrid, dit is meteen een goede plek om je nogmaals 
te bedanken dat je me, inmiddels heel wat jaren geleden, hebt aangestoken met jouw en-
thousiasme over en liefde voor ons vak. En uiteraard voor de fijne begeleiding tijdens mijn 
opleiding als infectioloog. Dr. S.C.E. Klein Nagelvoort-Schuit, beste Stephanie, ik bewonder 
jouw talent voor management en hoe je dit weet te combineren met de patiëntenzorg en 
het blijven klaarstaan voor de medewerkers die je onder je hoede hebt. Bedankt voor jouw 
vertrouwen in mij in jouw team van internisten. Dr. B.E. Hansen, beste Bettina, dankzij 
jouw statistische kennis, konden we van mijn ingewikkelde database uiteindelijk een mooi 
manuscript maken. Bedankt voor je geduld bij eindeloze aanpassingen. Prof. dr. T. van 
Gelder, beste Teun, bedankt voor je tijd, aandacht en oppositie.
Dr. S.H. Lowe, beste Selwyn, jij bent voor dit proefschrift net zo belangrijk geweest als de 
co-promotoren. Jij vormde de harde kern voor de brainstormsessies en vergaderingen, die 
ook altijd gezellig waren. Tevens bedankt voor jouw begeleiding tijdens mijn opleiding tot 
infectioloog, ik heb veel van je geleerd en het altijd heel fijn gehad in het Maastricht UMC+. 
Veel dank aan al mijn mede-auteurs, voor hun inzet en hulp bij het schrijven van alle ma-
nuscripten. In het bijzonder dr. P.A. Boonstra, beste Andre, de reikwijdte van dit proefschrift 
is dankzij jou breder gemaakt dan alleen ITPase. Bedankt voor de fijne samenwerking 
in dit project. Hopelijk werken we in de toekomst nog samen aan nieuwe hoofdstukken. 
Dr. J.C. Schoeman, beste Nelus, het overleg met jou en Andre was altijd goed en gezellig. 
Bedankt daarvoor en veel succes met je nieuwe baan. HIV-verpleegkundige J.A. Schippers, 
beste Jolanda, ik heb enorme bewondering voor de manier waarop jij de HIV-patiënten 
van de polikliniek in Maastricht psychologisch ondersteunt. Bedankt voor het delen van 
jouw ervaring. Dr. E.-R. Andrinopoulou, beste Elrozy, bedankt dat je altijd op korte termijn 
tijd vrij wilde maken voor al mijn statistische vragen. Dr. I.E.A. Wijting, beste Ingeborg, 
ik bewonder jouw inzet en enthousiasme, die nooit lijdt onder zwangere buiken of op de 
achtergrond aandacht trekkende kinderen. 
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De sectie Infectieziekten van het Erasmus MC, beste Dorine, Bart, Casper, Els, Eric, Han-
nelore, Jan, Karin, Lennert, Mariana en Perry, wil ik graag bedanken voor de fijne samen-
werking. Ik ben trots dat ik deel uit mag maken van deze groep. Mijn dank gaat ook uit 
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